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ABSTRACT 
 
 
Diabetes is one of the most challenging and growing health problems 
worldwide. Diabetes (mainly type 2; T2D) is an independent risk factor for 
development of several types of cancer. A great number of epidemiological 
studies have reported that T2D patients have an increased risk of breast cancer, 
and up to 16 % of breast cancer patients suffer from T2D or impaired glucose 
tolerance. The presence of T2D, as cancer-associated comorbidity, is linked to 
poorer prognosis and survival in breast cancer post-menopausal women. 
Hyperglycemia, the most important feature of T2D, is known to affect breast 
cancer cell proliferation. Little is known about the contribution of glucose on 
breast cancer cell drug resistance. Besides acting on cancer cells, glucose may 
affect surrounding cells as well as distant cells, which in turn may interfere 
with anti-cancer drug response. Breast cancer cell growth and/or metastasis 
predominantly occur as a result of the adipocyte-rich microenvironment in 
which breast cancer cells are embedded, and reflect a role for adipocytes in 
tumour maintenance and progression. Adipocytes secrete a variety of 
adipokines and proinflammatory cytokines that may contribute to drug 
resistance. Therefore, the aim of this work is to investigate whether and how 
hyperglycaemia and adipose-derived factors may affect cellular response of 
breast cancer cell to Tamoxifen, an antagonist of the estrogen receptor (ER), 
widely used as hormonal treatment of estrogen dependent breast cancer. It was 
observed that Tamoxifen reduced MCF7 breast cancer (ER+) cell viability by 
about 50 % when cells were cultured in glucose concentration corresponding to 
normal fasting glucose levels in humans (5.5 mM; Low Glucose-LG). 
Conversely, MCF7 cell sensitivity to Tamoxifen of was 2-fold reduced when 
cells were cultured in glucose concentration resembling hyperglycaemia in 
humans (25 mM; High Glucose-HG). Interestingly, shifting MCF7 cells from 
HG to LG medium restored their drug sensitivity, whereas the shift from LG to 
HG medium reduced their responsiveness to Tamoxifen. In addition, MCF7 
cell response to Tamoxifen in HG medium was worsened in presence of 
adipocyte-released factors. Notably, RNA-Sequencing revealed that glucose 
significantly deregulated gene expression and that 70 cell cycle-related genes 
were significantly down-regulated when MCF7 cells were shifted from HG to 
LG medium. Among those genes, CTGF and CYR61 were significantly 
reduced. Consistently, experimental evidences showed that both genes were 
overexpressed in MCF7 exposed to HG concentrations or to adipocytes 
released factors in HG concentrations. On the opposite, CTGF and CYR61 gene 
expression was reduced in MCF7 cells shifted from HG to LG concentrations. 
Interestingly, CTGF, while not CYR61, gene silencing significantly increased 
Tamoxifen sensitivity of MCF7 cells in HG medium. Hence, CTGF may be a 
novel diabetes associated predictive marker for chemo-sensitivity and may 
represent a potential therapeutic target to overcome Tamoxifen resistance, 
improving survival of T2D patients affected by breast cancer.  
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1. BACKGROUND 
 
1.1 Diabetes 
    
Diabetes mellitus is a group of metabolic diseases characterized by 
hyperglycemia resulting from defects in insulin secretion, insulin action, or 
both (Aronson 2008). Several pathogenic processes are involved in the 
development of diabetes. These range from autoimmune destruction of the β-
cells of the pancreas with consequent insulin deficiency to abnormalities that 
result in resistance to insulin action. Deficient insulin action results from 
inadequate insulin secretion and/or diminished tissue responses to insulin at 
one or more points in the complex pathways of hormone action. Impairment of 
insulin secretion and defects in insulin action frequently coexist in the same 
patient, and it is often unclear which abnormality, if either alone, is the primary 
cause of the hyperglycemia. According to the classification recommended by 
the American Diabetes Association (2008), the vast majority of cases of 
diabetes fall into two broad etiopathogenetic categories. In one category, type 1 
diabetes (T1D), the cause is an absolute deficiency of insulin secretion, making 
necessary insulin injection for survival. Individuals with increased risk of 
developing this type of diabetes can often be identified by serological evidence 
of an autoimmune pathologic process occurring in the pancreatic islets and by 
genetic markers. In the much more prevalent category, type 2 diabetes (T2D), 
the cause is a combination of resistance to insulin action in peripheral tissue, an 
inadequate compensatory insulin secretory response and excessive hepatic 
glucose production (Harrison 2009). In this category, a degree of 
hyperglycemia sufficient to cause pathologic and functional changes in various 
target tissues, but without clinical symptoms, may be present for a long period 
of time before diabetes is detected. People with T2D are not dependent on 
exogenous insulin, but may require the hormone for the control of glucose 
homeostasis if this is not achieved with diet alone or with oral hypoglycaemic 
agents. The etiology of T2D is multifactorial and genetically based, but it also 
has strong behavioral components. Several risk factors have been associated 
with T2D, including family history of diabetes, overweight, unhealthy diet, 
physical inactivity, increasing age, high blood pressure, ethnicity, impaired 
glucose tolerance. In addiction, diabetic patients have an increased risk of 
developing a number of other serious health problems. The chronic 
hyperglycemia can lead to long-term damage, dysfunction, and failure of 
various organs especially the eyes, kidneys, nerves, heart, and blood vessels. 
Therefore, long-term complications of diabetes include retinopathy with 
potential loss of vision; nephropathy leading to renal failure; peripheral 
neuropathy with risk of foot ulcers, amputations, and Charcot joints; and 
autonomic neuropathy causing gastrointestinal, genitourinary, and 
cardiovascular symptoms and sexual dysfunction. Patients with diabetes have 
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also an increased incidence of atherosclerotic cardiovascular, peripheral 
arterial, and cerebrovascular disease. Hypertension and abnormalities of 
lipoprotein metabolism are often found in people with diabetes. Impairment of 
growth and susceptibility to certain infections may also accompany chronic 
hyperglycemia (IDF Diabetes ATLAS 2013). Notably, the metabolic 
dysregulation and the chronic hyperglycemia associated with diabetes can 
potentially influence cancer both directly contributing to cancer risk on a 
molecular level both indirectly affecting cancer because of associated end 
organ damage that may influence screening and treatment choices, affect 
treatment toxicities, and lead to worse outcomes (Renehan et al. 2012; 
Srokowski et al. 2009). 
 
1.2 The global implications of diabetes and cancer 
 
The past two decades have seen an explosive increase in the number of 
people diagnosed with diabetes worldwide. Pronounced changes in the human 
environment, and in human behaviour and lifestyle, have resulted in escalating 
rates of diabetes. The diabetes epidemic relates particularly to T2D, and is 
taking place both in developed and developing nations (Zimmet et al. 2001). 
The International Diabetes Federation has projected that the number of people 
with diabetes in the world will increase from 387 million in 2014 to 592 
million in 2035 (Shi and Hu 2014) (Figure 1).  
 
 
Figure 1: Prevalence of diabetes worldwide (according to the International 
Diabetes Federation, 2014) 
 
A considerable challenge to the clinical and research communities is the recent 
surge of attention to the relationship between diabetes and cancer (Johnson and 
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Pollak 2010). Diabetes and cancer have been closely linked to each other both 
epidemiologically and biologically. Convincing evidences indicate that 
diabetes – mainly T2D - is associated with increased risk for developing cancer 
(Noto et al. 2010; Wotton et al. 2011). Meta-analyses have recognized that 
T2D increases the risk of site-specific cancers of the bladder (Larsson et al. 
2006), liver (El-Serag et al. 2006), colorectum (Larsson et al. 2005), pancreas 
(Huxley et al. 2005), endometrium (Friberg et al. 2007) and breast (Larsson et 
al. 2007). Moreover, strong evidence exists about the association between T2D 
and increased risk of mortality from liver, pancreatic, ovary, colorectum, lung, 
bladder and breast cancer (Seshasai et al. 2011). In addition to an increase in 
incidence and mortality, diabetes is associated with an increase in distant 
metastases in breast cancer patient, as well as with a greater chance of 
recurrence in lung, colorectum and breast cancer patients (Gallagher et al. 
2013). Furthermore, diabetes and cancer are frequently diagnosed in the same 
individuals, supporting the hypothesis that those two diseases share common 
risk factors and pathophysiological mechanisms (Ryu et al. 2014).  
 
1.3 Proposed biological mechanisms linking diabetes and cancer 
 
In diabetic patients, cancer may be favored by: i) general mechanisms 
that promote cancer initiation or progression in any organ because they are due 
to alterations that affect all tissues, and ii) site-specific mechanisms affecting 
carcinogenesis of a particular organ (Vignieri et al. 2009). Cancer cells 
originate from noncancer cells and exhibit very distinctive metabolic 
hallmarks, such as increased proliferation, survival, invasion and migration, 
and accumulation of mutations in DNA (Hanahan and Weinberg 2011). 
Potential biological explanations for the increased cancer risk in the diabetic 
population concern various i) hormonal, ii) immunological, or iii) metabolic 
characteristics of the disease and iv) antidiabetic treatments (Figure 2).  
 
! 10!
 
 
Figure 2: Potential biological link between diabetes and cancer. Summary of 
potential biological mechanisms contributing to increased cancer risk in 
diabetic population. Adapted from García-Jiménez et al. (2013). 
 
The major hormonal disorders occurring in diabetes are hyperinsulinemia and 
the associated increase in insulin-like growth factor 1 (IGF1) signaling. 
Hyperinsulinemia develops early in T2D as a physiological response to lower 
the increasingly high glucose levels in the blood. Insulin is a growth factor that 
can have direct tumorigenic effect thought activation of insulin receptors in 
tissues. It might also exert indirect influence thought increased bioactive IGF1, 
which has potential mitogenic actions on pre-neoplastic and neoplastic cells 
(Shi and Hu 2014). IGF1 exerts its action by interacting with IGF1 receptor, 
and this interaction is regulated by a group of specific binding proteins 
(IGFBPs). IGFBPs have many functions, including the stabilization of a large 
pool of circulating IGF1 and thus the regulation of IGF1 availability for 
binding to its receptor (Clemmons 1998). Chronically increased insulin 
concentrations lead to reduce synthesis and blood levels of IGFBP that in turn 
determine an increase in free bioavailable IGF1 levels and concomitant 
changes in cellular environment that promote tumor development (Calle and 
Kaaks 2004). Moreover, increased insulin and IGF1 concentrations in diabetes 
down-regulate the production of sex hormone binding globulin (SHBG), which 
increase free estradiol and testosterone (in women). Increased concentrations 
Diabetes! Cancer!
Diabetes treatment! Other associated factors!
Inflammation! Metabolic disorders!Hormonal disorders!
Insulin/IGF1! Adipokines! TNFα! IL6! Others!
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of sex hormones, particularly estrogen, are strongly associated with 
endometrial and postmenopausal breast cancer (Seshasai et al. 2011). Diabetes 
is also characterized by unbalanced adipokines secretion (Khandekar et al. 
2011) that strongly contributes to a chronic inflammatory state (similar to 
what occurs within the tumor environment) that induces an activation of 
monocytes and macrophages increasing the circulating inflammatory cytokines 
and chemokines (McCall et al. 1992). Moreover, in a subset of tumours, cancer 
growth and/or metastasis predominantly occur as a result of the adipocyte-rich 
microenvironments in which these tumours are embedded, and reflect a role for 
adipocytes in tumour maintenance and progression. Adipocytes secrete a large 
variety of adipokines and proinflammatory cytokines that may contribute to 
cancer phenotypes (Park J et al. 2011). For instance, tumor necrosis factor 
alpha (TNFα) and interleukin 6 (IL6) have been implicated in the pathogenesis 
of ovarian, prostate, colon and breast cancer and in the development of breast 
cancer metastasis by promoting the epithelial-mesenchymal transition 
(Gallagher et al. 2013). Leptin has been shown to promote proliferation in 
colorectal, prostate and breast cancer in vitro. In addition, TNFα and IL6 as 
well as leptin, stimulate estrogen biosynthesis by the way of aromatase 
induction (García-Jiménez et al. 2013). Moreover, adipocyte released factors 
provide a chemotactic gradient that attracts monocytes which in turn secrete 
their own chemokines, attracting additional macrophages and setting up a feed-
forward inflammatory process (Osborn and Olefsky 2012). Another aspect of 
diabetes and cancer’ pathophysiology is represented by diabetes-associated 
metabolic alterations, such as increased circulating levels of lipids and sugar 
represent. Increased levels of triglycerides have been correlated to a higher risk 
of overall cancer (Borena et al. 2011) and hyperglycemia, the best 
characterized metabolic alteration in all types of diabetes, has been associated 
with a higher proportion of patients with active cancer than patients in 
remission (Feng et al. 2011). Finally, the influence of specific antidiabetic 
medications on cancer risk is an area of active research. Epidemiological 
studies have reported an increased cancer risk associated with the diabetes 
medication such as the use of insulin and insulin analogs. Conversely, 
metformin and thiazolidinediones, which decrease insulin resistance and 
indirectly circulating insulin levels, have been associated with a decreased 
incidence of and mortality owing to breast cancer (Seshasai et al. 2011). Thus, 
the exact mechanisms underlying the relationship between T2D, medications 
for T2D, and cancer have not been fully elucidated (Onitilo et al. 2012).  
 
1.3.1 Proposed mechanisms relating hyperglycaemia and cancer 
 
Plausible connections between diabetes and cancer consist of 
hyperinsulinemia, higher levels of IGF1, insulin resistance, chronic 
inflammation, oxidative stress, and hyperglycemia. All of these factors 
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potentially promote tumor progression in various ways. Nevertheless, the 
impact of insulin, IGF1, and chronic inflammation in cancer progression has 
been extensively studied (Novosyadlyy and LeRoith 2010; Djiogue et al. 2013) 
whereas effects of hyperglycemia on cancer have received less attention, 
although hyperglycemia is one of the most widely studied metabolic changes in 
diabetes (Ryu et al. 2014). Over the last century, cancer patients have been 
reported to exhibit signs of early glucose intolerance and insulin insensitivity. 
On the other hand, enhanced glucose uptake is a well-known metabolic 
hallmark of cancer cells (Hanahan and Weinberg 2011). Thus, the relationship 
between hyperglycemia and cancer appears bidirectional: cancer can cause 
hyperglycemia, and hyperglycemia may facilitate cancer appearance and 
growth. Cancer cells acquire higher proliferation rates and migratory capacity 
coupled to senescence and apoptosis bypass. Moreover, enhanced angiogenesis 
in response to factors secreted by the tumor drives the genesis of new blood 
vessels that increase the supply of energetic substrates and building blocks 
needed to make new cells (García-Jiménez et al. 2013). The anabolic urge of 
tumor cells drives them to adapt with profound metabolic changes, among 
which the most remarkable is the switch from oxidative phosphorylation 
pathways toward aerobic glycolysis, known since 1956 as the ‘Warburg effect’ 
(O'Mahony et al. 2012). The recent resurgence of interest in this hypothesis 
and cancer energetics emphasizes the dependence of many cancers on 
glycolysis for energy (Giovannucci et al., 2010), strongly supporting the 
hypothesis that glucose could be a relevant mediator in the complexity of 
interactions between diabetes and cancer. The advantage of glycolytic 
metabolism is the production of glycolytic intermediates that can be used in 
anabolic pathways that allow synthesis of proteins, nucleic acids, and lipids 
needed for proliferation. An increase in glucose availability will generally 
speed up the metabolism, including oxidative phosphorylation. Cancer cells 
increase their glucose uptake and utilization but keep a reduced oxidative 
phosphorylation rate that in turn declines ROS production leading to increased 
cell survival and contributing to sustain pluripotency (García-Jiménez et al. 
2013). Thus, hyperglycemia may improve cancer through several cooperative 
mechanisms (Figure 3), both direct and indirect, that converge on cancer 
hallmarks.  
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Figure 3: Bidirectional relationship between hyperglycaemia and cancer. 
Summary of the bidirectional relationship between hyperglycaemia and 
cancer: cancer cells ensure high glucose supply (blue arrow) enhanced 
hyperglycaemia and hyperglycaemia favours tumor growth (red arrow). 
Adapted from García-Jiménez et al. (2013). 
 
The direct effects of high glucose on tumor cells include: i) increased growth 
factor signaling and accelerated cell cycle through the change in the expression 
of critical genes such as E2F and cyclins A and E (Masur et al. 2011), ii) 
reduced ROS production to ensure survival (García-Jiménez et al. 2013), iii) up 
regulation of chemo-attractants that promote invasion and migration (Masur et 
al. 2011) and iv) modified cancer-associated signaling pathways such as WNT 
signaling (Chocarro-Calvo et al. 2013) (Figure 3). Hyperglycemia also exerts 
indirect effects favouring tumor growth at the organism level: i) increased 
circulating levels of insulin, that in turn causes the reduction of IGFBP and 
SHBG synthesis and the increase of bioavailable IGF1, free estradiol and 
testosterone, ii) reduced immune surveillance, and iii) increased circulating 
inflammatory cytokines, such as TNFα and IL6, known to cause insulin 
resistance (Makino et al. 1998) that diminishes glucose consumption (by 
noncancer cells) thus contributing to hyperglycemia. On the other hand, cancer 
supports and enhances hyperglycemia in various ways: i) the metabolic switch 
in cancer cells drives increased glycolytic flux and lactate production, ii) tumor 
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growth induces an acute inflammatory response with increased production of 
inflammatory cytokines. Both the inflammatory state and the increased 
production of lactate increase hepatic glyconeogenesis. The reduced uptake of 
glucose from the blood and the increase supply from the liver strongly 
contribute to hyperglycemia (García-Jiménez et al. 2013). 
 
1.3.2 Hyperglycaemia and breast cancer 
 
Breast cancer is the most common female malignant neoplasia with the 
highest incidence in the industrialized world (Maccio et al. 2009). A great 
number of cohort (Weiderpass et al. 1997; Wideroff et al. 1997; Michels et al. 
2003; Coughlin et al. 2004; Silvera et al. 2005) and case–control studies 
(Talamini et al. 1997; Baron et al. 2001) have reported that patients with T2D 
have an increased risk of breast cancer (Larsson et al. 2007), and up to 16 % of 
breast cancer patients suffer from T2D or impaired glucose tolerance 
(Coebergh et al. 1999; Yancik et al. 2001). A number of epidemiological 
studies have also shown a direct association between breast cancer risk and the 
consumption of sweet foods with high glycaemic index (Lubin et al. 1981; 
Landa et al. 1994; Potischman et al. 2002; Tavani et al. 2006). Of note, animal 
models of diabetes have shown an increase in susceptibility to chemically 
induced mammary tumours (Shafie and Grantham 1981). Moreover, breast 
cancer is the fifth most common cause of cancer death in women (Yi et al. 
2013). It has been provided evidence that high carbohydrate intake is 
associated with poorer survival after diagnosis for early breast cancer (Krone 
and Ely 2005). Consistently, cancer mortality is geographically correlated with 
the level of dietary sugar intake; countries with the greatest sugar intake exhibit 
the highest rates of breast cancer mortality independent of other variables 
(Carroll 1977; Hems 1978). Although breast cancer is the most common cancer 
form in women (Youlden et al. 2012), and a numbers of studies strongly 
support the association of diabetes with an higher risk and a poor prognosis in 
women with breast cancer (Zeng et al. 2010), the direct or indirect effects of 
glucose on cancer cell is relatively unexplored, and more needs to be learned 
about which signaling pathways are involved and how they are controlled (Ryu 
et al. 2014).  
 
1.4 The emerging role of tumor microenvironment  
 
Cancers are not just masses of malignant cells but complex ‘rogue’ 
organs, to which many other cells are recruited and can be corrupted by the 
transformed cells. Interactions between malignant and non-transformed cells 
create the tumor microenvironment (Balkwill et al. 2012). The bidirectional 
communication between cells and their microenvironment is critical for both 
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normal tissue homeostasis and tumor growth. In particular, interactions 
between tumor cells and the associated stroma represent a powerful 
relationship that influences disease initiation, progression and patient prognosis 
(Quail and Joyce 2013). In cancer, the coordinated intercellular interactions 
present in normal adult tissues are disrupted as the tumor acquires the capacity 
to chronically circumvent normalizing cues from the microenvironment, and in 
turn, the microenvironment evolves to accommodate the growing tumor Thus, 
the non-malignant cells of tumor microenvironment have a dynamic and often 
tumor-promoting function at all stages of carcinogenesis (Bissell and Hines 
2011). However, the complexity of the interactions between neoplastic tumor 
cells and their microenvironment has become increasingly apparent, and at the 
same time, the number of agents entering clinical trials that specifically target 
interactive pathways between neoplastic and stromal cells has increased 
(Balkwill et al. 2012). About breast, it is a very heterogeneous tissue, 
characterized by a number of different cell types. Epithelial cells make up the 
parenchyma of the tissue, forming the ducts and glands involved in milk 
production, storage, and secretion. However, a highly relevant component of 
tumor microenvironment in mammary gland is represented by adipose tissue 
(AT).  
 
1.4.1 Adipose tissue  
 
AT is a type of loose connective tissue characterized by a marked 
cellular heterogeneity. Overall, fat tissue consists of approximately one-third of 
mature adipocytes. The remaining two-thirds contains the stromal-vascular 
fraction (SVF), a combination of mesenchymal stem cells (Ad-MSCs), T 
regulatory cells, endothelial precursor cells, fibroblasts, smooth muscle cells, 
pericytes, macrophages and preadipocytes in various stages of development. 
Preadipocytes have the ability to proliferate and differentiate into mature 
adipocytes, conferring AT a constant functional plasticity, which determines its 
ability to expand throughout the entire lifespan (Moreno-Navarrete and 
Fernández-Real 2012; Niemelä 2008; Zuk et al. 2002). AT has been 
traditionally regarded as an insulating and mechanically supportive site of 
energy storage, which is mobilized for peripheral organs during times of 
increased energy demand. However, over the past decade the traditional role of 
AT has evolved to a fully functioning endocrine organ, capable of regulating 
systemic energy and metabolic homeostasis through a complex network of 
endocrine, paracrine, and autocrine signals (Nieman et al. 2013; Poulos et al. 
2010; Galic et al. 2010). Indeed, adipocytes express and secrete various factors 
known to play a role in immunological responses, vascular diseases and 
appetite regulation (Figure 4).  
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Figure 4: Adipose tissue. Schematic representation of multicellularity of 
adipose tissue and its multiple adipose-derived factors. 
 
Among adipose-derived factors, leptin is made and secreted by mature 
adipocytes, and it has various biological activities, including effects on 
appetite, food intake and body weight regulation, fertility, reproduction and 
hematopoiesis (Flier 1998; Kim and Moustaid-Moussa 2000). AT is also an 
important site for estrogen biosynthesis and steroid hormone storage. In 
addition, AT secretes a variety of peptides, cytokines and complement factors, 
which act in autocrine and paracrine manner to regulate adipocyte metabolism 
and growth, as well as endocrine signals to regulate energy homeostasis  
 
1.4.2 Adipose tissue as mediator of indirect effect of glucose on breast 
cancer 
 
Although AT is vitally important to various normal processes of the 
human body, it has also many implications for human disease states. The 
excess of adiposity characterizes obesity, one of the most challenging and 
growing health problems worldwide and considered a major risk factor for 
T2D. Of note, similarly to diabetes, obesity has been associated to some types 
of cancer, including breast (Niemelä 2008). The role of AT, and more 
specifically of adipocytes, in tumor initiation, growth, and metastasis, is a 
relatively new area of investigation. AT may contribute to tumor phenotypes 
by either acting as an energy reservoir for embedded cancer cells either 
ADIPOKINES!
COMPLEMENT FACTORS!
METABOLITIES!
OTHERS!
HORMONES!
MATRIX PROTEINS!
VASOACTIVE FACTORS!
GROWTH FACTORS!
CLASSIC CYTOKINES!
ENZYMES!
CHEMOKINES!
TRANSCRIPTION FACTORS!
! 17!
through the secretion of signaling molecules such as adipokines, 
proinflammatory cytokines, chemokines, growth factors, hormones, 
proangiogenic factors and extracellular matrix constituents (Park J et al. 2014). 
Considering that breast cancer cells grow and metastasize to a predominantly 
adipocyte-dominated host environment (Calle and Kaaks 2004), virtually all of 
the adipocyte factors may be envisioned as contributing factors for cancer 
onset and/or progression. In this regard, it has been demonstrated that 
adipocytes may integrate inputs from the metabolic environment and promote 
growth of breast cancer cells (D’Esposito V et al. 2012). Since adipocytes 
respond to energy and nutrient metabolism through a complex network of 
signals (Rajala and Scherer 2003; Frühbeck et al. 2001), they are able to 
influence the function of mammary epithelial cells contributing to the stromal-
ductal epithelial cell-cell interaction within the mammary microenvironment 
(Iyengar et al. 2003). Consequently, it can not be excluded that adipocytes may 
integrate metabolic derangements characterizing T2D, such as hyperglycaemia 
influencing on several aspects of tumorigenesis, from inducing cell 
proliferation to promoting local invasion, angiogenesis, metastasis and drug 
resistance (Figure 5).  
 
 
 
 
Figure 5: Breast cancer cells and adipose tissue inter-relations. Graphic 
representation of breast cancer cells and adipose tissue inter-relation in the 
tumour microenvironment. 
 
 
 
!
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1.5 Tamoxifen therapy in estrogen sensitive breast cancer 
 
The development of chemotherapy resistance continues to be a major 
problem in the treatment of cancer patients. It can occur prior to drug treatment 
(primary or innate resistance) or may develop over time following exposure 
(Giaccone and Pinedo 1996). Moreover, chemotherapy has a wide range of 
acute and long-term side effects that substantially affect the patient's quality of 
life (Yi et al. 2013). In women younger than 50 years with breast cancer, 
chemotherapy increases the 15-year survival rate by 10 %, whereas the 
increase is only 3 % in older women. Newer agents, whether chemotherapeutic 
or targeted, are constantly being developed. Although most anticancer 
therapies will alter tumor growth, in most cases the effect is not long lasting 
and their failure impacts the survival of breast cancer patients.  
About 70 % of breast cancers are estrogen receptor (ER)-positive and depend 
on oestrogen to grow and proliferate (Peifer and Alessi 2009). Estradiol is 
mitogenic in up to 50 % of de novo breast cancers, causing recruitment of 
quiescent cells into G1 and shortening the G1-to-S phase interval (Cariou et al. 
2000). The binding of estrogen to ERs induces conformational changes in 
protein structure that allow for receptor dimerization, interaction with co-
activator molecules, and subsequent transcriptional activation of genes directly, 
through the interaction with estrogen response elements (EREs) in gene 
promoters, or indirectly through the binding to other transcription factors such 
as AP1, SP1 or NFκB. The efficacy of the activated receptor is regulated by 
several mechanisms, and the balance of these mechanisms could determine the 
tissue-specific activity of the receptor. In addition, a range of studies revealed 
‘non-genomic’, ‘non-nuclear’ or ‘non- transcriptional’ actions of ER. Non-
transcriptional functions of ER in the cytoplasm are characterized by fast and 
transient signal outputs that could potentially lead to a convergence of 
oestrogen signalling with other cellular signalling transduction pathways 
(Shang 2006; Bartella et al. 2012). A specific antagonist to the estrogen action 
or its deprivation must be considered as the most rational therapeutic approach 
for the prevention and treatment of hormone-dependent breast cancer (Maccio 
et al. 2009). Tamoxifen is one of the most widely prescribed antiestrogen drugs 
for the treatment of ER-positive breast cancer patients (Mojarrad et al. 2010). It 
is a pro-drug - metabolized in the liver to its active metabolite, 4-hydroxy-
tamoxifen (4-OHT) - that acts as selective estrogen receptor modulator 
competitively interacting with ER. Thus, it blocks the effects of estrogen 
producing a non-functional complex that fails to stimulate transcription (Peifer 
and Alessi 2009) and lead to a G0/G1 arrest in susceptible ER-positive breast 
cancer cells (Cariou et al. 2000) (Figure 6). 
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Figure 6: Tamoxifen mechanism of action. Tamoxifen competes with 
estrogen in binding to estrogen receptor. It determines a production of a 
complex that fails to stimulate transcription and in turn induces a cell cycle 
arrest. Adapted from Johnston and Dowsett (2003). 
 
Undoubtedly, the significant reduction in breast cancer mortality during the last 
decade is thought to be attributable to the widespread use of Tamoxifen (Yi et 
al. 2013). It has been shown to greatly prolong disease-free survival and induce 
remission in more than half of all patients with ER-positive metastatic disease 
(Knowlden et al. 2003; Gutierrez et al. 2005). Unfortunately, although 70 % of 
breast cancers express ER, almost 25 % of ER-positive breast cancer patients 
do not respond to Tamoxifen (Mojarrad et al. 2010). Moreover, approximately 
one-third of early-stage breast cancer patients will become resistant to 
Tamoxifen over the 5-year treatment period, making resistance to Tamoxifen 
treatment one of the major obstacles to the successful treatment of breast 
cancer (Peifer and Alessi 2009). Thus, despite the its indisputable benefits, 
resistance to Tamoxifen is the underlying cause of treatment failure in a 
significant number of patients with breast cancer, also contributing to an 
enhanced aggressive tumor phenotype and transition toward a mesenchymal 
phenotype (Yi et al. 2013). To be able to overcome cancer chemoresistance it 
is necessary to acquire a complete understanding of the molecular processes 
that make possible this effect. In this way, several studies have already 
revealed a number of mechanisms of Tamoxifen resistance, such as increased 
metabolism of Tamoxifen, loss or alterations of ERs expression, estrogen 
hypersensitivity, altered expression of co-regulators, and microRNA 
interference. Nevertheless, a more comprehensive understanding of the 
! 20!
molecular mechanisms and pathways underlying intrinsic and acquired 
resistance to Tamoxifen is of huge clinical importance and could result in 
novel strategies to overcome Tamoxifen resistance, further improving survival 
of breast cancer patients (Peifer and Alessi 2009; Mojarrad et al. 2010; Huber-
Keener et al. 2012). 
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2. AIM OF THE STUDY 
 
 
T2D is an independent risk factor and worsen the prognosis of multiple 
types of cancer. Indeed, a number of cancers such as pancreatic, liver, breast, 
and female reproductive cancers have shown an increased prevalence and a 
higher mortality rate in diabetic patients compared to healthy subjects (Ryu et 
al. 2014). The presence of T2D, as cancer-associated comorbidity, is linked to 
poorer prognosis and survival, particularly in breast cancer post-menopausal 
women. Nowadays, breast cancer is the most common cancer type in women 
(Youlden et al. 2012). Unfortunately, the development of chemotherapy 
resistance constitutes a major problem in the treatment of this type of cancer.  
T2D is a metabolic disorder characterized by chronic hyperglycemia due to 
insulin deficiency or insulin resistance. Hyperglycaemia, is known to affect 
breast cancer cell proliferation. Little is known about the contribute of glucose 
to the progression of the malignant phenotype of breast cancer cells, and 
particularly to drug resistance. Another important determinant of the 
responsiveness of cancer cells to anti-neoplastic drugs is the tumor 
microenvironment. The common features of tumor microenvironment in 
different cancer types suggest that targeting the non-malignant cells, or the 
mediators of their communication (e.g. secreted molecules), is a promising 
avenue to treat different tumor types as it may represent a valid adjuvant 
treatment option (Balkwill et al. 2012). Adipocytes represent one of the most 
abundant cell type in breast tumor microenvironment. Over the past decade, the 
adipose tissue has been demonstrated to be an active source of endocrine and 
metabolic activity playing a more dynamic role than previously recognized in 
many physiological processes (Niemelä 2008). In this scenario, understanding 
how T2D-associated metabolic perturbations may affect cellular response to 
anti-cancer agents is of crucial importance to identify novel biomarkers and to 
tailor targeted strategies to overcome chemoresistance. The increased 
concentrations of glucose, typical of T2D patients, may either directly or 
indirectly affect cancer cell phenotypes. Indeed, besides acting on cancer cells, 
glucose may simultaneously act on surrounding and distant cells, thus 
interfering with anti-cancer drug response. Therefore, the aim of this project is 
to investigate whether and how T2D-associated metabolic perturbations (i.e. 
Hyperglycaemia) and tumor microenvironment (i.e. Adipose tissue) may affect 
cellular response to breast cancer cell sensitivity to Tamoxifen, the 
chemotherapic agent commonly used as adjuvant hormonal treatment of 
estrogen dependent breast cancer.  
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3. MATERIALS AND METHODS 
3.1 Cell Culture 
 
MCF7 human breast cancer cells (ER-positive), available in host 
laboratory, were cultured in Dulbecco’s modified Eagle’s medium (DMEM) 
supplemented with 10 % fetal bovine serum (FBS), 2 mM glutamine, 100 
units/ml penicillin and 100 units/ml streptomycin. 48 hours before the 
induction of the experiments, MCF7 cells were shifted to RPMI-1640 without 
phenol red supplemented with 10 % Charcoal Stripped (C/S) FBS, 2 mM 
glutamine, 100 units/ml penicillin and 100 units/ml streptomycin.  
Adipose derived human Mesenchymal Stem Cells (Ad-MSCs) were obtained 
by abdominal biopsy. Briefly, adipose tissue was cut in small pieces and 
treated with 1 mg/ml collagenase in DMEM and Ham’s F12 (1:1) 
supplemented with 10 % FBS, 2 mM glutamine, 100 units/ml penicillin, and 
100 µM streptavidin, for 45 minutes at 37°C. The isolated cells were filtered 
through a 250 µm nylon mesh and incubated at room temperature until to 
observe the separation of two phases: the upper phase consisting of adipocytes, 
and the lower phase containing the stromal vascular fraction (SVF). The SVF 
fraction, containing Ad-MSCs, was collected and washed twice before seeding 
in T25 Flask in culture medium DMEM-F12 (1:1) supplemented with 10 % 
FBS, glutamine and antibiotics.  
Cultures were maintained in a humidified atmosphere of 95 % air and 5 % CO2 
at 37°C. Media, sera and antibiotics for cell cultures were from Lonza (Basel, 
Switzerland). 
 
3.2 Adipocyte differentiation and Oil-Red O staining 
 
Adipocyte differentiation was achieved as described by Isakson and 
colleagues (Isakson et al. 2009). Briefly, Ad-MSCs were seeded (2x105) and 
cultured in six-well plates until confluence. Adipocyte differentiation was 
induced with a differentiation cocktail consisting of 850 nmol/l insulin, 10 
µmol/l dexamethasone, 0.5 mM isobutylmethylxanthine, 10 µM pioglitazone, 
33 µM biotin and 17 µM pantothenate in DMEM-F12 (1:1) supplemented with 
3 % FBS, 2 mM glutamine and antibiotics. After 3 days, the medium was 
changed to a medium containing only insulin and pioglitazone in DMEM-F12 
(1:1) supplemented with 10 % FBS, glutamine and antibiotics. Culture medium 
was then changed every 2 days for another 8 days up to obtain a complete 
adipocyte differentiation of Ad-MSCs. Lipid accumulation was determined by 
Oil red O staining as described by Isakson and colleagues (Isakson et al. 2009). 
Briefly, cells were fixed with 10 % formalin for 20 minutes and then stained 
with Oil red O for 60 minutes. After a careful wash of the stained cells, optical 
density for Oil red O was determined by the addiction of isopropanol to each 
! 23!
well and the incubation at room temperature for 10 minutes. Optical density 
was measured at 510 nm. The absorbance of cells that had undergone 
differentiation was then related to that of undifferentiated cells. 
 
3.3 Cell viability/sulforhodamine assay 
 
MCF7 cells (2x103) were seeded into 96-well microplates in complete 
medium. The cells were stimulated with 100 nM Estradiol (E2) and/or different 
concentrations of 4-idrossi-Tamoxifen (4-OHT) in RPMI 10 % C/S FBS 
containing 5.5 mM glucose (Low Glucose; LG) or 25 mM glucose (High 
Glucose; HG). After 4 days, cell viability was assessed by sulforhodamine 
assay (Chiba et al. 1998). Briefly, the cells were fixed with 50 % 
trichloroacetic acid for at least 2 hours at 4°C. Then, cells were washed 5 times 
with distilled and de-ionized water. After air-drying, cells were stained for 30 
minutes with 100 µl 0.4 % sulforhodamine B dissolved in 1 % acetic acid. 
Unbound dye was removed by five washes with 1 % acetic acid. After air-
drying, 10 mM Tris solution (pH 7.5) was added to dissolve the protein-bound 
dye. Cell survival was assessed by optical density determination at 510 nm 
using a microplate reader. Three replicate wells were used for each data point. 
Each experiment was performed three times. E2 (dissolved in ethanol), 4-OHT 
(dissolved in dimethyl sulfoxide) and all reagents for sulforhodamine assay 
were from Sigma-Aldrich (St. Louis, MO).  
 
3.4 Conditioned media system  
 
Ad-MSCs were differentiated in mature adipocytes as described in 
Paragraph 3.2. Differentiated Ad-MSCs were washed two times with sterile 
phosphate-buffered saline (PBS) before the incubation with serum-free RPMI 
(HG) supplemented with 0,25 % albumin bovine serum (BSA). After 8 hours, 
the conditioned medium was collected and centrifuged to remove cellular 
debris. Then, it was applied on serum-starved MCF7 cells, seeded into 96-well 
microplates (2x103), and treated with 5 µM 4-OHT and/or 100 nM E2. After 4 
days, cell viability was assessed by sulforhodamine assay (see Paragraph 3.3). 
Three replicate wells were used for each data point. Each experiment was 
performed three times. 
3.5 Co-Culture system 
 
Ad-MSCs (4x104) were seeded and differentiated (see Paragraph 3.2) 
on the bottom of a 12-transwell chamber. MCF7 cells (2x104) were seeded in 
the upper chamber of the transwell culture system and treated with 5 µM 4-
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OHT and/or 100 nM E2 in presence or absence of differentiated adipocytes. 
After 24 hours, cell viability was assessed by crystal violet. Briefly, cells were 
fixed with 11 % glutaraldehyde for 15 minutes at room temperature, washed 
three times with PBS, and stained with 0.1 % crystal violet-20 % methanol for 
20 minutes at room temperature. After three PBS washes and complete drying 
at room temperature, crystal violet was solubilized by the immersion of the 
filters in 10 % acetic acid. The concentration of the solubilized crystal violet 
was evaluated by optical density determination at 540 nm using a microplate 
reader. Each experiment was performed three times. 
 
3.6 RNA isolation and quantitative/qualitative analysis  
 
MCF7 cells (15x104) were seeded into 100 mm dishes in complete 
medium. The cells were stimulated with 100 nM E2 in RPMI 10 % C/S FBS 
LG or HG. After 4 days, total RNA was isolated from cells, using TRIzol 
solution (Life Technologies, Carlsbad, CA, USA) according to the 
manufacturer's instructions. All RNA samples were quantified by measuring 
the absorbance at 260 nm and 280 nm (NanoDrop spectrophotometer, Life 
Technologies, Carlsbad, CA, USA). Integrity of RNA samples was further 
analyzed by using the digital electrophoresis system Experion with the “RNA 
StdSens Kit” (Biorad, Hercules, CA, USA), following the manufacturer's 
instructions. Briefly, the Experion automated electrophoresis system performs 
electrophoresis of samples within a microfluidic chip. Within each chip, a 
series of microchannels connects the sample wells to a separation channel and 
buffer wells. A set of electrodes in the electrophoresis station applies a voltage 
across the microchannels, causing charged molecules in the samples to migrate 
into and through the separation channel. The run and result analysis were 
performed by the Experion software. RNA samples with a RNA Quality 
Indicator (RQI) value ≥ 9 were considered good for the further analyses 
(Figure 7). 
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Figure 7: RNA samples Experion profile. RNA samples integrity was 
evaluated based on RNA Quality Indicator (RQI) value obtained by using the 
Experion system. 
 
3.7 Preparation of paired-end cDNA libraries for RNA-Sequencing 
 
Paired-end cDNA libraries were prepared for Next Generation 
Sequencing (NGS) on the Illumina Hi-Seq 2000 platform using “TruSeq RNA 
Sample Preparation kit” (Illumina). According to manufacturer's protocol, 
oligo-dT attached magnetic beads were used to capture polyA mRNA 
molecules from 4 µg of isolated total RNA. Resulting polyA RNA was 
fragmented and reverse transcribed - using random hexamers - into first and 
second strand cDNA. The overhangs resulting from fragmentation were 
converted into blunt ends - by end repair process - before the adenylation of 3’ 
ends with a single ‘A’ nucleotide preventing the ligation between fragments. 
Subsequently, multiple indexing adapters were ligated to the ends of the 
dsDNA; a single ‘T’ nucleotide on the 3’ end of the adapters provides a 
complementary overhang for ligating to the adenylated fragments. Finally, 
enrichment of dsDNA fragments with adapter molecules on both ends was 
performed by PCR amplification using a primer cocktail annealing to the ends 
of the adapters. Yield of purified PCR products was assessed by using the 
“Qubit dsDNA HS (High Sensitivity) Assay Kit” on Qubit Fluorometer (Life 
Technologies, Carlsbad, CA, USA). For each cDNA library, size distribution 
of fragments and sample purity were evaluated by using “Experion DNA 1K 
Analysis Kit” (Biorad, Hercules, CA, USA) and the Experion system. The 
electrophoresis run and the subsequent data analysis were carried out using the 
Experion software. In particular, peak median values were determined at 
approximately 200-260 bp. Sample concentration and peak median values were 
used to calculate molar concentration of cDNA libraries. Given that for each 
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sample a different index was used, one pool of cDNA libraries was attached on 
the flow cell (a multi-lane glass-based substrate) in the cluster station and 
amplified to form clusters for sequencing. Subsequently, one strand was 
selectively linearized and blocked to prevent the sequencing of non-specific 
sites. After strand denaturation and hybridization of the first sequencing 
primer, the flow cell was mounted on the Illumina Hi-Seq 2000 platform and 
subjected to 36 cycles of “sequencing-by-synthesis”. Subsequently, the 
extended sequencing primer was removed and, after strand linearization, 
blocking and denaturation, the second primer was hybridized. Thus, further 36 
cycles of sequencing were performed, reaching a read length of 2 x 70 
nucleotides. Hi-Seq data collection was carried out by line scanning mode and 
four camera system that detects the intensities of all four bases simultaneously. 
The sequencing run in paired-end mode of the samples required about one 
week (Figure 8). 
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Figure 8: RNA-Sequencing. The polyadenilated fractions of total RNA 
isolated from MCF7-HG and MCF7-HG→LG have been used to create cDNA 
libraries (a). For each cDNA library, size distribution of fragments and sample 
purity were evaluated by using the Experion system (b). cDNA libraries were 
used for “cluster generation” and subsequent sequencing at high depth of 
coverage on the Illumina HiSeq 2000 (c). 
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3.8 RNA-Seq data processing, visualization and gene expression analysis 
 
Quality of sequenced reads was assessed using the quality control tool 
“FastQC” (http://www.bioinformatics.babraham.ac.uk/projects/fastqc/). 
Subsequently, the TopHat software (version 2.0.10) was used to map the reads 
against the reference human genome (hg19, Genome Reference Consortium 
GRCh37) and the RefSeq human transcripts annotation, with default 
parameters. RefSeq track was downloaded from Table Browser of UCSC 
Genome Browser (http://genome.ucsc.edu) in GTF format, selecting protein 
coding gene annotation. Only uniquely mapped reads (about 90 % of 
sequenced reads) were used for further analyses. SAMTools and BEDTools 
were used to convert file formats (.sam/.bam/.bed). Precisely, coverage files in 
bedgraph format were produced using BED Tools. Visual inspection of filtered 
reads and coverage files on UCSC was used to assess the overall quality of the 
RNA-Seq experiment and to inspect gene-specific features. Quantification of 
gene expression, and analysis of differential expression were carried out using 
the “RNASeqGUI” (http://bioinfo.na.iac.cnr.it/RNASeqGUI; Russo and 
Angelini, 2014), an open source graphical user interface for the differentially 
expression analysis of RNA-Seq data. The analysis was carried out in five 
steps: (1) the exploration of the bam files, (2) the counting process of the 
mapped reads against the gene annotation file, (3) the exploration of count-data 
and on pre-processing of the data, including the normalization procedures, (4) 
the identification of the differentially expressed genes by “NOISeq” method 
and (5) the inspection of the results and the quantitative comparison among 
them. In particular, by using the R Bioconductor package NOISeq (Tarazona et 
al. 2011), it was exploited the non-parametric approach NOISeq-real, 
optimized for technical replicates. Low count features were filtered has by 
Wilcoxon test. For each gene a “probability of differential expression” (Pr) was 
attributed. Genes with Pr≥0.7 were considered as differentially expressed 
(DEGs) (Figure 9).  
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Figure 9: Schematic workflow of the RNA-Seq computational analysis. In the 
left panel, the reads' mapping schema is shown. After quality filtering, visual 
inspection on a genomic browser (e.g. UCSC Genome Browser) of RNA-Seq 
data is used to qualitatively evaluate the bona fide of the experiment (center 
panel). Example of a plot showing differentially expressed genes of a typical 
RNA-Seq experiment.  
 
Finally, pathway and gene ontology analysis was performed using the “Protein 
ANalysis THrough Evolutionary Relationships” (PANTHER) 
(http://www.pantherdb.org).   
 
3.9 RT-PCR and Quantitative Real-Time PCR assays  
 
Previously isolated RNA samples (1 µg), were reverse transcribed using 
SuperScript II Reverse Transcriptase with oligo dT primers (Invitrogen, 
Carlsbad, CA, USA) according to the manufacturer's instructions. To check the 
amplifiable template RNA/cDNA, RT-PCR amplification of a housekeeping 
gene (hypoxanthine guanine phosphoribosyl transferase; HPRT) was 
performed in all samples. For each data point, as negative control, a sample 
without reverse transcriptase was amplified under the same conditions than the 
reverse transcribed RNA. Each amplification reaction was set-up using 
AmpliTaq Gold (Life Technologies, Carlsbad, CA, USA) and specific primer 
pairs, designed using Oligo 4.0 and listed in Table 1.  
 
Table 1: Primer pairs used in RT-PCR and qReal-Time PCR analysis  
 
GENE Primer Forward T
m 
F Primer Reverse T
m 
R Product 
Size 
CYR61 TGCGGCTGCTGTAAGGTC 58°C ACAGAGGAATGCAGCCCAC 60°C 253 bp 
EGR3 AAGCTGCCGGTGACCATGA 60°C GTAGGTCACGGTCTTGTTGC 62°C 234 bp 
EGR1 CAGCAGCAGCACCTTCAAC 60°C GTGGGTGCCGCTGAGTAAA 60°C 381 bp 
JUN TCCAGCAACGGGCACATCA 60°C GTTGCTGAGGTTTGCGTAGA 60°C 279 bp 
FOS ACTCACCCGCAGACTCCTT 60°C GGGCTCTGGTCTGCGATG 60°C 186 bp 
EGR2 CCCCTTTGACCAGATGAAC 58°C TGGATGAGGCTGTGGTTGA 58°C 266 bp 
ATF3 CATCACAAAAGCCGAGGTAG 60°C CACTCCGTCTTCTCCTTCTT 60°C 114 bp 
E2F2 CCTCTCCCCTCTACCTCCA 62°C CAGGTCCCCAAGGTCGTAG 62°C 354 bp 
FOSB TCCTTCGGCAGTCCACCCA 62°C TGGAAGAGATGAGGGTGGG 60°C 145 bp 
E2F7 CAGGTCCCCAAGGTCGTAG 60°C GGGACAGTCGGGTTCAGAG 62°C 303 bp 
CTGF GGGAAATGCTGCGAGGAGT 58°C GATAGGCTTGGAGATTTTGG 58°C 237 bp 
 
 
PCR products were analyzed by electrophoresis on agarose gel and Sanger 
sequencing. Then, cDNAs obtained were used as template for Quantitive Real-
Time PCRs (qReal-Time PCR) performed by iTaq Universal SYBR Green 
Supermix (Biorad, Hercules, CA, USA), according to the manufacturer’s 
instructions for the CFX Connect Real Time system (Biorad, Hercules, CA, 
USA). Relative quantification of gene expression was measured by using 
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2−ΔΔCt method. Expression levels were normalized for the reference sample 
(MCF7-HG) using HPRT as housekeeping gene. Each assay was performed in 
triplicate in all samples. 
3.10 Gene silencing/RNA interference 
 
MCF7 cells (2x104) were seeded in 24-well microplates. The following 
day, the cells at about 70 % confluence were transfected with Dicer-substrate 
RNAs (DsiRNAs, IDT Coralville, Iowa, USA) recognizing CTGF or CYR61 
genes. For each gene, three different DsiRNAs were tested. In detail, to 
optimize transfection conditions, the cells were transfected with DsiRNA 
control or each DsiRNA, in different conditions (doses and times). The 
transfection was carried out by Lipofectamine 3000 (Life Technologies, 
Carlsbad, CA, USA), in RPMI without antibiotics and serum, according to 
manufacturer's instructions. After 6 hours, the cells were feed with RPMI 10 % 
C/S FBS, removing the transfection medium. Transfected cells were stimulated 
with 100 nM E2 and/or 4-OHT, and incubated for further 24 hours. Therefore 
(after 30 hours of transfection) sulforhodamine assay was performed to assess 
cell viability (see Paragraph 3.3). Simultaneously, gene silencing was checked 
analyzing the expression of CTGF or CYR61 genes by qReal-Time PCR (see 
Paragraphs 3.9) using as reference sample the cells transfected with DsiRNA 
control. Each experiment was performed three times. 
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4. RESULTS 
 
4.1 Glucose directly modifies MCF7 breast cancer cell responsiveness to 4-
OHT. 
   
To investigate the effect of glucose on MCF7 response to 4-OHT 
treatment, the cells have been cultured in 5.5 mM glucose (MCF7-LG) - a 
concentration corresponding to normal fasting glucose levels in humans - or in 
25 mM glucose (MCF7-HG) - corresponding to the regular culture condition 
for this cell line, but resembling hyperglycaemia in humans – for one month. 
MCF7-HG and MCF7-LG have been treated with 100 nM E2 and raising 
concentrations of 4-OHT (100 nM, 1 µM and 5 µM) in RPMI 10 % C/S FBS 
for 4 days. Next, cell viability has been assessed by sulforhodamine assay (see 
Paragraph 3.2.). As control, MCF7 cells have been incubated with RPMI 10 % 
C/S FBS (negative control) or treated with E2 alone (positive control). As 
expected, E2 was able to increase cell viability of MCF7 cells both in HG and 
in LG medium (data not shown). Interestingly, 100 nM and 1 µM 4-OHT 
treatment significantly reduced MCF7 viability in LG medium of about 25 %, 
whereas it did not determine the same effect on cells grown in HG medium. 
The increase of 4-OHT concentration (5 µM) did not induce a further reduction 
of MCF7-LG viability whereas it significantly reduced of about 20 % the 
number of viable MCF7 cells in HG medium. These results indicate that 
glucose concentration modifies MCF7 breast cancer cells' sensitivity to 4-OHT 
(Figure 10). 
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Figure 10: Effect of glucose concentration on MCF7 cells' responsiveness to 
4-OHT treatment. MCF7-HG and MCF7-LG cells have been cultured in RPMI 
10 % C/S FBS red phenol free for 48 hours before treatment with 100 nM, 1 
µM or 5 µM 4-OHT in presence of 100 nM E2. After 4 days cell viability has 
been analyzed by sulforhodamine assay. The results have been reported as 
percentage of viable cells compared to cells treated with E2 alone, considered 
as 100 % viable cells. * p < 0.05, ** p < 0.001 denote statistically significant 
values compared to positive control; # p < 0.05 indicates statistically 
significant value compared to MCF7-HG. 
 
Subsequently, to evaluate the effect of increasing glucose concentration on 4-
OHT responsiveness, MCF7-LG cells have been shifted from 5.5 mM to 25 
mM glucose concentration (MCF7-LG→HG) and treated with 100 nM 4-OHT 
for 4 days. As previously reported (Figure 10), the treatment with 100 nM 4-
OHT was able to reduce of about 25 % cell viability of MCF7-LG. 
Interestingly, 4-OHT treatment did not affect cell viability of MCF7 cells 
shifted to higher glucose concentrations (MCF7-LG→HG), indicating that 
increasing glucose concentration impairs cell responsiveness to 4-OHT (Figure 
11).  
 
 
 
FIGURE 11: Effect of increasing glucose concentration on MCF7 cells' 
responsiveness to 4-OHT. MCF7-LG cells have been cultured in RPMI 10 % 
C/S FBS red phenol free for 48 hours. They have been shifted in HG medium 
(MCF7-LG→HG) when treated with 100nM 4-OHT in presence of 100 nM E2. 
After 4 days, cell viability has been assessed by sulforhodamine assay. The 
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results have been reported as percentage of viable cells compared with cells 
treated with E2 alone, considered as 100 % viable cells. Asterisks denote 
statistically significant values (* p < 0.05; ** p < 0.001).  
 
Similarly, to evaluate the response of MCF7-HG to 4-OHT in presence of 
reduced glucose concentrations, cells have been shifted from 25mM to 5.5mM 
glucose (MCF7-HG→LG) and treated with 5µM 4-OHT. As previously shown 
(Figure 10), the treatment with 5µM 4-OHT reduced cell viability of MCF7-
HG of about 20 %. Of note, 4-OHT treatment significantly reduced the 
percentage of viable MCF7-HG cells - shifted to LG - of about 50 %. These 
data indicate that reducing glucose concentration significantly ameliorates 
MCF7-HG sensitivity to 4-OHT (Figure 12). 
 
 
 
FIGURE 12: Effect of reducing glucose concentration on MCF7 cells' 
responsiveness to 4-OHT. MCF7-HG cells have been cultured in RPMI 10 % 
C/S FBS red phenol free for 48 hours. Then, they have been shifted in LG 
medium (MCF7-HG→LG) when treated with 5 µM 4-OHT in presence of 100 
nM E2. After 4 days, cell viability has been assessed by sulforhodamine assay. 
The results have been reported as percentage of viable cells compared with 
cells treated with E2 alone, considered as 100 % viable cells. Asterisks denote 
statistically significant values (* p < 0.05; ** p < 0.001).  
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4.2 Adipocyte released factors impairs MCF7 breast cancer cell 
responsiveness to 4-OHT. 
 
It has been demonstrated that glucose enhances the ability of adipocytes 
to produce factors involved in the control of cancer cell phenotypes 
(D’Esposito et al. 2012). Therefore, to investigate whether adipose-derived 
factors may affect MCF7 response to 4-OHT treatment in HG medium, Ad-
MSC cells, an established model of differentiating adipocyte, have been 
isolated from adipose tissue (see Paragraph 3.1) and differentiated in mature 
adipocytes (see Paragraph 3.2) (Figure 13). 
 
 
FIGURE 13: Adipocyte differentiation of Ad-MSCs. Ad-MSCs (a) have been 
cultured in DMEM-F12 (1:1) 10 % FBS until confluence. Adipocyte 
differentiation has been inducted with a differentiation cocktail consisting of 
850 nM insulin, 10 µmol/l dexamethasone, 0.5 mM isobutylmethylxanthine, 10 
µM pioglitazone, 33 µM biotin and 17 µM pantothenate in DMEM-F12 (1:1) 3 
% FBS. After 3 days (b), the medium was changed to a medium containing only 
insulin and pioglitazone in DMEM-F12 (1:1) supplemented with 10 % FBS, 
glutamine and antibiotics. Culture medium was then changed every 2 days for 
another 8 days up to obtain a complete adipocyte differentiation of hMSCs (c). 
Lipid accumulation was determined by Oil red O staining (d). 
d!c!
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Conditioned media from differentiated adipocytes (hAdipo-CM) have been 
applied onto serum-starved MCF7-HG cells during the treatment with 5µM 4-
OHT. After 4 days, cell viability has been assessed by sulforhodamine assay 
(see Paragraph 3.3). As described in Paragraph 3.4, hAdipo-CM have been 
collected by using RPMI (HG) 0,25 % BSA without serum. Therefore, and 
differently to the experiments reported in Paragraph 4.1, MCF7 cells have been 
incubated with serum-free RPMI 0,25 % BSA as negative control. As positive 
control the cells have been treated with E2. As expected, E2 increased cell 
viability of MCF7 cells both in presence and in absence of hAdipo-CM (Figure 
14). As shown, conditioned media from Ad-MSCs were able to significantly 
increase MCF7 cell viability (compared to negative control), reaching the 
levels observed for cells treated with E2 (positive control). Interestingly, 4-
OHT treatment reduced the percentage of viable MCF7-HG cells of about 50 
% whereas, in presence of hAdipo-CM, the effect of 4-OHT is reduced to 
about 30 %, suggesting that adipocyte released factors interferes with MCF7 
responsiveness to 4-OHT (Figure 14). 
 
 
 
 
FIGURE 14: Effect of adipocyte conditioned media on MCF7 cells' 
responsiveness to 4-OHT. MCF7-HG cells have been cultured in RPMI 10 % 
C/S FBS red phenol free for 48h. Then, they have been incubated with RPMI 
0,25 % BSA (RPMI-BSA) or adipocyte conditioned medium (hADIPO-CM) 
when treated with 5 µM 4-OHT in presence of 100 nM E2. After 4 days, cell 
viability has been assessed by sulforhodamine assay. The results have been 
reported as percentage of viable cells compared with cells treated with E2 
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alone, considered as 100 % viable cells. Asterisks denote statistically 
significant values (* p < 0.05; ** p < 0.001). 
 
Simultaneously, MCF7 cells have been co-coltured with human adipocytes 
differentiated in the lower chambers of a transwell system (see Paragraph 3.5) 
and treated with 5 µM 4-OHT in serum free RPMI 0,25 % BSA. After 24 
hours, cell viability has been assessed by crystal violet (see Paragraph 3.5). 
Similarly to the experiments performed by using hAdipo-CM, MCF7 cells 
have been incubated with RPMI 0,25 % BSA without serum as negative 
control, or treated with E2 as positive control. As previously observed, E2 was 
able to increase cell viability of MCF7 cells both in presence and in absence of 
mature adipocytes (Figure 15). As reported, MCF7 cell viability was 
significantly increased in presence of mature adipocytes (compared to negative 
control), reaching similar levels to those observed for cells treated with E2 
(positive control). Interestingly, 4-OHT treatment reduced the percentage of 
viable MCF7-HG cells of about 40 % whereas, in presence of mature 
adipocytes, the effect of 4-OHT was reduced to 20 % (Figure 15).  
 
 
 
 
FIGURE 15: Effect of adipocyte on MCF7 cells' responsiveness to 4-OHT. 
MCF7-HG cells have been cultured in RPMI 10 % C/S FBS red phenol free for 
48 hours. Then, they have been seeded in the upper chambers of a transwell 
system in RPMI 0,25 % BSA (RPMI-BSA). Then, treated with E2 100 nM 
and/or 5 µM 4-OHT in presence or absence of differentiated adipocytes. After 
24 hours, cell viability has been assessed by crystal violet. The results have 
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been reported as percentage of viable cells compared with cells treated with E2 
alone, considered as 100 % viable cells. Asterisks denote statistically 
significant values (* p < 0.05; ** p < 0.001). 
 
Taken together - data obtained by both conditioned media and co-colture 
approaches - strongly support the hypothesis that adipocytes' released factors 
reduce MCF7 cells responsiveness to 4-OHT. 
 
4.3 Glucose modifies the transcriptome of MCF7 breast cancer cells  
 
Since it was observed that MCF7-HG displayed the worst sensitivity to 
4-OHT, while the shifting in LG ameliorated their drug sensitivity (see 
Paragraph 4.1), it has been chosen to investigate whether glucose may induce 
changes in the expression profile of MCF7. Thus, RNA-Sequencing on a Next 
Generation Sequencing (NGS) platform has been performed to explore the 
entire transcriptome of MCF7-HG and MCF7-HG→LG. RNA-Sequencing 
generated more than 80 million of paired-end reads per sample. The 
computational analysis of RNA-Seq datasets (see Paragraph 3.8) revealed that 
494 genes were differentially expressed (DEGs) between the analyzed 
conditions (Figure 16).  
 
 
 
FIGURE 16: MA plot of expressed genes. MA plot (M means log ratios and A 
mean average) showing expressed genes (black dots) and differentially 
expressed genes (red dots). On y axis are reported the normalized expression 
values indicated as log differences per gene (logHG-logHGLG). On x axis 
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are reported the normalized expression values as log sum per gene 
(logHG+logHGLG). 
 
In detail, 310 genes were up-regulated and 184 genes were down-regulated 
(about 60 % and 40 %, respectively) in MCF7 shifted in LG compared to 
MCF7-HG. Thus, the reliability of the RNA-Seq experiment was assessed 
through the validation - by qReal-Time PCR - of randomly selected genes 
(both not expressed and not differentially expressed; data not shown). Then, 
functional enrichment analysis performed on DEGs has been carried out using 
the “Protein ANalysis THrough Evolutionary Relationships” (PANTHER) 
(http://www.pantherdb.org). This analysis revealed that the most represented 
pathway was “cell cycle” (70/494 DEGs; FDR < 0.05) (Figure 17). 
 
  
 
FIGURE 17: Identification of DEGs. RNA-Sequencing data analysis revealed 
that 184 genes were up-regulated and 310 were down-regulated in MCF7-
HG→LG compared to MCF7-HG. Pathway enrichment on DEGs has been 
performed by “Protein ANalysis THrough Evolutionary Relationships” 
(http://www.pantherdb.org) (Bonferroni correction for multiple testing). 
 
A more stringent dataset of DEGs was selected by using a posterior probability 
threshold of 80 % (Pr value ≥ 0.8) (Figure 18a). Using this criterion, 11 out of 
70 "cell cycle" genes were selected for further validations. In detail, all these 
genes were down-regulated when MCF7-HG were shifted in low glucose 
medium (Figure 18b). Therefore, based on RNA-Seq data analysis, the 
expression levels of 11 "cell cycle" genes were measured by qReal-Time PCR 
(as described in Paragraph 3.9). Remarkably, the extent of deregulation for 
these genes was also confirmed in two independent experiments. These data 
(Figure 18c) confirmed the previous observations and RNA-seq analysis, 
except for 2 out of 11 genes selected, and indicated that glucose regulates the 
expression of at least 9 "cell cycle" genes in MCF7-HG cells. Among them, 7 
encoded transcription factors, such as those belonging to the EGR family, 
whereas two (CTGF and CYR61) belong to the same growth factor family 
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(CCN family of immediate-early genes). The latter two genes were selected for 
further investigations, in order to prove their possible role in MCF7 cells 
responsiveness to 4-OHT. 
 
 
FIGURE 18: DEGs analysis and validation. Venn diagram of DEGs showing 
the selection of DEGs involved in cell cycle with higher statistic probability of 
differential expression (Pr ≥ 0,8) (a). Heatmap showing 11 out of 70 cell cycle 
DEGs selected (b). Experimental validation by qReal-Time PCR has been 
performed using the expression of the housekeeping HPRT gene as internal 
control. Data have been reported as mean values and results analyzed by 
paired Student’s t test. Asterisks denote statistically significant values (* p < 
0.05; ** p < 0.001) (c).  
 
a!
494 DEGs!
9!17!
0!11!
175!282!
59!
b!
MCF7-HG!MCF7-HG!LG!
CYR61!
!
EGR3!
!
EGR1!
!
JUN!
!
FOS!
!
EGR2!
!
ATF3!
!
E2F2!
!
FOSB!
!
E2F7!
!
CTGF!
Color 
Key!
Value!
100! 200! 300! 400!
0!
0,2!
0,4!
0,6!
0,8!
1!
1,2!
1,4!
1,6!
1,8!
2!
CYR61!EGR3! EGR1! JUN! FOS! EGR2! ATF3! E2F2! FOSB! E2F7! CTGF!
Colonna2!
Colonna1!
Re
lat
ive
 E
xp
re
ss
ion
 (A
U)
!
*
*
*
*
*
**
*
*
c!
MCF7-HG!LG!
MCF7-HG!
! 40!
4.4 Human adipocyte conditioned medium induces CTGF gene expression 
in MCF7 cells 
 
It has been demonstrated, by using either conditioned media either co-
colture system, that adipose-derived factors impair MCF7 cell responsiveness 
to 4-OHT in HG medium (Paragraph 4.2). In order to investigate whether 
adipocyte released factors in HG medium may affect the expression of CTGF 
and CYR61 genes, conditioned media obtained from differentiated Ad-MSCs 
have been collected (see Paragraph 3.4) and applied onto MCF7-HG for 4 days 
in presence of E2. As control, MCF7 cells have been treated with E2 in serum-
free RPMI 0,25 % BSA. CTGF and CYR61 gene expression has been evaluated 
by qReal-Time PCR. Interestingly, hAdipo-CM significantly increases the 
expression of both CTGF and CYR61 gene (Figure 19), indicating that 
adipocyte released factors in HG medium induce expression changes of CTGF 
and CYR61 genes in MCF7 cells. 
 
 
 
FIGURE 19: CTGF and CYR61 gene expression in MCF7 exposed to 
hAdipo-CM. MCF7-HG cells have been cultured in RPMI 10 % C/S FBS red 
phenol free for 48 hours. Then, they have been incubated with RPMI 0,25 % 
BSA (RPMI-BSA) or adipocyte conditioned medium (hADIPO-CM) when 
treated 100 nM E2. After 4 days, CTGF and CYR61 gene expression has been 
evaluated by qReal-Time PCR. The expression of the housekeeping HPRT gene 
has been used as internal control. Asterisks denote statistically significant 
values (** p < 0.001). 
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4.5 CTGF silencing increases MCF7 responsiveness to 4-OHT treatment  
 
Since glucose and adipocyte-released factors reduced MCF7 sensitivity 
to Tamoxifen and modify different genes in cancer cells, among which CTGF 
and CYR61, we wondered whether these genes might be involved in drug 
responsiveness. Therefore, MCF7-HG cells were transfected with three 
different anti-CTGF or anti-CYR61 DsiRNAs to setup the correct experimental 
conditions to induce gene silencing. The cells were transfected with 10 nM of 
each DsiRNA. Gene silencing was evaluated by qReal-Time PCR (see 
Paragraph 3.9). As shown in Figure 20a, both DsiRNA 2 and DsiRNA 3 
induced CTGF gene silencing of about 60 % upon 48 hours transfection. 
DsiRNA 2 was able to silence CTGF gene already after 24 hours of 
transfection (Figure 20b). 
 
 
FIGURE 20: DsiRNA anti-CTGF selection. MCF7-HG cells have been 
transfected with 10 nM of each DsiRNA recognizing CTGF gene, in RPMI 
without serum and antibiotics. After 6 hours, the transfection medium has been 
removed and replaced with RPMI 10 % C/S FBS red phenol free. After 48 
hours and 24 hours gene silencing has been evaluated by qReal-Time PCR. 
The expression of the housekeeping HPRT gene has been used as internal 
control.  
 
Both 5 nM and 10 nM DsiRNA anti-CYR61 displayed a toxic effect on MCF7 
cells (data not shown). Thus, the transfection was performed with 1 nM 
DsiRNA. As shown in Figure 21, either upon 48 hours (a) and 24 hours (b) of 
transfection, only DsiRNA 3 was able to induce a marked reduction (about 50 
%) of CYR61 expression. 
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FIGURE 21: DsiRNA anti-CYR61 selection. MCF7-HG cells have been 
transfected with 1 nM of each DsiRNA recognizing CYR61 gene, in RPMI 
without serum and antibiotics. After 6 hours, the transfection medium has been 
removed and replaced with RPMI 10 % C/S FBS red phenol free. After 48 
hours and 24 hours gene silencing has been evaluated by qReal-Time PCR. 
The expression of the housekeeping HPRT gene has been used as internal 
control.  
 
Therefore, in order to investigate the role of CTGF and CYR61 genes on 
MCF7-HG responsiveness to 4-OHT, the cells have been transfected with 
DsiRNA anti-CTGF 2 or DsiRNA anti-CYR61 3. As control, MCF7 cells have 
been transfected with DsiRNA control. After 6 hours, the cells have been 
treated with 5 µM 4-OHT in presence of E2. As positive control, the cells have 
been treated with E2. After 24 hours, cell viability has been assessed by 
sulforhodamine assay (Paragraph 3.3). Of note, CTGF gene silencing induced a 
significant reduction of about 40 % of viable MCF7 upon treatment with 4-
OHT compared to cells transfected with DsiRNA control – resembling the 
effect of glucose concentration reduction (Figure 22). On the opposite, CYR61 
gene silencing did not affect the response of MCF7-HG to 4-OHT treatment 
(Figure 22). 
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FIGURE 22: Effect of CTGF and CYR61 silencing on MCF7-HG cells’ 
responsiveness to Tamoxifen. MCF7-HG cells have been transfected with 10 
nM DsiRNA recognizing CTGF gene or 1 nM DsiRNA recognizing CYR61 in 
RPMI without serum and antibiotics. After 6 hours, the transfection medium 
has been removed and replaced with RPMI 10 % C/S FBS red phenol free. The 
cells have been treated with 5 µM 4-OHT in presence of 100 nM E2. After 24 
hours, cell viability has been assessed by sulforhodamine assay. The results 
have been reported as percentage of viable cells compared with cells treated 
with E2 alone, considered as 100 % viable cells. Asterisks denote statistically 
significant values (* p < 0.05).  
 
In parallel, mRNA levels of the other DEGs genes obtained by RNA-Seq 
experiment have been measured in MCF7 cells transfected with DsiRNA anti-
CTGF gene. Interestingly, the expression of these genes did not change after 
CTGF silencing in MCF7-HG cells (data not shown) suggesting that the effect 
on 4-OHT responsiveness is largely due to the silencing of CTGF gene. 
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5. DISCUSSION 
 
Chronic hyperglycaemia is the most important metabolic dysregulation 
associated with diabetes and contributes to long-term complications of diabetes 
such as nephropathy, retinopathy and neuropathy. Convincing evidence 
indicates that diabetes is also associated with increased incidence and mortality 
related to several type of cancer, including breast cancer. Although a number 
of studies strongly support the association of diabetes with a higher risk and a 
poor prognosis in women with breast cancer (Zeng et al. 2010), the effects of 
glucose on cancer cell phenothype, and in particular on drug response, still 
remains to be determined. Besides acting on cancer cells, glucose may well 
affect surrounding cells as well as distant cells, which in turn may interfere 
with cancer phenotype. Breast cancer cells grow and metastasize to a 
predominantly adipocyte-dominated host environment (Calle and Kaaks 2004). 
Adipocytes may integrate metabolic derangements that are typical of T2D, 
such as hyperglycaemia, and may drive an indirect influence on several aspects 
of tumorigenesis. Indeed, adipocyte-released factors can induce cell 
proliferation, promote local invasion, angiogenesis, metastasis and drug 
resistance. Of note, despite the proven survival benefit of systemic adjuvant 
chemotheraphy in patients with breast cancer, a significant number of them 
still develops metastatic disease and responds only transiently to conventional 
treatment. The significant reduction of the mortality due to breast cancer 
during the last decade is thought to be attributable to the widespread use of 
Tamoxifen (Yi et al. 2013). It has been shown to greatly prolong disease-free 
survival and induce remission in more than half of all patients with estrogen 
dependent metastatic disease (Knowlden et al. 2003; Gutierrez et al. 2005). 
Unfortunately, despite the its indisputable benefits, resistance to Tamoxifen is 
the underlying cause of treatment failure in a significant number of patients 
with breast cancer, also contributing to an enhanced aggressive tumor 
phenotype and transition toward a mesenchymal phenotype (Yi et al. 2013). To 
be able to overcome cancer chemoresistance, a more comprehensive 
understanding of the molecular mechanisms and pathways underlying intrinsic 
and acquired resistance to Tamoxifen is of huge clinical importance. In this 
PhD thesis, it has first been investigated the effect of glucose on breast cancer 
cell response to Tamoxifen treatment. I have shown that cells treated in a 
glucose concentration resembling hyperglycaemia in humans are less sensitive 
to Tamoxifen compared to cells grown in a concentration corresponding to 
normal fasting glucose levels in humans. Thus, it is necessary to use a higher 
concentration of drug to reduce the viability of cells growing in a high-sugar 
environment. Interestingly, the reduction of glucose concentration significantly 
ameliorates breast cancer cell sensitivity to Tamoxifen. Therefore, I 
demonstrated that glucose directly affect breast cancer cell response to 
Tamoxifen treatment. To better understand the effect of glucose on breast 
cancer cells, I investigated whether reduced glucose levels may induce 
significant changes in the expression profile of breast cancer cells, potentially 
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explaining their increased sensitivity to Tamoxifen treatment. Thus, using 
RNA-Sequencing on a Next Generation Sequencing platform I was able to 
investigate the entire cell transcriptome of these cells under different glucose 
concentrations. In particular, as describe in the Results, the reduction of 
glucose levels determines to a statistically significant down-regulation of 
several genes involved in cell cycle. Among them, some encode transcription 
factors, including those belonging to the EGR family, and two- CTGF and 
CYR61 - belonging to the “CCN family of immediate-early genes”. CCN 
proteins are known to regulate adhesion, apoptosis, extracellular matrix 
production, migration, proliferation, differentiation, survival and gene 
expression (Brigstock 2003). CYR61 gene encodes a known pro-angiogenic 
factor named cysteine-rich 61. It is overexpressed in invasive and metastatic 
human breast cancer cells and tumor biopsies and is able to promote 
invasiveness in vitro and tumorigenesis in vivo (Tsai et al. 2002a; Tsai et al. 
2002b). CTGF gene encodes connective tissue growth factor. Among its 
various functions, it is involved in tumor development and progression (Shi-
Wen et al. 2008). Consistently with its induction by estrogen, CTGF 
expression is high in different cancers including steroid-dependent breast 
tumors (Xie et al. 2001; Brigstock 2003). Particularly, CTGF enhances 
clonogenic ability, cell viability and migration in breast cancer cells (Chien et 
al. 2011). Since a previous study showed that glucose enhance the ability of 
adipocytes to produce factors involved in the control of breast cancer cell 
phenotype (D’Esposito et al. 2012), I hypothesized that adipocytes could 
integrate metabolic input (i.e. hyperglycaemia) and in turn affect drug 
response. Thus, I investigated the effect of adipocytes released factors in high 
glucose concentration on breast cancer cell response to Tamoxifen. In the 
present thesis, I have shown that adipocyte-released factors reduce breast 
cancer cell responsiveness to Tamoxifen, indicating that the tumor 
microenvironment, and in particular adipocytes integrate metabolic input and 
interfere with cancer cell drug response. Starting from RNA-Seq data, I 
investigated the role of CTGF and CYR61 in Tamoxifen response, evaluating 
their expression in breast cancer cells exposed to adipocytes' released factors. 
Consistently, I found that these factors induce a significantly over-expression 
of CTGF and CYR61 genes in breast cancer cells, that in turn may explain their 
reduced sensibility to Tamoxifen. Given previous considerations and in line 
with obtained data, I hypothesized that CTGF and CYR61 genes might exert a 
possible role in breast cancer cell responsiveness to Tamoxifen. Accordingly, 
CTGF gene silencing induces a significant increase in Tamoxifen sensitivity in 
breast cancer cell grown in high glucose medium. The cells reach a drug 
sensitivity similar to those obtained for cells cultured in lower glucose 
concentrations. It strongly suggests that the effect of glucose concentration on 
breast cancer cells’ sensitivity to Tamoxifen is altered by CTGF gene. In 
particular, based on these data, I hypothesize that the reduction of glucose 
levels induces a down-regulation of CTGF gene that in turn increases breast 
cancer cells sensibility to Tamoxifen. In summary, the major finding described 
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in this PhD thesis is that hyperglycaemia significantly reduces Tamoxifen 
sensitivity of human breast cancer cells and that this effect is worsened in 
presence of adipocytes-released factors. Moreover, by using NGS technology 
to profile the entire cell transcriptome, this study revealed that the altered 
sensitivity to Tamoxifen response is associated to the deregulation of specific 
gene pathways. Combining NGS data to gene silencing I could demonstrate 
that such effects are likely to be mediated by the reduced expression of CTGF 
gene. Previous studies have shown that CTGF is critical in tumor development, 
progression as well as in tumor survival (Shi-Wen et al. 2008). Moreover, it 
confers resistance to doxorubicin- and paclitaxel- induced apoptosis in breast 
cancer cells (Wang et al. 2009). In line with these data, I have shown that 
Tamoxifen response in breast cancer cells correlates with CTGF gene 
expression, providing additional clues to the hypothesis that CTGF is one of 
the most relevant contributors to chemotheraphy sensitivity in breast cancer. 
Interestingly, a higher expression of CTGF has been also shown in diabetes 
(Brigstock 2003). Hence, CTGF may be a novel predictive marker for chemo-
sensitivity and could be considered as a potential therapeutic target in novel 
strategies to overcome Tamoxifen resistance further improving survival of 
diabetic patients affected by breast cancer. 
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6. CONCLUSION 
 
In this PhD thesis I have described that high glucose levels, that mimic 
hyperglycaemia in humans, are able to dramatically impair breast cancer cell 
sensitivity to Tamoxifen, a drug widely used to treat estrogen-sensitive 
cancers. Reducing glucose concentrations, to levels corresponding to normal 
fasting glucose in humans, it is possible to rescue breast cancer cell sensitivity 
to this drug. I also found that adipocyte-released factors impair Tamoxifen 
responsiveness of breast cancer cells, indicating the crucial role of the tumor 
microenvironment in cancer drug responsiveness. CTGF gene was 
experimentally demonstrated to be a potential contributor to the onset of 
Tamoxifen resistance in breast cancer cells.  
Hence, the results obtained in this PhD project, strongly support the hypothesis 
of CTGF as a therapeutic target in novel strategies to overcome Tamoxifen 
resistance in breast cancer. These findings also suggest that the expression of 
this gene in breast biopsies may represent a potential novel predictive marker 
for chemo-sensitivity, even though further studies are needed to confirm this 
hypothesis. 
The identification of CTGF as a potential gene responsible of breast cancer 
sensitivity to Tamoxifen, is likely to represent a solid starting point to design 
new adjuvant therapeutic strategies to overcome tamoxifen resistance, 
particularly in presence of metabolic comorbidities. 
The results of my PhD project also highlight the relevant role of hyperglycemia 
and of adipocyte-released factors in the onset of drug resistance. It indicates 
that the glycemic control in diabetic women affected from breast cancer is of 
primary importance for the effectiveness of chemotherapy. 
  
! 48!
7. ACKNOWLEDGMENT 
 
…grazie a tutte le persone che hanno fatto parte di questo percorso…e grazie 
alle persone che solo per breve tempo l’hanno incrociato…perche tutti hanno 
contribuito a renderlo speciale e soprattutto hanno contibuito alla mia crescita 
personale e professionale… 
 
…grazie a tutti…da chi mi ha insegnato a chi mi ha messo alla prova, da chi mi 
ha dato consigli a chi mi ha semplicemente regalato un sorriso… 
 
…grazie a chi, nonostante la mia assenza, non ha mai smesso di considerarmi e 
tenermi presente come parte del gruppo…e grazie a che mi ha accolta, ha 
imparato a conoscermi e fin da subito mi ha fatta sentire a casa… 
 
…grazie a Pietro, per me esempio di intelligenza, correttezza ed umiltà… oltre 
che di entusiasmo ed amore per la ricerca…lo ringrazio per avermi concesso di 
far parte del suo gruppo di lavoro…per avermi dato fiducia…e per essere stato 
sempre disponibile nonostante i suoi mille impegni… 
 
…grazie al Prof. Alfredo Ciccodicola, per avermi dato la fiducia e 
l’opportunità di realizzare questo progetto di tesi, per l’affetto e per essere 
sempre stato esempio di professionalità e serietà… 
 
…grazie al Prof. Francesco Beguinot, i cui consigli sono stati fondamentali per 
la buona riuscita di questo progetto di tesi… 
 
…grazie a Vittoria…anche se non credo potrei mai trovare le parole adatte per 
ringraziare la persona che, forse più di tutti, e talvolta più di me stessa, ha 
creduto in me…che, sempre paziente e disponibile, è stata parte di questo 
percorso dall’inizio alla fine…che con me ha affrontato dubbi e difficoltà…che 
insieme a me ha condiviso ogni soddisfazione e sorriso…che mi ha insegnato, 
consigliato e supportato…e che oggi è per me un’amica prima di ogni altra 
cosa… 
 
…grazie a Mimmo…perchè come un padre ha saputo essere preciso nei suoi 
insegnamenti e severo nei suoi richiami, ma non ha mai saputo nascondere la 
tenerezza nei suoi occhi…  
 
...grazie a Valerio…per i suoi consigli, i suoi suggerimenti e le sue 
critiche…per avermi sempre tenuta in considerazione dimostrandomi stima e 
fiducia...per aver contribuito alla mia crescita professionale e personale con 
affetto e premura…  
 
…grazie a Marianna…un dolce tesoro nel lavoro e nella vita… 
! 49!
…grazie a Giusy, Ale e Francy perchè mi hanno insegnato che la complicità è 
un qualcosa di innato tra le persone e per avermi dato prova che “l’unione” fa 
davvero “la forza”!!! 
 
…grazie a Daniela…per le chiacchiere infinite…per gli sfoghi e le confidenze 
che ha saputo accogliere e soprattutto per il coraggio e la forza che ha saputo 
trasmettermi… 
 
…grazie alla mia famiglia…in particolare alla mia mamma ed al mio 
papa…perchè ancora una volta hanno sostenuto le mie scelte senza mai 
mancare di incondizionato supporto, attenzione e soprattutto amore… 
 
…grazie a Peppe…per essere il mio sicuro rifugio…perchè con tutto il suo 
amore (e spesso tanta pazienza) è sempre al mio fianco…  
 
…infine grazie a chi, purtroppo, non è più qui…ma ha vegliato e veglia sempre 
su di me… 
 
…grazie a tutti coloro che non ho avuto modo di citare ma che hanno 
contribuito a rendere questi anni più lieti… 
 
…perchè se potessi tornare indietro non c’è nessuno che non vorrei aver 
incontrato…perchè ciascuno mi ha regalato “un pezzetto” di sè contribuendo a 
rendermi la persona che sono oggi! 
 
…davvero un grazie di cuore a tutti!!!! 
 
 
  
! 50!
8. REFERENCES 
 
Aronson D. Hyperglycemia and the pathobiology of diabetic 
complications. Adv Cardiol 2008; 45:1-16.  
 
Balkwill FR, Capasso M, Hagemann T. The tumor microenvironment at 
a glance. J Cell Sci 2012; 125(Pt 23):5591-6.  
 
Baron JA, Weiderpass E, Newcomb PA, Stampfer M, Titus-Ernstoff L, 
Egan KM, Greenberg ER. Metabolic disorders and breast cancer risk (United 
States). Cancer Causes and Control 2001; 12:875–880. 
 
Barone BB, Yeh HC, Snyder CF, Peairs KS, Stein KB, Derr RL, Wolff 
AC, Brancati FL. Postoperative mortality in cancer patients with preexisting 
diabetes: systematic review and meta-analysis. Diabetes Care 2010; 33(4): 
931-9.  
 
Bartella V, De Marco P, Malaguarnera R, Belfiore A, Maggiolini M. 
New advances on the functional cross-talk between insulin-like growth factor-I 
and estrogen signaling in cancer. Cell Signal 2012; 24(8):1515-21.  
 
Bissell MJ, Hines WC. Why don't we get more cancer? A proposed role 
of the microenvironment in restraining cancer progression. Nat Med 2011; 
17(3): 320-9.  
 
Borena W, Stocks T, Jonsson H, Strohmaier S, Nagel G, Bjørge T, 
Manjer J, Hallmans G, Selmer R, Almquist M, Häggström C, Engeland A, 
Tretli S, Concin H, Strasak A, Stattin P, Ulmer H. Serum triglycerides and 
cancer risk in the metabolic syndrome and cancer (Me-Can) collaborative 
study. Cancer Causes Control 2011; 22(2):291-9.  
 
Brigstock DR. The CCN family: a new stimulus package. J Endocrinol 
2003; 178(2):169-75.  
 
Calle EE, Kaaks R. Overweight, obesity and cancer: epidemiological 
evidence and proposed mechanisms. Nat Rev Cancer 2004; 4:579-91. 
 
Cariou S, Donovan JC, Flanagan WM, Milic A, Bhattacharya N, 
Slingerland JM. Down-regulation of p21WAF1/CIP1 or p27Kip1 abrogates 
antiestrogen-mediated cell cycle arrest in human breast cancer cells. Proc Natl 
Acad Sci USA 2000; 97(16):9042-6.  
 
Carroll KK. Dietary factors in hormone-dependent cancers. Curr 
Concepts Nutr 1977; 6:25-40. 
 
! 51!
Chiba K., Kawakami K., Tohyama K. Simultaneous evaluation of cell 
viability by neutral red, MTT and crystal violet staining assays of the same 
cells. Toxicol In Vitro 1998; 12(3), 251-258.  
 
Chien W, O'Kelly J, Lu D, Leiter A, Sohn J, Yin D, Karlan B, 
Vadgama J, Lyons KM, Koeffler HP. Expression of connective tissue growth 
factor (CTGF/CCN2) in breast cancer cells is associated with increased 
migration and angiogenesis. Int J Oncol 2011; 38(6):1741-7.  
 
Chocarro-Calvo A, García-Martínez JM, Ardila-González S, De la 
Vieja A, García-Jiménez C. Glucose-induced β-catenin acetylation enhances 
Wnt signaling in cancer. Mol Cell 2013; 49(3):474-86.  
Clemmons DR. Role of insulin-like growth factor binding proteins in 
controlling IGF actions. Mol Cell Endocrinol 1998; 140:19–24. 
 
Coebergh JW, Janssen-Heijnen ML, Post PN, Razenberg PP. Serious 
co-morbidity among unselected cancer patients newly diagnosed in the 
southeastern part of The Netherlands in 1993–1996. Journal of Clinical 
Epidemiology 1999; 52 1131–1136. 
 
Coughlin SS, Calle EE, Teras LR, Petrelli J, Thun MJ. Diabetes 
mellitus as a predictor of cancer mortality in a large cohort of US adults. 
American Journal of Epidemiology 2004; 159 1160–1167. 
 
D'Esposito V, Passaretti F, Hammarstedt A, Liguoro D, Terracciano D, 
Molea G, Canta L, Miele C, Smith U, Beguinot F, Formisano P. Adipocyte-
released insulin-like growth factor-1 is regulated by glucose and fatty acids and 
controls breast cancer cell growth in vitro. Diabetologia 2012; 55(10):2811-22.  
 
Djiogue S, Nwabo Kamdje AH, Vecchio L, Kipanyula MJ, Farahna M, 
Aldebasi Y, Seke Etet PF. Insulin resistance and cancer: the role of insulin and 
IGFs. Endocr Relat Cancer 2013; 20(1):R1-R17.  
 
El-Serag HB, Hampel H, Javadi F. The association between diabetes 
and hepatocellular carcinoma: a systematic review of epidemiologic evidence. 
Clin Gastroenterol Hepatol 2006; 4(3):369-80.  
 
Feng YH, Velazquez-Torres G, Gully C, Chen J, Lee MH, Yeung SC. 
The impact of type 2 diabetes and antidiabetic drugs on cancer cell growth. J 
Cell Mol Med 2011; 15(4):825-36.  
 
Flier JS. Clinical review 94: What's in a name? In search of leptin's 
physiologic role. J Clin Endocrinol Metab 1998; 83(5):1407-13. 
 
! 52!
Friberg E, Orsini N, Mantzoros CS, Wolk A. Diabetes mellitus and risk 
of endometrial cancer: a meta-analysis. Diabetologia 2007; 50(7):1365-74.  
 
Frühbeck G, Gómez-Ambrosi J, Muruzábal FJ, Burrell MA. The 
adipocyte: a model for integration of endocrine and metabolic signaling in 
energy metabolism regulation. Am J Physiol Endocrinol Metab 2001; 
280(6):E827-47.  
 
Galic S, Oakhill JS, Steinberg GR. Adipose tissue as an endocrine 
organ. Mol Cell Endocrinol 2010; 316(2):129-39.  
 
Gallagher EJ, LeRoith D. Epidemiology and molecular mechanisms 
tying obesity, diabetes, and the metabolic syndrome with cancer. Diabetes 
Care. 2013; 36 Suppl 2:S233-9.  
 
García-Jiménez C, García-Martínez JM, Chocarro-Calvo A, De la Vieja 
A. A new link between diabetes and cancer: enhanced WNT/β-catenin 
signaling by high glucose. J Mol Endocrinol. 2013; 52(1):R51-66.  
 
Giaccone G, Pinedo HM. Drug Resistance. Oncologist 1996; 1(1 & 
2):82-87. 
 
Giovannucci E, Harlan DM, Archer MC, Bergenstal RM, Gapstur SM, 
Habel LA, Pollak M, Regensteiner JG, Yee D. Diabetes and cancer: a 
consensus report. CA Cancer J Clin 2010; 60(4):207-21.  
 
Gutierrez MC, Detre S, Johnston S, Mohsin SK, Shou J, Allred DC, 
Schiff R, Osborne CK, Dowsett M. Molecular changes in tamoxifen-resistant 
breast cancer: relationship between estrogen receptor, HER-2, and p38 
mitogen-activated protein kinase. J Clin Oncol 2005; 23(11):2469-76.  
 
Hanahan D, Weinberg RA. Hallmarks of cancer: the next generation. 
Cell. 2011; 144(5):646-74.  
 
Harding JL, Shaw JE, Peeters A, Cartensen B, Magliano DJ. Cancer 
risk among people with type 1 and type 2 diabetes: disentangling true 
associations, detection bias, and reverse causation. Diabetes Care 2015; 
38(2):264-70.  
Harrison. Principi di Medicina Interna. Il Manuale 17/ed 2009. 
 
Hems G. The contributions of diet and childbearing to breast-cancer 
rates. Br J Cancer 1978; 37 974-982. 
 
! 53!
Huber-Keener KJ, Liu X, Wang Z, Wang Y, Freeman W, Wu S, 
Planas-Silva MD, Ren X, Cheng Y, Zhang Y, Vrana K, Liu CG, Yang JM, Wu 
R. Differential gene expression in tamoxifen-resistant breast cancer cells 
revealed by a new analytical model of RNA-Seq data. PLoS One 2012; 
7(7):e41333.  
Huxley R, Ansary-Moghaddam A, Berrington de González A, Barzi F, 
Woodward M. Type-II diabetes and pancreatic cancer: a meta-analysis of 36 
studies. Br J Cancer 2005; 92(11):2076-83.  
 
International Diabetes Federation. IDF Diabetes Atlas, 6th edn. 
Brussels, Belgium: International Diabetes Federation, 2013. 
 
Isakson P, Hammarstedt A, Gustafson B, Smith U. Impaired 
preadipocyte differentiation in human abdominal obesity: role of Wnt, tumor 
necrosis factor-alpha, and inflammation. Diabetes 2009; 58(7):1550-1557. 
 
Iyengar P, Combs TP, Shah SJ, Gouon-Evans V, Pollard JW, Albanese 
C, Flanagan L, Tenniswood MP, Guha C, Lisanti MP, Pestell RG, Scherer PE. 
Adipocyte-secreted factors synergistically promote mammary tumorigenesis 
through induction of anti-apoptotic transcriptional programs and proto-
oncogene stabilization. Oncogene 2003; 22(41) 
Johnson JA, Pollak M. Insulin, glucose and the increased risk of cancer 
in patients with type 2 diabetes. Diabetologia 2010; 53(10):2086-8.  
 
Johnston SR, Dowsett M. Aromatase inhibitors for breast cancer: 
lessons from the laboratory. Nat Rev Cancer 2003; 3(11):821-31.  
 
Khandekar MJ, Cohen P, Spiegelman BM. Molecular mechanisms of 
cancer development in obesity. Nat Rev Cancer 2011; 11(12):886-95.  
 
Kim S, Moustaid-Moussa N. Secretory, endocrine and 
autocrine/paracrine function of the adipocyte. J Nutr 2000; 130(12):3110S-
3115S. 
 
Knowlden JM, Hutcheson IR, Jones HE, Madden T, Gee JM, Harper 
ME, Barrow D, Wakeling AE, Nicholson RI. Elevated levels of epidermal 
growth factor receptor/c-erbB2 heterodimers mediate an autocrine growth 
regulatory pathway in tamoxifen-resistant MCF-7 cells. Endocrinology 2003; 
144(3):1032-44.  
 
Krone CA, Ely JT. Controlling hyperglycemia as an adjunct to cancer 
therapy. Integr Cancer Ther 2005; 4:25-31. 
 
! 54!
Landa MC, Frago N, Tres A. Diet and the risk of breast cancer in Spain. 
European Journal of Cancer Prevention 1994; 3:313–320. 
 
Larsson SC, Orsini N, Wolk A. Diabetes mellitus and risk of colorectal 
cancer: a meta-analysis. J Natl Cancer Inst 2005; 97(22):1679-87.  
 
Larsson SC, Orsini N, Brismar K, Wolk A. Diabetes mellitus and risk 
of bladder cancer: a meta-analysis. Diabetologia 2006; 49(12):2819-23.  
 
Larsson SC, Mantzoros CS, Wolk A. Diabetes mellitus and risk of 
breast cancer: a meta-analysis. International Journal of Cancer 2007; 121:856–
862. 
 
Lubin JH, Burns PE, Blot WJ, Ziegler RG, Lees AW, Fraumeni JF Jr. 
Dietary factors and breast cancer risk. International Journal of Cancer 1981; 
28:685–689. 
 
Macciò A, Madeddu C, Mantovani G. Adipose tissue as target organ in 
the treatment of hormone-dependent breast cancer: new therapeutic 
perspectives. Obes Rev 2009; 10(6):660-70.  
 
Makino T, Noguchi Y, Yoshikawa T, Doi C, Nomura K. Circulating 
interleukin 6 concentrations and insulin resistance in patients with cancer. Br J 
Surg 1998; 85(12):1658-62.  
 
Masur K, Vetter C, Hinz A, Tomas N, Henrich H, Niggemann B, 
Zänker KS. Diabetogenic glucose and insulin concentrations modulate 
transcriptome and protein levels involved in tumour cell migration, adhesion 
and proliferation. Br J Cancer 2011; 104(2):345-52.  
 
McCall JL, Tuckey JA, Parry BR. Serum tumour necrosis factor alpha 
and insulin resistance in gastrointestinal cancer. Br J Surg 1992; 79(12):1361-
3.  
 
Michels KB, Solomon CG, Hu FB, Rosner BA, Hankinson SE, Colditz 
GA, Manson JE. Type 2 diabetes and subsequent incidence of breast cancer in 
the Nurses’ Health Study. Diabetes Care 2003; 26:1752–1758. 
  
Mojarrad M, Momeny M, Mansuri F, Abdolazimi Y, Tabrizi MH, 
Ghaffari SH, Tavangar SM, Modarressi MH. Autocrine human growth 
hormone expression leads to resistance of MCF-7 cells to tamoxifen. Med 
Oncol 2010; 27(2):474-80.  
 
! 55!
Moreno-Navarrete JM, Fernández-Real JM. Adipocyte Differentiation. 
In: Symonds ME, editor. Adipose Tissue Biology. New York: Springer; 2012. 
p. 17-38  
 
Nieman KM, Romero IL, Van Houten B, Lengyel E. Adipose tissue and 
adipocytes support tumorigenesis and metastasis. Biochim Biophys Acta 2013; 
1831(10):1533-41.  
 
Niemelä S, Miettinen S, Sarkanen JR, Ashammakhi N. Adipose Tissue 
and Adipocyte Differentiation: Molecular and Cellular Aspects and Tissue 
Engineering. Ashammakhi N, Reis R, Chiellini F, editors. Applications Topics 
in Tissue Engineering, Vol. 4. Oulu, Finland: University of Oulu; 2008. p. 1-26 
Noto H, Osame K, Sasazuki T, Noda M. Substantially increased risk of 
cancer in patients with diabetes mellitus: a systematic review and meta-
analysis of epidemiologic evidence in Japan. J Diabetes Complications 2010; 
24(5):345-53.  
 
Novosyadlyy R, LeRoith D. Hyperinsulinemia and type 2 diabetes: 
impact on cancer. Cell Cycle 2010; 9(8):1449-50.  
 
O'Mahony F, Razandi M, Pedram A, Harvey BJ, Levin ER. Estrogen 
modulates metabolic pathway adaptation to available glucose in breast cancer 
cells. Mol Endocrinol 2012; 26(12):2058-70.  
 
Onitilo AA, Engel JM, Glurich I, Stankowski RV, Williams GM, Doi 
SA. Diabetes and cancer II: role of diabetes medications and influence of 
shared risk factors. Cancer Causes Control 2012; 23(7):991-1008.  
 
Osborn O, Olefsky JM. The cellular and signaling networks linking the 
immune system and metabolism in disease. Nat Med 2012; 18(3):363-74.  
 
Park J, Morley TS, Kim M, Clegg DJ, Scherer PE. Obesity and cancer-
mechanisms underlying tumour progression and recurrence. Nat Rev 
Endocrinol 2014; 10(8):455-65.  
 
Peifer C, Alessi DR. New anti-cancer role for PDK1 inhibitors: 
preventing resistance to tamoxifen. Biochem J 2009; 417(1):e5-7.  
 
Potischman N, Coates RJ, Swanson CA, Carroll RJ, Daling JR, Brogan 
DR, Gammon MD, Midthune D, Curtin J, Brinton LA. Increased risk of early-
stage breast cancer related to consumption of sweet foods among women less 
than age 45 in the United States. Cancer Causes and Control 2002; 13:937–
946. 
 
! 56!
Poulos SP, Hausman DB, Hausman GJ. The development and 
endocrine functions of  adipose tissue. Mol Cell Endocrinol 2010; 323(1):20-
34.  
 
Quail DF, Joyce JA. Microenvironmental regulation of tumor 
progression and metastasis. Nat Med 2013; 19(11):1423-37.  
 
Rajala MW, Scherer PE. Minireview: The adipocyte--at the crossroads 
of energy  homeostasis, inflammation, and atherosclerosis. Endocrinology 
2003; 144(9):3765-73. 
 
Renehan AG, Yeh HC, Johnson JA, Wild SH, Gale EA, Møller H; 
Diabetes and Cancer Research Consortium. Diabetes and cancer (2): evaluating 
the impact of diabetes on mortality in patients with cancer. Diabetologia 2012; 
55(6):1619-32.  
 
Russo F, Angelini C. RNASeqGUI: a GUI for analysing RNA-Seq 
data. Bioinformatics 2014; 30(17):2514-6.  
Ryu TY, Park J, Scherer PE. Hyperglycemia as a risk factor for cancer 
progression. Diabetes Metab J 2014; 38(5):330-6.  
 
Seshasai SR, Kaptoge S, Thompson A, Di Angelantonio E, Gao P, 
Sarwar N, Whincup PH, Mukamal KJ, Gillum RF, Holme I, Njølstad I, 
Fletcher A, Nilsson P, Lewington S, Collins R, Gudnason V, Thompson SG, 
Sattar N, Selvin E, Hu FB, Danesh J. Diabetes mellitus, fasting glucose, and 
risk of cause-specific death. N Engl J Med 2011; 364(9):829-41.  
 
Shafie SM & Grantham FH. Role of hormones in the growth and 
regression of human breast cancer cells (MCF-7) transplanted into athymic 
nude mice. Journal of the National Cancer Institute 1981; 67:51–56. 
 
Shang Y. Molecular mechanisms of oestrogen and SERMs in 
endometrial carcinogenesis. Nat Rev Cancer 2006; 6(5):360-8.  
 
Shi Y, Hu FB. The global implications of diabetes and cancer. Lancet 
2014; 383(9933):1947-8.  
 
Shi-Wen X, Leask A, Abraham D. Regulation and function of 
connective tissue growth factor/CCN2 in tissue repair, scarring and fibrosis. 
Cytokine Growth Factor Rev 2008; 19(2):133-44.  
 
Silvera SA, Jain M, Howe GR, Miller AB, Rohan TE. Dietary 
carbohydrates and breast cancer risk: a prospective study of the roles of overall 
! 57!
glycemic index and glycemic load. International Journal of Cancer 2005; 
114:653–658. 
 
Srokowski TP, Fang S, Hortobagyi GN, Giordano SH. Impact of 
diabetes mellitus on complications and outcomes of adjuvant chemotherapy in 
older patients with breast cancer. J Clin Oncol. 2009; 27(13):2170-6.  
Talamini R, Franceschi S, Favero A, Negri E, Parazzini F, La Vecchia 
C. Selected medical conditions and risk of breast cancer. British Journal of 
Cancer  1997; 75:1699–1703. 
 
Tarazona S, Garcia-Alcalde F, Dopazo J, Ferrer A, Conesa A. 
Differential expression in RNA-seq: a matter of depth. Genome research 2011; 
21(12), pp. 4436. 
 
Tavani A, Giordano L, Gallus S, Talamini R, Franceschi S, Giacosa A, 
Montella M, La Vecchia C. Consumption of sweet foods and breast cancer risk 
in Italy. Annals of Oncology 2006; 17:341–345. 
 
Tsai MS, Bogart DF, Li P, Mehmi I, Lupu R. Expression and regulation 
of Cyr61 in human breast cancer cell lines. Oncogene 2002; 21(6):964-73 (a). 
 
Tsai MS, Bogart DF, Castañeda JM, Li P, Lupu R. Cyr61 promotes 
breast tumorigenesis and cancer progression. Oncogene 2002; 21(53):8178-85 
(b). 
Vigneri P, Frasca F, Sciacca L, Pandini G, Vigneri R. Diabetes and 
cancer. Endocr Relat Cancer 2009; 16(4):1103-23.  
 
Wang MY, Chen PS, Prakash E, Hsu HC, Huang HY, Lin MT, Chang 
KJ, Kuo ML. Connective tissue growth factor confers drug resistance in breast 
cancer through concomitant up-regulation of Bcl-xL and cIAP1. Cancer Res 
2009; 69(8):3482-91.  
 
Weiderpass E, Gridley G, Persson I, Nyren O, Ekbom A, Adami HO. 
Risk of endometrial and breast cancer in patients with diabetes mellitus. 
International Journal of Cancer 1997; 71:360–363. 
 
Wideroff L, Gridley G, Mellemkjaer L, Chow WH, Linet M, Keehn S, 
Borch-Johnsen K, Olsen JH. Cancer incidence in a population-based cohort of 
patients hospitalized with diabetes mellitus in Denmark. Journal of the 
National Cancer Institute 1997; 89:1360–1365. 
 
Wotton CJ, Yeates DG, Goldacre MJ. Cancer in patients admitted to 
hospital with diabetes mellitus aged 30 years and over: record linkage studies. 
Diabetologia 2011; 54(3):527-34.  
! 58!
Xie D, Nakachi K, Wang H, Elashoff R, Koeffler HP. Elevated levels 
of connective tissue growth factor, WISP-1, and CYR61 in primary breast 
cancers associated with more advanced features. Cancer Res 2001; 
61(24):8917-23.  
Yancik R, Wesley MN, Ries LA, Havlik RJ, Edwards BK, Yates JW. 
Effect of age and comorbidity in postmenopausal breast cancer patients aged 
55 years and older. Journal of the American Medical Association  2001; 
285:885–892. 
 
Yi EH, Lee CS, Lee JK, Lee YJ, Shin MK, Cho CH, Kang KW, Lee 
JW, Han W, Noh DY, Kim YN, Cho IH, Ye SK. STAT3-RANTES autocrine 
signaling is essential for tamoxifen resistance in human breast cancer cells. 
Mol Cancer Res 2013; 11(1):31-42.  
 
Youlden DR, Cramb SM, Dunn NA, Muller JM, Pyke CM, Baade PD. 
The descriptive epidemiology of female breast cancer: an international 
comparison of screening, incidence, survival and mortality. Cancer Epidemiol 
2012; 36(3):237-48.  
 
Zeng L, Biernacka KM, Holly JM, Jarrett C, Morrison AA, Morgan A, 
Winters ZE, Foulstone EJ, Shield JP, Perks CM. Hyperglycaemia confers 
resistance to chemotherapy on breast cancer cells: the role of fatty acid 
synthase. Endocr Relat Cancer 2010; 17(2):539-51.  
 
Zimmet P, Alberti KG, Shaw J. Global and societal implications of the 
diabetes epidemic. Nature 2001; 414(6865):782-7.  
 
Zuk PA, Zhu M, Ashjian P, De Ugarte DA, Huang JI, Mizuno H, 
Alfonso ZC, Fraser JK, Benhaim P, Hedrick MH. Human adipose tissue is a 
source of multipotent stem cells. Mol Biol Cell 2002; 13(12): 4279-95. 
 
FROM GENETICS TO EPIGENETICS: IMPLICATIONS IN NEURODEGENERATIVE DISORDERS (P JIN, SECTION EDITOR)
Non-coding RNA in Neurodegeneration
Alfredo Ciccodicola & Maria Rosaria Ambrosio &
Margherita Scarpato & Valerio Costa
Published online: 8 September 2012
# Springer Science+Business Media, LLC 2012
Abstract Aging-associated chronic diseases, such as neu-
rodegenerative disorders, have a dramatic impact on
healthcare systems. Despite progresses in understanding
their etiology, unsolved questions still exist. These com-
plex disorders share a common inflammatory status and
are influenced by common post-transcriptional mecha-
nisms of gene regulation. MicroRNAs, key players in
modulating gene expression, and other non-coding RNAs
have specific spatial-temporal expression in the brain,
and a critical role in neurogenesis and neurodegenerative
diseases. Here, we review the emerging impact of non-
coding RNAs in their pathogenesis, also performing a
computational analysis on microRNAs and target genes.
Our findings strengthen the notion of an inflammatory-
related component in neurodegenerative disorders, con-
firming the contribution of microRNA-dependent gene
expression regulation in the etiology of such diseases.
Keywords Non-coding RNA . miRNAs .
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Introduction
Life expectancy has greatly increased worldwide during the
last decades, due to the fact that the elderly population (60 y.o.
or over) has tripled over the last 50 years and it is expected to
triple again over the next 50 years [1]. Along with the increas-
ing number of elderly persons, aging-associated chronic dis-
eases are assuming a significant relevance. In particular, the
prevalence of neurodegenerative disorders (NDs), which rises
in step with the aging of the population, is having a broad
impact on healthcare systems and is predicted to worsen in the
near future [2]. A growing number of studies focusing on NDs
are still in progress to understand the pathogenesis and the
molecular mechanisms underlying these disorders, with the
aim to develop effective programs for prevention and therapy.
Nevertheless, many questions remain unanswered and much
can still be brought to light.
NDs constitute a wide class of disorders, including Alz-
heimer’s, Parkinson’s and Huntington’s diseases (AD, PD
and HD, respectively), frontotemporal dementia (FTD),
amyotrophic lateral sclerosis (ALS), spinocerebellar ataxia
(SCA), and Prion diseases. In addition, young individuals
with Down syndrome (DS) develop an early impairment of
cognitive functions with Alzheimer-like phenotype [3].
These conditions are all - except DS - characterized by a
progressive loss of neuronal cells in adulthood [4]. Neuro-
degeneration is initially limited to a specific cell type in the
central nervous system (CNS), in line with the heterogeneity
of clinical symptoms. Cortical and hippocampal regions are
affected in AD, dopaminergic neurons in the substantia
nigra in PD, frontal and/or temporal lobes in FTD, motor
neurons in the brain and spinal chord in ALS, the basal
ganglia in HD [5]. In later stages, neuronal cell death
progressively extends to wider CNS regions, gradually
leading to a severe physical and cognitive disability, fre-
quently including loss of body control, speech impairment
and dementia [6].
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Although their etiology is not fully understood, the presence
of intracellular or extracellular aggregates of misfolded proteins
in the brain is a common feature. Amyloid plaques, consisting
of deposits of β-amyloid protein - a fragment derived from
altered processing of amyloid protein precursor (APP) - in
extracellular parenchyma, and intracellular neurofibrillary
tangles, containing aggregation of hyperphosphorylated tau
protein, represent histopathological signatures of AD [7]. Tau
aggregates are also observed in FTD [8], whereas TDP-43
inclusions are common in frontotemporal lobar degeneration
(FTLD) and in ALS [9]. In PD, dopaminergic neurons are
characterized by cytoplasmic inclusions ofα-synuclein, known
as Lewy bodies [10]. Protein aggregates, due to polyglutamine
expansion in huntingtin and ataxin proteins, are detected in HD
and SCA, respectively [11, 12]. Moreover, Prion diseases are
characterized by the accumulation of conformationally-
modified glycoprotein PrP [13]. Since the deposits of abnormal
proteins are a distinctive feature of all NDs, it is reasonable to
assume that protein misfolding and the aggregation process
represent a crucial step in neurodegenerative mechanisms
[14]. Although each ND shows a different histological pheno-
type, the abnormal protein accumulation triggers the activation
of inflammatory and oxidative-stress pathways. Thus, a chronic
inflammatory state has a relevant impact on neuronal cell death,
consistent with the “age-based theory” of neurodegeneration’s
pathogenesis, since the levels of oxidative damage increase
with aging and, conversely, the anti-oxidative defenses de-
crease [15].
Most of the molecular causes underlying NDs are still
unclear, although in the last three decades the application of
molecular cell biology’s techniques to CNS study has im-
proved our knowledge about neurodegenerative processes
[16]. In the “pre-genomic era”, the genetic bases of NDs
have been investigated by linkage analyses, and a restricted
subset of causative genes identified by positional cloning.
So, more than 200 disease-causing mutations have been
identified in three different genes, APP (amyloid precursor
protein), PSEN1 (presenilin1) and PSEN2 (presenilin2), as-
sociated with AD [17], whereas more than 300 pathogenic
mutations have been identified in five genes, α-synuclein
(SNCA), parkin (PARK2), PTEN-induced putative kinase 1
(PINK1), DJ-1 (PARK7), and Leucine-rich repeat kinase 2
(LRRK2) in PD families [18]. Moreover, five established
genes for Mendelian forms of FTD and thirteen for ALS have
been identified [4]. In addition, hereditary forms of Prion
diseases, such as Creutzfeld-Jacob disease, have been associ-
ated to mutations in the gene encoding PrP (PRNP) [5].
Despite the impact of their genetic component, NDs are
complex traits and only few cases can be explained by a
typical Mendelian inheritance. More than 90 % of cases,
defined as “sporadic” or “idiopathic” forms, appear to be
regulated by an intricate network of genes and environmental
factors. Particularly, the recent application of genome-wide
association studies (GWAS) has led to the identification of
many single nucleotide polymorphisms (SNPs) in susceptibil-
ity genes, associated with the etiology of NDs, i.e. APOE-ε4
in AD [17]. However, for all human diseases it has been
estimated that about 90 % of currently identified disease-
associated SNPs are intronic or intergenic, and GWAS explain
only a small percentage of NDs cases [19]. Therefore, a
significant portion of “missing hereditability” remains. More-
over, variation in gene expression has recently been shown to
affect susceptibility to complex diseases [20], such as the
Alzheimer-like dementia occurring in DS individuals, strictly
linked to the presence of an extra copy of critical genes on
chromosome 21 [21].
Changes in gene expression occur during aging, and
these are accelerated in some forms of neurodegeneration
[22••]. Epigenetic mechanisms dynamically regulate gene
expression, acting at several levels. In this scenario, other
contributors are the non-coding RNAs (ncRNAs) - tran-
scribed from DNA regions considered for a long time to
be evolutionary debris and junk sequences - which represent
a major portion of transcriptome acquiring an emerging
pivotal role as determinants of gene expression regulation,
revealing an unexpected involvement in human diseases
[23••]. Evidences show the contribution of ncRNAs in com-
plex regulatory networks of differentiation and develop-
ment, acting through chromatin modification, transcription,
RNA modification, splicing, mRNA translation and RNA
stability [24]. Moreover, it should also be considered that
some classes of ncRNAs have specific spatial-temporal
patterns of expression in CNS, suggesting a role in neuro-
genesis and neuronal functions and, consequently to their
deregulation, in neuronal pathological processes [25].
Among them, miRNAs are becoming major players in
shaping cell functionality, as well as in determining cell
fate. Indeed, they are crucial factors in cell differentiation,
and in many other cell processes fundamental for neurons,
such as neurotransmission and synaptic plasticity [26••].
In addition, several long non-coding RNAs (lncRNAs)
display specific localization limited to restricted brain
regions, particular neuronal cell-type or subcellular com-
partments, suggesting their deregulation might contribute
to NDs’ onset [27].
Therefore, given the inability to explain all NDs cases by
a typical Mendelian inheritance, and also considering the
potential impact of ncRNAs on gene expression and on
disease onset/progression, it is reasonable to speculate
ncRNAs might be involved in their pathogenesis.
Neurodegeneration and Non-coding RNA
Only 2–4 % of the mammalian genome encodes mRNAs.
The ncRNA fraction has been long considered non-
functional, with the exception of the common infrastructural
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RNAs involved in protein synthesis, transport and splicing
[28]. However, researchers have increasingly focused their
attention on the part of human genome transcribed and never
translated, trying to clarify the genetic information contained
therein, and its functions [26••, 29, 30]. In recent years,
interesting results have been obtained, challenging the tradi-
tional view of RNA as a simple intermediary between DNA
and protein, and thus showing that the vast majority of the
genome encodes functional RNA species [24].
A large variety of ncRNAs has been progressively identi-
fied in the CNS, and their roles in neurogenesis, neural stem
cell maintenance, synaptic and neural network connectivity
and plasticity have been highlighted [25]. These evidences
suggest a strong connection between the regulatory potential
of ncRNAs and CNS complexity [31]. Consequently, it is
intuitive that altered expression and function of ncRNAs
may be directly linked to the onset of CNS disorders.
The most widely studied class of small-ncRNAs (<400
nucleotides) is microRNAs (miRNAs), highly conserved
molecules of 20–22 nucleotides in length, found in almost
all eukaryotic cells [32•]. Mature miRNAs are generated
through a multi-step process. They are post-transcriptional
regulators of gene expression which, binding to comple-
mentary sequences, downregulate target mRNAs’ levels,
causing the degradation of related transcripts or the inhibi-
tion of their translation [23••, 33–35]. Whereas some miR-
NAs regulate specific individual targets, others can function
as master regulators of a process, or through the simulta-
neous regulation of hundreds of genes, or acting coopera-
tively on target genes [31, 36].
miRNAs are involved in numerous biological processes,
including cell proliferation, development, stress responses
and apoptosis [36]. In mammals, they are predicted to con-
trol the activity of more than 50 % of all protein-coding
genes [33]. About 70 % of miRNAs are expressed in spe-
cific brain regions, and experimental evidences have shown
their role in terminal differentiation and maintenance of
many neuronal types, suggesting a relevant functional role
in brain activities [31, 36, 37]. A growing number of reports
have shown that miRNA deregulation is associated with the
pathogenesis of human NDs [38]. For instance, altered
miRNA levels have been directly linked to AD pathogenesis
[39••]. Analyses performed on the brains of AD patients,
with deregulated levels of β-site APP cleaving enzyme
(encoded by BACE1), have displayed a significant alteration
in miRNA expression. BACE1 contributes to the accumulation
of toxic Aβ fragment, and is a target of several miRNAs
[40–43].
In addition, it is reasonable to speculate that miRNAs may
represent a crucial regulatory mechanism also linking AD and
DS pathogenesis. Indeed, both the overexpression of specific
genes located on chromosome 21 (HSA21) - such as APP -
and HSA21 miRNAs have been reported in DS patients. The
simultaneous downregulation of their target genes has sug-
gested a relevant role for HSA21 miRNAs on their expression
during DS pathological processes. Therefore, these molecules
may represent good candidates for the onset of the Alz-
heimer’s-like dementia occurring in young DS individuals,
as well as for other NDs [44, 45]. Interestingly, accumulating
evidences of miRNAs’ role have been reported also in PD.
Two miRNAs (miR-7 and miR-153) have been demonstrated
to inhibit SNCA - encoding α-synuclein - crucially related to
PD pathogenesis [46]. Furthermore, expression profiling of
miRNAs in adult PD vs. normal midbrain, revealed the down-
regulation of miR133b - normally enriched in the midbrain -
possibly acting as negative regulator in dopaminergic neuron
maturation, targeting the transcription factor (TF) Pitx3 [39••].
The evidence of direct and indirect roles of miRNAs has
also been progressively suggested in other NDs, such as in
HD onset. Patients affected by HD show a pathogenic poly-
glutamine expansion in huntingtin, responsible for disrupted
interaction with the transcription factor REST that, in normal
neurons, is sequestered in the cytoplasm by the protein
huntingtin. In HD, its aberrant nuclear-cytoplasmic traffick-
ing is promoted, and the expression of its target genes is
deregulated. REST target genes include not only
protein-coding, but also miRNAs and other ncRNAs
[39••]. Interestingly, REST regulates the expression lev-
els of miR9 and miR9*, which in turn can regulate
REST itself, suggesting a negative feedback loop during
HD development [47, 48]. ALS is another member of
NDs in which miRNAs play a critical role. Notably,
mutations in the components of Drosha microprocessor
complex - involved in biogenesis of miRNAs - cause up
to 50 % of familiar cases of ALS [49].
Although experimental evidences have shown the rele-
vant role of miRNAs in ND pathogenesis, further studies
have gradually highlighted the involvement of other
ncRNAs in their onset. Among them, lncRNAs (>400
nucleotides) represent one of the most abundant classes
[26••, 50]. They derive from genomic loci proximal to
protein-coding genes, and are usually regulated by the same
transcriptional and epigenetic mechanisms. These transcripts
are fundamental in a plethora of subcellular processes, in-
cluding formation of cellular structural compartments,
neuronal differentiation, hippocampal development and
oligodendrocyte myelination [51•]. Indeed, their expres-
sion is largely reported in the brain and, interestingly,
some of them have been shown to interact with pro-
moter elements and TFs, critically modulating the tran-
scriptional activity. For instance, the Sox2OT lncRNA
may have a regulatory effect on Sox2, a TF required for
neural induction and maintenance of neural stemness
[52]. Similarly, Nkx2.2AS lncRNA modulates the ex-
pression of Nkx2 and other factors involved in oligo-
dendocyte lineage specification [53].
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Furthermore, lncRNAs can regulate post-transcriptional
mRNA processing and translation by interacting with spe-
cific sequences [54] and modulating the epigenetic status of
protein-coding genes through cis and trans mechanisms. In
addition, lncRNAs may be the precursor of small ncRNAs,
such as miRNAs [55]. Interestingly, a large number of
studies have revealed a very dynamic profile of expression
- and functions - for lncRNAs during the development of
adult tissues, including brain and several neural cell sub-
types [51•]. Deregulation of lncRNAs has been associated
with the pathogenesis of different NDs, including ATXN80S
in SCA8 [56–58], BACE1-AS and BC200 in AD [59, 60].
Moreover, further findings have suggested that some
lncRNAs might be involved in molecular mechanisms un-
derlying ALS and HD [51•].
Our recent transcriptome analysis in DS has revealed
lncRNAs’ deregulation in trisomic vs. euploid cells, sug-
gesting their involvement in some pathological features
typical of DS [61]. Finally, it is reasonable to assume many
disease-associated SNPs, identified in intronic and inter-
genic regions in patients affected by NDs, are likely to fall
in previously unannotated non-coding transcripts, such as
lncRNA, possibly contributing to the disease.
It should be mentioned that another class of ncRNAs, the
small nucleolar RNAs (snoRNAs), has been directly linked
to Prader-Willi syndrome characterized by neonatal muscu-
lar hypotonia, obesity, hypogonadism, behavioral problems
and mental retardation. In particular, HBII-52 snoRNA,
which regulates alternative splicing of 5-HT2CR mRNA, is
silenced in patients, leading to the production of different
isoforms compared to healthy individuals [62].
In light of these evidences, studying the function, spatial-
temporal localization and regulation of ncRNAs in neurons
is becoming essential to understanding physiological neuro-
genesis and neural plasticity, as well as to disclose the
molecular bases of neurodegenerative processes occurring
in patients’ brains.
miRNAs in Neurodegeneration
As mentioned above, miRNAs represent the major and
better-studied class of ncRNAs involved in neurodegen-
erative processes. Given their relevant contribution to ND
onset and severity, and also considering the large amount
of molecular data available from gene expression studies,
and consequently, the growing number of well-curated
miRNA databases, we focused our analysis on this
ncRNA species.
In particular, after browsing commonly used databases, we
collected frommiRWalk [63] and mir2disease [64] all miRNAs
with a proven involvement in NDs and neurodegenerative
processes (listed in Table 1). miRBase was also used to retrieve
additional information about the selected miRNAs [65].
The newly developed miRWalk algorithm was used to
predict miRNA binding sites within the complete set of
annotated human genes, particularly those implicated in
crucial biological pathways. Unlike other algorithms pro-
ducing prediction of miRNAs binding sites within 3’UTRs
of target genes, the “Validated Targets module” of miRWalk
provides information on experimentally validated miRNA-
gene interactions, dramatically reducing the rate of false
positive sites. Such analysis was performed by pooling -
for each disease - miRNAs retrieved by both miRWalk and
mir2disease databases. The number of identified target
genes is also indicated in Table 1. The PANTHER (Protein
ANalysis THrough Evolutionary Relationships) tool was
used to classify target gene lists according to their molecular
function as well as their involvement in specific cellular
pathways [66]. Notably, as shown in the bar graphs
(Fig. 1), the most recurrent pathways for almost all exam-
ined NDs were inflammation, integrin, interleukin and Wnt
signaling, angiogenesis and apoptosis pathways. These find-
ings are of particular interest since chronic inflammatory
state is a common feature in NDs (as discussed in detail in
“Neurodegeneration and Inflammation”). Intersection
among the lists of miRNAs’ target genes for each disease
was performed with a custom Matlab script in order to
explore all possible combinations (schematically shown in
Fig. 1). A significant overlap of genes among some NDs
was disclosed, as indicated by the heat map in Fig. 1. In
addition, by using the Genetic Association Database [67], an
archive of human genetic association studies for complex
diseases, we identified - as expected - that a significant
fraction of common genes is associated with aging, neuro-
logical and psychiatric disorders (pie charts in Fig. 1).
Neurodegeneration and Inflammation
Neurodegenerative process is characterized by unremitting
activation of the inflammatory response, which might trig-
ger neuronal cell death [68•]. Enduring inflammation
implies the persistence of the inflammatory stimulus, which
may consist of environmental (exogenous) factors or endog-
enous molecules perceived by the immune system as
“stranger” or “danger” signals. Therefore, it is reasonable
that in each ND, misfolded proteins accumulated in cyto-
plasm or parenchyma of specific brain regions are recog-
nized as “non-self” by the immune system [69••]. Thus, a
chronic inflammatory state might be a direct consequence of
the inflammatory response triggered by abnormal protein
deposits, a common feature of NDs. Moreover, the age
advancement is associated with increased levels of oxidative
stress and reduced effectiveness of antioxidative defense
mechanisms, in line with the late onset of such diseases
[70]. Both evidences could explain the typical alterations
in inflammatory status observed during neurodegenerative
222 Curr Tran Geriatr Gerontol Rep (2012) 1:219–228
processes. Indeed, a wide spectrum of studies has highlight-
ed the involvement of activated microglia and reactive
astrocytes in NDs [71]. Inflammatory response activation
implies the synthesis of a wide range of proinflammatory
mediators and the production of free radicals and oxygen/
nitrogen reactive species (ROS and RNS), increasing the
oxidative damage and determining a positive feedback [72].
In addition, dysfunctions of mitochondria, involved in the
defense mechanisms against oxidative stress, occur in all
major NDs [73]. Notably, mutations in SOD1 gene - encoding
for the superoxide dismutase enzyme responsible for destroy-
ing toxic superoxide radicals - is associated with ALS [74] and
evidence of altered expression of the SOD1 gene has been
reported in DS for several cells/tissues [75, 76]. Definitively,
the immune response to chronic inflammatory state might
play a pivotal role in synaptic dysfunction and selective neu-
ronal loss, strongly contributing to the onset and progression
of neurodegeneration.
Recent evidence shows that miRNAs have a determinant
function in modulating immune response in NDs. For in-
stance, miR-125b, miR-146a and miR-155 downregulate
the Complement Factor H encoding gene (CFH) in AD e
DS [77]. In addition, miR-146a overexpression in Prion
diseases is involved in microglia activation [78], whereas
miR-101 contributes to the regulation of the APP gene in
response to the proinflammatory cytokine interleukin-1β
(IL-lβ) [79].
Such findings stimulate further research aimed at the
comprehension of the connection among the three elements
of the triad ncRNAs-inflammation-neurodegeneration.
Table 1 Deregulated miRNAs in neurodegenerative diseases
Disease miR2Disease db miRWalk db N° target
genes
Ref
AD ↑ miR125b, miR-128a,
miR-146, miR-146a,
miR-197, miR-320,
miR-511, miR-9
N/A miR-101, miR-146a, miR-
146a*, miR-298, miR-29a,
miR-29a*, miR-29b, miR-
29b-1*, miR-29b-2*, miR-
29c, miR-29c*, miR-328,
miR-338-3p, miR-34a,
miR-34a*
1025 [40–43] [88–91]
↓
let-7i, miR-101, miR-106b, miR-107, miR-124a,
miR15a, miR-181c, miR-210, miR-22, miR-26b,
miR-298, miR-29a, miR-29b-1, miR-328,
miR-34a, miR-363, miR-9, miR-93
PD ↑ miR-433 N/A miR-30a, miR-30a*, miR-30b,
miR-30b*, miR-30c, miR-30c-
1*, miR-30c-2*, miR-30d,
miR-30d*, miR-30e,
miR-30e*, miR-433
622 [37] [92–94]
↓ miR-133b, miR-64, miR-65, miR-7
HD ↑ miR-29a, miR-330 320 [99] [100] [47]
↓ miR-128, miR-22, miR-132, miR-9,
miR-9*
FTLD N/A let-7b, let-7b*, miR-663 628
FTD ↑ miR-659 N/A miR-107, miR-29b,
miR-29b-1*, miR-29b-2*,
miR-659
153 [96]
ALS N/A let-7b, let-7b*, miR-206,
miR-29a*, miR-29a,
miR-29b, miR-338-3p,
miR-663
804
SCA ↑ miR-144, miR-144* N/A miR-144, miR-144* 112 [97, 98]
↓ miR-101, miR-130, miR-19
DS ↑ let-7c, miR-125b-2, miR-155,
miR-802, miR-99a
N/A let-7c, miR-125b-2, miR-155,
miR-802, miR-99a let7c*,
miR-125b, miR-125b-2*,
miR-155*, miR-99a*
967 [45]
Prion ↑ miR-342-3p N/A miR-342-3, miR-494 40 [95]
HD, Huntington’s disease; PD, Parkinson’s disease; AD, Alzheimer’s disease; FTLD, Frontotemporal Lobar Degeneration; FTD, Frontotemporal
dementia; SCA, spinocerebellar ataxia; DS, Down Syndrome; ALS, Amyotrophic Lateral Sclerosis; Prion, Prion diseases.↑ , ncRNAs upregulated
and ↓, downregulated
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Inflammation-Related miRNAs and Genes: A Bridge
to Neurodegeneration?
NDs display different histological phenotypes and clinical
symptoms, although the production of abnormal proteins and
their pathological accumulation into cellular aggregates are
common features [12]. Such events, as above described, have
been correlated with a chronic inflammatory state, and conse-
quently to neuronal cell death [15]. The finding that a signifi-
cant fraction of genes targeted by ND-related miRNAs belongs
to inflammatory-related pathways (described in “miRNAs in
Neurodegeneration”; Fig. 1) further suggests a direct, and
perhaps strong, impact of inflammation in the etiology of
NDs. Thus, to observe the extent of such overlap we first
catalogued annotated human genes involved in inflammatory-
related pathways (retrieved by PANTHER) and then identified
the validated miRNAs that regulate them (mirWalk).
Interestingly, as shown in Table 2, the examined NDs -
except DS - share a very significant fraction of “disease-
associated” miRNAs with analyzed inflammatory-related
genes, with, on average, 84 % of common miRNAs. These
data further support the notion that an altered expression of
inflammation-related genes, possibly due to miRNA dereg-
ulation and thus a chronic activation of the inflammatory
cascade, may significantly contribute to neurodegenerative
Fig. 1 Graphical representation of target genes of miRNAs involved
in all examined NDs. The matrix, shown on a blue background,
was built considering “disease-specific” target genes and all com-
binations of those genes shared by two or more NDs. Color
intensity of vertical blocks indicates the number of common
genes, according to the heat map (on the left). NDs are indicated
in the rows and, on the right, the bar graphs show the most recurrent
pathways in each disease. For the most numerous sets of shared target
genes, pie charts (on the bottom) display the percent of common genes
associated with aging, neurological and psychiatric disorders according to
the Genetic Association Database
Table 2 Disease- vs. Inflammation- specific miRNAs
Disease Validated miRNAs
Disease-specific Common Inflammation-specific
AD 5 29 (85,3 %) 351
PD 2 14 (87,5 %) 366
ALS 0 8 (100,0 %) 372
FTD 1 4 (80,0 %) 376
FTLD 0 3 (100,0 %) 377
SCA 2 3 (60,0 %) 377
HD 1 6 (85,7 %) 374
Prion 1 2 (66,7 %) 378
DS 8 2 (20,0 %) 378
AD, Alzheimer’s Disease; PD, Parkinson’s Disease; ALS, Amyotro-
phic Lateral Sclerosis; FTD, Frontotemporal Dementia; FTLD, Fron-
totemporal Lobar Degeneration; SCA, Spinocerebellar Ataxia; HD,
Huntington’s disease; Prion, Prion Diseases; DS, Down Syndrome
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processes, possibly triggering the onset (or determining the
severity) of NDs, in line with previous findings [68•].
RNA-Seq: A Promising Tools for Transcriptome Profiling
in NDs
NDs have been widely studied from a “DNA perspective.”
The search for causative mutations in few disease-causing
genes or for SNPs and loci associated with disease suscep-
tibility have only partially explained NDs inheritance and
the molecular causes of such diseases. In the last decade,
gene expression studies have gradually been employed to
investigate many human genetic disorders, including NDs
[80••]. Transgenic animal models, post-mortem brains and
patient-derived cell lines have been frequently used for gene
expression analyses [81•].
Most of the gene expression studies performed so far,
mainly on microarray platforms, have focused on PD, AD
andHD, although conflicting results have been reported. Tech-
nological drawbacks [82], the variable quality/integrity of
RNAs and the fragile nature of RNA samples from brains have
been reported as the main causes of such discrepancies [81•].
Sequencing-based assays, such as Serial and Cap Analy-
sis of Gene Expression have been successfully used in PD,
AD and DS [83]. The introduction of NGS platforms for
high-resolution analyses, and particularly of accurate meth-
ods for massive-scale transcriptomics (RNA-Seq), allows
exploration of such NDs from a different perspective [84].
Indeed, RNA-Seq has been revealed to be a promising tool
to study human diseases and to analyze transcriptomics’
changes, also in NDs’ patients [85]. Nonetheless, to date,
only one group has employed RNA-Seq on AD patients’
brains [86••]. In particular, they observed significant differ-
ences in the expression, and promoter usage, for different
APOE splice isoforms in normal vs. AD brains, indicating
that alternative splicing plays a crucial role in the progres-
sion of neurodegeneration in AD patients.
Of note, another group has profiled human neurons derived
from induced pluripotent stem cells proposing a model to
study defective neurogenesis [87]. In addition, our group has
recently analyzed by RNA-Seq the transcriptome of endothe-
lial progenitor cells - impaired in DS - showing that coupling a
protocol of rRNA depletion to RNA-Seq allows investigation
of transcriptome in pathological conditions [61].
Conclusions
In recent years, the increased prevalence of NDs is having a
dramatic impact on healthcare systems worldwide. Despite
steps taken toward an understanding of the etiology behind
neurodegenerative processes, there are still many molecular
aspects to clarify. Studies aimed at identifying disease-causing
mutations in the Mendelian forms of NDs and large-scale
GWAS have only partially explained their pathogenesis,
showing a substantial lack of knowledge. Gene expression
studies, particularly those investigating the role of ncRNAs,
have started to highlight the contribution of these molecules to
ND pathogenesis. Particularly, miRNAs and lncRNAs are
showing relevant roles in neural cell plasticity and in neuro-
degenerative processes [39••].
Moreover, it has been recognized that despite having
different histological phenotypes, distinction in brain areas
affected, and varying clinical symptoms, there are distinc-
tive common features among NDs. Pathological deposits of
misfolded proteins are the first step toward formation of cell
aggregates [14], and activation of inflammatory and
oxidative-stress pathways, possibly leading to neuronal cell
death, are common characteristics of these diseases [16].
Our analysis of miRNAs and their target genes retrieved
interesting results, confirming that recurrent pathways for all
examined NDs are inflammation-mediated by chemokines and
cytokines, integrin and Wnt signaling, angiogenesis and apo-
ptosis pathways. Moreover, a significant fraction of miRNA
target genes common to more NDs was associated to aging,
neurological and psychiatric disorders according to the Genetic
Association Database.
Such observations further strengthen the evidence of an
inflammatory-related component in NDs, confirming the rel-
evant contribution of miRNA-dependent gene expression reg-
ulation in the etiology of such diseases.
However, functional studies are needed to validate such
findings, and large-scale expression analyses of ncRNAs in
these diseases will surely provide a significant contribution.
Despite the fact that NGS application to NDs is still in its
infancy, and few groups have currently employed RNA-Seq to
profile the transcriptome of neuronal cells [87, 88], we expect
it will rapidly reveal its great potential, generating a major
improvement in the knowledge of the molecular etiology of
many neurodegenerative disorders.
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Transcriptome studies have shown the pervasive nature of transcription, demonstrating almost all the genes undergo
alternative splicing. Accurately annotating all transcripts of a gene is crucial. It is needed to understand the impact of
mutations on phenotypes, to shed light on genetic and epigenetic regulation of mRNAs and more generally to widen our
knowledge about cell functionality and tissue diversity. RNA-sequencing (RNA-Seq), and the other applications of the next-
generation sequencing, provides precious data to improve annotations’ accuracy, simultaneously creating issues related to
the variety, complexity and the size of produced data. In this ‘scenario’, the lack of user-friendly resources, easily accessible
to researchers with low skills in bioinformatics, makes difficult to retrieve complete information about one or few genes
without browsing a jungle of databases. Concordantly, the increasing amount of data from ‘omics’ technologies imposes to
develop integrated databases merging different data formats coming from distinct but complementary sources. In light of
these considerations, and given the wide interest in studying Down syndrome—a genetic condition due to the trisomy of
human chromosome 21 (HSA21)—we developed an integrated relational database and a web interface, named ALE-HSA21
(AnaLysis of Expression on HSA21), accessible at http://bioinfo.na.iac.cnr.it/ALE-HSA21. This comprehensive and user-
friendly web resource integrates—for all coding and noncoding transcripts of chromosome 21—existing gene annotations
and transcripts identified de novo through RNA-Seq analysis with predictive computational analysis of regulatory
sequences. Given the role of noncoding RNAs and untranslated regions of coding genes in key regulatory mechanisms,
ALE-HSA21 is also an interesting web-based platform to investigate such processes. The ‘transcript-centric’ and easily-
accessible nature of ALE-HSA21 makes this resource a valuable tool to rapidly retrieve data at the isoform level,
rather than at gene level, useful to investigate any disease, molecular pathway or cell process involving chromosome
21 genes.
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Introduction
In the past years, transcriptome studies have largely
shown the pervasive nature of transcription in living organ-
isms (1–4). In particular, the GENCODE Consortium, by
combining computational analysis, manual curation and
experimental validations, has identified a plethora of new
coding and noncoding RNA transcripts expressed in human
cells (5). Altogether these studies demonstrate that a
significant fraction of transcribed regions stands outside
known genes and most of them undergo alternative spli-
cing (AS). Therefore, defining a curated and validated gene
annotation is difficult, even though crucial for several rea-
sons. For instance, annotating all the transcripts of a given
gene is strictly necessary to postulate the functional impact
of nucleotide variations, particularly those located in gen-
omic regions till now recognized as ‘nongenic’. The most
striking evidence is mutations accounting for Mendelian
disorders (6) or common variants associated to complex
traits and diseases (7). Moreover, a correct annotation of
mRNAs’ untranslated regions (UTRs) would significantly
help to investigate their role in the regulation of transcrip-
tion and translation (8). Finally, identifying novel tissue or
cell-specific coding and noncoding transcripts would signifi-
cantly improve the knowledge of cell functionality.
Large-scale data sets produced by RNA-sequencing (RNA-
Seq), an application of the next-generation sequencing, are
revealing an optimal source to improve the accuracy of
gene annotations (9). However, the variety, the complexity
and the size of available data have exponentially increased,
making them difficult to handle, analyze, store, share and
integrate with those stored in existing databases (10). It is
common for research groups—and/or large consortia—to
annotate the same transcript, gene or protein isoform
using different identifiers (id), often confounding unskilled
users. For this reason, comparing and combining these data
from different resources still represent a difficult task.
Another hurdle to overcome is data dispersion. For in-
stance, having a complete landscape of regulatory mol-
ecules for a specific transcript of interest is challenging, as
most of the available resources are difficult to browse with-
out any expertise in bioinformatics, and often they appear
too specialized. Several Web sites and tools have been spe-
cifically developed for the ‘sequence-based’ predictions of
transcription factors’ or microRNAs’ binding sites but, to
the best of our knowledge, such information has not
been systematically integrated into already existing gen-
omic resources. Such issues often limit the access to com-
plete information for a transcript, gene or protein of
interest without browsing different databases. Therefore,
given the substantial lack of comprehensive and user-
friendly Web sites for researchers or medical geneticists
with low experience in bioinformatics, it is crucial to imple-
ment easy-to-use web resources. Concordantly, the massive
production of ‘omics’ data makes urgent the need to de-
velop integrated databases.
In light of these considerations, and given our interest in
studying the expression of genes mapping on human
chromosome 21 (HSA21)—whose triplication causes Down
Syndrome (DS)—we developed an open-access integrated
relational database and a web interface, ALE-HSA21
(AnaLysis of Expression on HSA21; http://bioinfo.na.iac.cnr.
it/ALE-HSA21). Because RNA-Seq studies have indicated the
need to investigate biological processes and disease mech-
anisms at isoform level, rather than at gene level, we de-
signed our database as a ‘transcript-centric’ web portal.
It integrates—for all transcripts generated by AS from
HSA21 genes—nucleotide sequences and exon/intron struc-
tures with data about regulatory sequences. The latter con-
sist of computational predictions for canonical and
noncanonical regulatory motifs within promoters, exons,
introns and 30 UTRs. Links to widely used genotype and
phenotype databases are also integrated in ALE-HSA21,
avoiding the user to browse different resources over the
web. Finally, it contains a set of de novo discovered tran-
scripts, identified through a robust computational analysis
of our recently published RNA-Seq data sets (11).
This web portal clearly represents an estimable source of
information for researchers and clinicians interested in
studying DS. Given the proven role of HSA21 genes’
dosage imbalance in DS clinical outcomes (11), having a
comprehensive set of information about all HSA21 genes,
and their alternative transcripts, is of major interest for
researchers studying DS. The database is also a valuable
resource for medical geneticists interested in other
HSA21-related diseases. Disruption or alteration of binding
sites for auxiliary splicing factors as well as of other gene
regulatory regions—promoter and 30 UTR—may affect
mRNA transcription, processing and translation, in turn
playing a pathological role.
This kind of information is available in ALE-HSA21
through an easily accessible web interface, designed to rap-
idly provide heterogeneous data in a scientifically rigor-
ous—even though user-friendly—way.
Materials and Methods
Links to the external databases, files and software (with ver-
sion and parameters) are shown in Supplementary File S1.
RNA-Seq data processing and gene annotations
Raw files containing short reads of 50bp (.csfasta and .ual
formats from SOLiD v3) originated by the massive-scale
sequencing of endothelial progenitor cells (11), were filtered
out for quality values, homology to adapters and rRNA
sequences. Filtered reads were aligned with TopHat software
version 1.1.4 (12) against the reference human genome
(release hg19). Without providing annotated gene models,
.............................................................................................................................................................................................................................................................................................
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splice junctions were de novo determined by the software,
and reported as a list in a standard tabular format (BED).
Reads uniquely mapped on the reference genome—ex-
tracted from the output alignment file (BAM)—and junc-
tions supported by at least three high-quality reads were
used. For further analyses we extracted only HSA21 mapping
reads. A coverage file (BEDGRAPH format) for HSA21 was
created and loaded into an open-access session of
University of California Santa Cruz (UCSC) Genome
Browser, named ALE-HSA21. The track ‘Comprehensive
Gene Annotation Set GENCODE Version 12’ was downloaded
from Table Browser of UCSC in GTF format. The exact
number and the category of HSA21 transcripts considered
in our further analyses, and reported in ALE-HSA21, are
listed in Supplementary Table S1. Manual curation was
used—in some cases—to correctly assign, if any, the corres-
ponding RefSeq ID to annotated GENCODE transcripts.
Discovery of intronic and intergenic transcription
To identify potentially new exons and/or transcripts in in-
trons and intergenic intervals, uniquely mapped reads were
converted into sorted files in BED format using SAMtools
and BEDtools (13, 14). Results were visualized in UCSC
Genome Browser to assess the quality and the consistency
of the mapping analysis. A customized workflow was built
to extract the genomic coordinates of intronic and inter-
genic HSA21 transcripts from GENCODE annotation, as well
as reads mapping within these regions. In detail, we divided
intronic and intergenic intervals in windows of 200 and
500bp, respectively, and we counted the number of reads
falling within such windows. Putative windows were re-
ported as potential new transcribed regions if the
number of mapped reads was sufficiently large. Signal en-
richment was evaluated by using a Poisson test similar in
the spirit to MACS (15). The background (no-signal) inten-
sity, !, was independently estimated for intronic and inter-
genic regions by maximum likelihood approach. In
particular, a subset of intergenic regions—>1Mb and
10 kb distant from gene boundaries—was used to estimate
!intergenic. For the estimation of !intronic we used intronic
intervals >300kb and 1 kb away from exon boundaries.
Poisson P-values computed in each window underwent
Benjamini and Hochberg False Discovery Rate correction
(16). Significant windows were merged in larger genomic
regions when the distance among them was smaller or
equal to the window size. Transcriptionally active regions
were defined ‘high coverage peaks’ (HCPs). In addition, to
assess the transcription upstream transcription start sites,
and downstream the last nucleotide of annotated tran-
scripts, we used windows of variable size (50–1000bp).
Coverage was evaluated by counting the number of reads
mapping within these windows. We selected the transcripts
to experimentally validate after the intersection with gen-
omic coordinates of expressed sequence tags and gene
predictions (AceView database), as well as by visual inspec-
tion in UCSC and Integrative Genomic Viewer.
Computational analysis of splicing isoforms
The output of TopHat, i.e. the list of de novo determined
splice junctions, was used to infer the evidence of unanno-
tated isoforms generated by AS for each HSA21 gene. Each
junction (j) consists of two connected blocks, left (Lj) and
right (Rj). The length of each block, here defined as MOLj
and MORj, is given by the Maximal Overhang (MO) over all
reads mapping within Lj and Rj, respectively (12).
The genomic coordinates (i.e. the starting and ending
sites, S and E, respectively) of Lj and Rj were defined as
follows:
Lj ¼ SLj, ELj
! "
and Rj ¼ SRj, ERj
! "
where
SLj 5
0 startð Þ ¼ Sj and ELj 30 endð Þ ¼ Sj þMOLj
and
SRj 5
0 startð Þ ¼ Ej %MORj and ERj 30 endð Þ ¼ Ej
For the ‘plus’ strand, Sj is the 50 start genomic and Ej is the 30
end coordinate of j. Vice versa, for the ‘minus’ strand, Sj is
the 30 end genomic coordinate of junction j and Ej is the 50
start coordinate of j. Thus, we independently intersected
intervals Lj and Rj with the genomic coordinates of all
exons of the HSA21 GENCODE v12 annotation by using
the intersectBed function of BEDtools (13). Seven different
categories of junctions were defined through this analysis
(schematized in Supplementary Figure S1): (i) ‘annotated’
and (ii) ‘exon skipping’ if Lj and Rj map to consecutive or
nonconsecutive exons on the same transcript, respectively;
(iii) ‘only one side’, if only Lj or Rj map to one exon of a
transcript and the other does not; (iv) ‘intra-exonic’ if both
Lj and Rj map within the same exon; (v) ‘different tran-
scripts’ if Lj maps to an exon of a transcript and Rj maps
to an exon of another transcript belonging to the same
gene; (vi) ‘trans-splicing’ if Lj and Rj map to exons of two
different (adjacent) genes and (vii) ‘intronic/intergenic’ if
both Lj and Rj do not map to any exon of an annotated
transcript. Because a splice junction may belong to multiple
categories (i.e. it may be ‘annotated’ for a given transcript
but ‘exon skipping’ for another), we established a junction
hierarchy (from category 1 to 7) in which junctions assigned
to a category cannot be assigned to the next one.
Finally, each HSA21 GENCODE transcript was associated
to a known official gene symbol to identify potentially new
splice isoforms.
Computational prediction of regulatory sequences
Nucleotide sequences for each promoter, exon, intron and
30 UTR were downloaded in FASTA format from UCSC data-
base. In detail, of 1702 HSA21 protein-coding transcripts,
.............................................................................................................................................................................................................................................................................................
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1295 were exclusively annotated in the ‘Comprehensive
Gene Annotation Set from GENCODE Version 12’, 139
only in RefSeq (release 56) and 268 in both of them.
Simultaneously, 462 HSA21 noncoding transcripts were
divided in 10 classes according to GENCODE v12
(Supplementary Table S1 and illustrated in the right panel
of Figure 1B). For miRNAs, a comprehensive list of 30
entries was created merging information from different
databases (GENCODE, RefSeq, Ensembl and miRBase). For
the other noncoding transcripts, we retrieved from the
‘Comprehensive Gene Annotation Set from GENCODE v12’
a list of 220 long intergenic noncoding RNAs (lincRNAs), 24
pseudogenes, 15 sense-intronic transcripts, 80 antisense
transcripts, 40 processed transcripts, 21 small nuclear
RNAs, 19 small nucleolar RNAs (snoRNAs), 5 rRNAs and 8
miscellaneous RNA. Promoters’ sequences (!1kb from tran-
scription start site) of coding transcripts were scanned for
the presence of TF binding sites using the ‘matrix scan’
option of Regulatory Sequence Analysis Tools (RSAT) web
server (17). Position weight matrices of 78 human transcrip-
tion factors (TFs) were downloaded from JASPAR database.
The ‘DNA pattern’ tool of RSAT web server was used to
determine the presence of ‘consensus’ sequences for 106
exonic splicing enhancer and 50 silencer (ESE/ESS), 54 in-
tronic splicing enhancer and 32 silencer (ISE/ISS).
Regulatory sequences were downloaded from RegRNA
web server (18). The number of analyzed exons and introns
is shown in Table 1.
For the identification of miRNA responsive elements
(MREs) within the mRNA 30 UTRs, the complete list of
6121 mammalian miRNAs of TargetScan database was fil-
tered for 4582 nonhuman miRNAs. Thus, targetscan_60.pl
script downloaded from TargetScan was used to analyze
1201 30UTRs of protein-coding transcripts, searching for
binding sites of 1539 miRNAs. Of note, the number of
30UTRs analyzed for the presence of MREs is smaller than
the total number of transcripts because some of them lack
UTR in the GENCODE annotation or are annotated as ‘pro-
cessed transcripts’, ‘retained introns’ and other categories
lacking the typical 30UTR.
The same analysis was performed also to predict MREs
within the entire nucleotide sequences of 220 lincRNAs’
and 24 pseudogenes’ transcripts mapping on HSA21.
RNAfold web server, with default parameters (19), was
used to predict—and visualize—the secondary structure of
19 snoRNA and 30 pre-miRNA sequences (figures available
on ALE-HSA21). Such analysis represents predictions of sec-
ondary structures based on minimum free energy and par-
tition functions, and the images do not represent in vivo
structures.
For the 19 HSA21 miRNAs annotated in miRBase (20), the
mature miRNA sequence was also highlighted in such draw-
ings. miRNA target genes (MiTGs) were predicted by
miRWalk [using algorithms both for ‘validated’ and
‘predicted’ genes; (21)] and CoMeTa databases (22).
Complete data were available for five miRNAs (miR99a,
miR125b, miR155, miR802 and let-7 c). Finally, the three
lists of MiTGs were intersected to determine a common
pool using Venny (23).
Database development and description
ALE-HSA21 is a database-driven Web site, more properly
driven on a Relational Database Management System. It
allows to structure the information contained in the web
portal and to display them in tables. Overall, the database
contains 534 HSA21 genes, consisting of 33.394 different
genomic elements (Table 1). Database was implemented
using server version 5.1.67—10.04.1 (Ubuntu)—and a web
server Apache/2.2.14 (Ubuntu). MySQL client version
5.1.67—10.04.1 (Ubuntu)—and the free tool phpMyAdmin
version 3.3.2 deb1ubuntu were used to handle the admin-
istration of MySQL over the World Wide Web.
ALE-HSA21 Web site
The web-oriented side was created using the scripting lan-
guage PHP. The Javascript technology for dynamic contents,
the markup language HTML for static contents and style
sheet CSS 2.0 were also used. All 3D images have been
implemented using the ‘clickable image maps’ method,
thus making only a certain portion of the image sensitive
to mouse clicks, linking to different destinations and con-
tents. The ALE-HSA21 code is validated according to the
standard web of the international community W3C (World
Wide Web Consortium: http://www.w3.org/) and therefore,
although optimized for Mozilla Firefox, it is easily visible
and accessible by all browsers and smartphones.
The web resource will be regularly updated on the basis
of the progress of our study.
Results
Global organization of ALE-HSA21 web portal
ALE-HSA21 is an open-access user-friendly web resource
built on a relational database. This web portal is a compre-
hensive ‘transcript-centric’ database for HSA21, in which
data from different sources are dynamically integrated
(Figure 1A). ALE-HSA21 contains 2164 annotated tran-
scripts, generated through AS from 534 genes.
Particularly, 1702 transcripts derive from 238 protein-
coding genes and 462 from 296 noncoding genes
(Table 1; Supplementary Figure S2). Moreover, ALE-HSA21
also collects 11 transcripts (of protein-coding genes)
identified—and validated—through the computational
reanalysis of our RNA-Seq data sets.
The web resource consists of five main sections, schemat-
ically shown in the block diagram of Supplementary Figure
S3 and in the ‘Sitemap’ of ALE-HSA21. The core is
.............................................................................................................................................................................................................................................................................................
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Figure 1. Schematic overview of data collected in ALE-HSA21 and of the computational analysis. Panel (A) shows a list of open-
access databases used to retrieve information and the cartoon of the computational workflow used to analyze the data. Data
derived from these sources were collected and integrated into our relational database and its web interface, represented on the
right by the Homepage of ALE-HSA21. On the left part of panel (B) is schematically illustrated the computational approach used
to analyze RNA-Seq data sets. In the right part it is depicted the workflow of the in silico analysis performed on the regulatory
sequences for both coding and noncoding transcripts of chromosome 21. Green boxes indicate data files; in orange are indicated
the computational tools used to perform the analysis; in blue are indicated the ‘features’ of interest; in white are indicated the
databases and the regulatory data sets retrieved from them.
.............................................................................................................................................................................................................................................................................................
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represented by the sections ‘Coding genes’—divided in
‘Annotated’ and ‘Novel’—and ‘Noncoding genes’. The
‘Novel’ subsection hosts transcripts identified de novo by
the analysis of our RNA-Seq data sets by merging custom
computational workflows to open source tools and public
databases (Figure 1B). In this subsection, only experimen-
tally validated new HSA21 transcripts are reported. For all
of them, sequences have been submitted and approved by
EMBL Nucleotide Sequence Database.
Both sections, ‘Coding genes’ and ‘Noncoding genes’,
contain two types of data: genomic/structural and regula-
tory. In particular, for all HSA21 transcripts, ALE-HSA21 pro-
vides a brief gene/category description, sequences in FASTA
format and 3D structures. These dynamic images are linked
to the regulatory data, consisting of computationally pre-
dicted motifs within nucleotide sequences. In addition, for
coding genes, this web resource integrates links to public
repositories of expression data, gene networks and ontol-
ogies, nucleotide variations, proteins and association to dis-
ease (Gene Expression Atlas, Gene Networks, dbSNP,
UniProt and OMIM, respectively).
In silico identification and experimental validation of
novel HSA21 transcripts
Our RNA-Seq data sets (11) were reanalyzed using a custom
computational workflow (see ‘Materials and Methods’ sec-
tion; schematized in Figure 1B). Through this in silico ap-
proach we identified different intronic/intergenic regions
possibly representing novel transcripts (Supplementary File
S2). Additionally, we checked the presence/absence of in-
tronic/intergenic HCPs in two independent RNA-Seq data
sets from HeLa and K562 cell lines (24) and tumor samples
(manuscript in preparation), observing these are not cell-spe-
cific. Similarly, for known HSA21 genes putative extended
UTRs and novel splice junctions—according to our categor-
ization method—were also detected (Supplementary Files S3
and S4). Filtering out signals (i.e. mapped reads) from pre-
mRNAs and repeats, and considering their overlap with
AceView predictions and/or expressed sequence tags, we
confirmed the presence of 11 novel transcripts arising from
six HSA21 genes (Table 2). Their bona fide was confirmed in
progenitor cells used in our previous study (11), as well as in
other cell lines (data not shown). Nucleotide sequences of
these new transcripts were submitted to the EMBL
Nucleotide Archive, and accession numbers are listed in
Table 2. Newly identified transcripts were added to ALE-
HSA21 database and included in the computational analyses,
further described.
Of note, potentially new transcripts reported in the
Supplementary Files S2–S4, not yet validated by reverse
transcriptase-polymerase chain reaction and Sanger
sequencing, are, however, supported by RNA-Seq data
(HCPs with uniquely mapped reads and/or a sufficient
number of reads mapping on the splice junctions).
However, as RNA-Seq data sets come from fragment
libraries of 50bp reads, and given the heuristic nature of
algorithms for reads’ alignment, despite our checks, false-
positive alignments may have occurred.
Computational analysis of regulatory sequences in
protein-coding transcripts
Predictive in silico analysis of regulatory sequences within
gene promoters, exons, introns and 30 UTRs was performed
for both annotated and newly identified HSA21 protein-
coding transcripts (Table 1). The ‘consensus’ sequences for
78 human TFs were predicted within gene promoters.
Similarly to the RSAT output, the results are provided to
the final user as tables with a ‘weight score’ column mea-
sured by the ‘Background model estimation method’ (17).
Such tables, dynamically integrated on the web portal, can
be accessed through the clickable ‘Promoter’ button in the
3D structure of each transcript (Figure 2C and D). In add-
ition, to provide the users with ChIP-Seq (chromatin immu-
noprecipitation followed by massive sequencing) data for
TFs of the ENCODE project, we also integrated a clickable
button linked to these tracks, loaded into an open-access
custom session of UCSC Genome Browser. This kind of ap-
proach, based both on computational predictions of TFs’
binding motifs and experimental large-scale data, repre-
sents a starting point to investigate differential TFs’ binding
among distinct genes and, more interestingly, among dif-
ferent transcripts of the same gene.
Moreover, as ‘noncanonical’ exonic and intronic se-
quences are known to affect splicing—and mutations
herein can cause monogenic or can be associated to com-
plex disorders—we computationally predicted ESE/ESS and
ISE/ISS within all exons/introns of each HSA21 transcript.
Similar to the predictive analysis of TFs’ binding sites,
data in tabular format were included within ALE-HSA21
and dynamically integrated in 3D transcripts’ models. The
user can access these results by clicking the exon/intron of
interest on the 3D structures (Figure 2C and D).
Table 1. Number of analyzed gene elements collected in ALE-
HSA21 database
Genes Transcripts Promoters Exons Introns 30 UTR
Coding 238 1713 1713 14 177 12 454 1201a
Noncoding 296 462 244 b
Total 534 2175 1713 14 177 12 454 1445
aThe number of 30 UTRs analyzed for the presence of MREs is
smaller than the total number of transcripts because some of
them lack UTR in the GENCODE annotation or are currently anno-
tated as ‘processed transcripts’, ‘retained introns’ and other cate-
gories lacking a typical 30 UTR.
bFor noncoding RNAs, the entire sequences of 220 lincRNAs and
24 pseudogenes have been analyzed for the presence of MREs.
.............................................................................................................................................................................................................................................................................................
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Figure 2. Screenshots from ALE-HSA21 web resource. Panel (A) shows the Homepage with Navigation Bar; panel (B) shows the
list of HSA21 transcripts in the ‘Coding genes’ section in tabular format. Official gene symbol, ID, genomic coordinates, the sense
of transcription, the number of exons and UniProt IDs are reported. The Black arrow and circle indicate an example of a clickable
item (SOD1 gene in the example). By clicking there, the users access the Gene Description page, depicted in Panel (C). Interactive
3D graphical representation for each transcript is embedded in this web page. Each gene element is linked to results of in silico
analysis. Colored circles—red for ‘Promoter’, green for ‘exons’, light blue for ‘introns’ and gray for ‘30 UTRs’—correspond to the
clickable elements of the 3D images. The same color scheme is used in panel (D) to indicate the relative results for the com-
putational analyses of those elements.
Table 2. Novel transcripts identified by RNA-Seq analysis
Gene symbol Transcript Accession number Primer sequence (50–30)
Forward primer Reverse primer
IFNAR2 IFNAR2_var1 HG380509 CTGGGAGTCCGCTTTCGTT GGAGACTTTATTACTGCTTGC
MCM3AP MCM3AP_HF584748 HF584748 AGTGCTGAGCGAACCGGAAG GGCTCAACAGGAAATGGTAAA
NRIP1 NRIP1_HF584749 HF584749 GAGAGCTGCTGAAGAAGTAG TAAATGAGAAAAAATGCATTGTC
NRIP1 NRIP1_HF584750 HF584750 GAGAGCTGCTGAAGAAGTAG TAAATGAGAAAAAATGCATTGTC
POFUT2 POFUT2_var1 HG380510 GGGCCATGGCGACACTCA TGTGTTTCTCAGCAGCAGGG
POFUT2 POFUT2_var2 HG380511 GGGCCATGGCGACACTCA TTTATCCCTGGCGCTGCAC
SAMSN1 SAMSN1_all_skip HG380514 GCACACTGCTGACTGTTTTC ATCTTCCTCTCCTATTTGACG
SAMSN1 SAMSN1_var1 HG380512 GCACACTGCTGACTGTTTTC ACTATAGAAGTGCTTGGTACT
SAMSN1 SAMSN1_var2 HG380513 GCACACTGCTGACTGTTTTC ATCTTCCTCTCCTATTTGACG
DYRK1A DYRK1A_var1 HF584751 TGTTATAGTTTTGCCGCTGGA CTGTTGGTCACTTATGTTTGG
DYRK1A DYRK1A_var2 HF584752 TGTTATAGTTTTGCCGCTGGA CTGTTGGTCACTTATGTTTGG
.............................................................................................................................................................................................................................................................................................
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In addition, given the crucial role of miRNAs in the
posttranscriptional regulation of mRNAs through their bind-
ing to 30 UTRs (25, 26), we added to our resource this layer of
gene regulation. Particularly, we computationally predicted
the binding sites of all annotated human miRNAs within 30
UTRs sequences of HSA21 mapping mRNAs. Results of such
predictive analysis can be accessed through the ‘30 UTR’
button integrated within the 3D graphical representation
of each transcript (Figure 2C and D). Predicting the presence
of differential MREs within distinct transcripts of the same
gene can be rapidly and easily assessed browsing data of our
computational analyses integrated in ALE-HSA21.
Computational analysis for noncoding transcripts
Recent evidences have shown that pseudogenes sequester
miRNAs and act as competitive endogenous RNAs, and a
similar mechanism has been proposed for lincRNAs (27).
The role of these transcripts as miRNAs’ sponges has been
directly linked to carcinogenesis and muscle differentiation
(28–30), and proposed for the onset of neurodegenerative
diseases (31). Given these considerations, using prediction
algorithms we searched for MREs in HSA21 lincRNAs and
pseudogenes. The results were dynamically integrated in
tabular format within the ‘Noncoding genes’ section of
ALE-HSA21, accessible by clicking the ‘miRNA binding
sites’ button located in the web page of the related tran-
script. In addition, using three different prediction algo-
rithms, we also independently predicted—for the five
HSA21 miRNAs available in CoMeTa and miRWalk data-
bases—the putative MiTGs, not limiting such analysis to
HSA21 genes. Data integrated in the web portal are pro-
vided in tabular format (Figure 3A). Moreover, the intersec-
tions between the three above-mentioned lists of
computationally predicted MITGs—one for each prediction
algorithm used—are shown as Venn diagrams (Figure 3B).
These data allow rapidly observing a common pool of
target genes, possibly regulated by the same HSA21
miRNA. Finally, as miRNAs and snoRNAs have a peculiar
folding, which in turn determines their biological functions,
we predicted their secondary structures and integrated
these data as static images within ALE-HSA21 (Figure 3C).
More in detail, in each miRNA and snoRNA drawing, nu-
cleotides are colored by the base-pair probabilities, accord-
ing to local measures of reliability, as described in (32). For
all 19 HSA21 miRNAs, currently annotated in miRBase, we
highlighted the nucleotide sequences corresponding to the
mature—and functional—form of these miRNAs.
Exploring ALE-HSA21
The intuitive interface of ALE-HSA21makes this web resource
an easy and fast—although scientifically accurate, compre-
hensive and updated—tool to retrieve, in few clicks, relevant
information about HSA21 genes and transcripts. A detailed
user’s guide on how to browse ALE-HSA21 and how to
extract useful information is provided as Supplementary
File S5 and also available on the web portal. The homepage
is shown in Figure 2A. From the navigation bar the user can
access to the different sections of the portal. Within the
‘Coding genes’ section there is the complete and updated
list of HSA21 transcripts, both known and newly identified
in this study, in a user-friendly tabular format (Figure 2B). For
each transcript, there is the official gene symbol, ID (NM and/
or ENST according to the RefSeq and the GENCODE annota-
tions), the genomic coordinates with a link to an open-access
session of UCSC Genome Browser, ad hoc created with
chromosome 21 coverage files, the sense of transcription
(indicated by ‘+/-’ strand), the number of exons and the cor-
responding, if any, UniProt IDs. Each feature has a link to
other sections of the web portal as well as to other external
widely used databases. From the gene list table (Figure 2B)
the user can easily access an interactive 3D graphical repre-
sentation of all the transcripts. A ‘Search by Gene’ button
allows a direct and quick access to all information for a
given gene of interest. For each gene, such information con-
sist of (i) full gene name and gene symbol, (ii) brief gene
description with eventual literature references, (iii) links to
gene expression data, gene networks and ontologies, (iv)
single-nucleotide polymorphisms, (v) involvement in human
diseases and (vi) 3D structures of all transcripts generated by
AS (Figure 2C). In the 3D structures, each gene element (i.e.
promoter, exons, introns and 30 UTR) is clickable, allowing to
directly access the results of our in silico analysis of regulatory
sequences. As previously described, these data are provided
in easily comprehensible tabular format, as illustrated in
Figure 2D. In addition, for each element, below the results
table, the nucleotide sequences are viewable and download-
able (FASTA format).
The ‘Noncoding genes’ section contains the comprehen-
sive list of all HSA21 noncoding transcripts, divided in 10
categories, as depicted in Figure 1B. Similar to the ‘Coding
genes’ section, by clicking on a specific transcript ID, the
users can retrieve structural and regulatory data, described
in the previous paragraph. In particular, for lincRNAs and
pseudogenes, clickable ‘miRNA binding sites’ button allows
accessing a complete list of predicted MREs in tabular
format. Furthermore, the ‘Target genes’ button, included
within the web pages dedicated to miRNAs, is directly
linked to the results of our analysis on genes predicted to
be targets of the selected miRNA.
Finally, a ‘Search by Features’ section has been imple-
mented to ease the browsing ALE-HSA21 for specific fea-
tures of interest, such as Gene Symbol, Transcript ID and
UniProt ID.
Conclusion
RNA-Seq studies have clearly shown that the vast majority
of—if not all—human genes undergo AS, generating
.............................................................................................................................................................................................................................................................................................
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different transcripts (33, 34). These can be transcribed from
alternative promoters and may possibly be regulated by
different TFs as well as epigenetic factors (i.e. methylation
and/or histone modifications). Transcripts with alternative
30 UTRs may also undergo different co- and posttranscrip-
tional regulation by miRNAs. In light of this, ALE-HSA21 is
designed to provide, at the transcript level, computational
predictions of TFs’ binding sites in promoters as well as
MREs in 30 UTRs. Nonetheless, the presence of in silico pre-
dicted binding motifs does not guarantee a specific regula-
tory factor will bind that sequence. Future studies, based on
ChIP-Seq data sets for TFs and sequencing of small RNAs,
will surely allow us to improve the accuracy of this analysis.
Understanding if alternative transcripts may be targets of
different miRNAs, or if their transcription may be triggered
by the same TFs, is clearly important to address their
differential regulation, both in physiological and patho-
logical conditions.
Moreover, it is known that different transcripts can arise
from the same gene through the usage of alternative canon-
ical splice sites, as well as noncanonical splicing enhancer/si-
lencer sequences. Mutations within these regions affect
splicing, causing diseases (35). Among them, familial isolated
growth hormone deficiency type II is caused by different
mutations occurring in the 50 splice site, ISE and ESE that
increase splicing of the exon 3 of GH1 gene (36–38). In add-
ition, aberrant splicing events—such as those caused by mu-
tations in WT1 gene in Frasier syndrome—may alter isoform
abundance, affecting several cell processes (39–41). Thus, cat-
aloguing the predicted binding sites for auxiliary splicing
factors within all the splicing isoforms of a gene is an
added value for clinicians studying human diseases.
Figure 3. Example of the data provided for miRNAs in ALE-HSA21 web portal. In panel (A) and (B) are shown the results of the
computational prediction of MiTGs in tabular format and Venn diagrams, respectively. Such data are accessible by clicking the
‘Target genes’ button embedded within miRNA web pages. ‘Validated’, ‘predicted’ and ‘co-expressed’ correspond to the target
genes according to miRWalk and CoMeTa databases. Panel (C) shows a prediction of the secondary pre-miRNA structure
obtained by RNAfold. Mature miRNA sequences are indicated by black brackets.
.............................................................................................................................................................................................................................................................................................
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Moreover, incomplete annotation of transcripts can lead
to misinterpret the effect of nucleotide variations, both
mutations and single-nucleotide polymorphisms. On the
opposite, the exact knowledge of all splicing isoforms is
crucial for clinicians to identify disease-causing mutations.
The discovery of a 30 terminal exon of RPGR gene—mutated
in 60% of X-linked retinitis pigmentosa patients—is one of
the first and most convincing examples of the link between
AS and human diseases (6).
Such evidence highlights the importance to study at the
isoform level, rather than at gene level, both physiological
processes and disease mechanisms. The recently developed
DataBase of Alternative Transcripts Expression (DBATE),
valuable source of expression data for AS variants, is a
good example (42).
In this ‘scenario’, our pilot transcript-centric database
represents a fast and intuitive resource for medical geneti-
cists interested in HSA21-related pathologies (such as DS),
as well as for researchers investigating any molecular path-
way or cell process involving HSA21 genes. Because ALE-
HSA21 is an easy-to-use resource, it is accessible to all
scientists with low experience in computational biology or
informatics. ALE-HSA21 has been conceived to simply and
rapidly provide the user with data usually dispersed in dis-
tinct databases or accessible by independently using differ-
ent computational tools. The presence of genomic data, as
well as of in silico predictions of regulatory sequences, links
to gene expression, mutation and gene network databases
in a unique Web site is an added value of ALE-HSA21.
Finally, our resource is in line with the growing interest
for ncRNAs—supported by the wide diffusion of databases
such as miRBase (20), miRWalk (21), lncRNome (43), lncRNA
db (44), NONCODE (45) and Pseudofam (46). ALE-HSA21
provides open-access computational predictions about
the presence of regulatory sequences for pseudogenes,
lncRNAs and miRNAs, known to be involved in several bio-
logical processes.
This study is likely to represent an interesting proof-
of-concept and a starting point for implementing similar
resources with the aim to integrate information available
in different databases to ‘omics’ data, generated by next-
generation sequencing (RNA-Seq, ChIP-Seq and MeDIP-Seq)
or by other large-scale technologies.
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'e nuclear receptor PPAR훾 is a key regulator of adipogenesis, and alterations of its function are associated with di(erent
pathological processes related to metabolic syndrome. We recently identi)ed two PPARG transcripts encoding dominant negative
PPAR훾 isoforms. 'e existence of di(erent PPARG variants suggests that alternative splicing is crucial to modulate PPAR훾
function, underlying some underestimated aspects of its regulation. Here we investigate PPARG expression in di(erent tissues
and cells a(ected in metabolic syndrome and, in particular, during adipocyte di(erentiation of human mesenchymal stem cells.
We de)ned the transcript-speci)c expression pattern of PPARG variants encoding both canonical and dominant negative isoforms
and identi)ed a novel PPARG transcript, 훾1ORF4. Our analysis indicated that, during adipogenesis, the transcription of alternative
PPARG variants is regulated in a time-speci)c manner through di(erential usage of distinct promoters. In addition, our analysis
describes—for the )rst time—the di(erential contribution of three ORF4 variants to this process, suggesting a still unexplored role
for these dominant negative isoforms during adipogenesis. 'erefore, our results highlight crucial aspects of PPARG regulation,
suggesting the need of further investigation to rule out the di(erential impact of all PPARG transcripts in both physiologic and
pathologic conditions, such as metabolism-related disorders.
1. Introduction
Peroxisome proliferator-activated receptors (PPARs, also
known as nuclear receptor family 1C, NR1C) are ligand-
dependent transcription factors belonging to the nuclear
hormone receptor superfamily.'ree members of the PPAR
family—known as PPAR훼, PPAR훽/훿, and PPAR훾—encoded
by di(erent genes located on di(erent chromosomes have
been identi)ed [1–3].
Undoubtedly, PPAR훾 is the most extensively studied and
characterized member of PPARs, given its involvement in
several physiological states, as well as pathological condi-
tions. Indeed, it modulates the expression of several genes
that play a central role in glucose, lipid and cholesterol
metabolism, in*ammation, angiogenesis, proliferation, and
di(erentiation [4–7]. In particular, PPAR훾 is the master
regulator of adipogenesis, since it regulates the transcription
of a wide number of genes involved in cellular di(erentiation
and lipid accumulation [8, 9]. Defects in PPAR훾, signaling
its altered expression and/or activation, as well as polymor-
phisms/mutations, are implicated in di(erent pathological
conditions occurring in metabolic syndrome, such as insulin
resistance, obesity [10], dyslipidemia, and hypertension, that
markedly increase the risk of type 2 diabetes [11–13], as well
as cardiovascular diseases and cancer [3, 4, 14–17].
'e prevalence of metabolic syndrome is increasing to
epidemic proportions and, to date, an adequate therapy has
not been yet established. Of great clinical interest, synthetic
ligands of PPAR훾, belonging to the class of thiazolidinediones
(TZDs), such as troglitazone, pioglitazone, and rosiglitazone,
function as insulin sensitizers and are used for treating
hyperglycemia in patients with type 2 diabetes [7, 18–20].
Hindawi Publishing Corporation
PPAR Research
Volume 2014, Article ID 537865, 11 pages
http://dx.doi.org/10.1155/2014/537865
2 PPAR Research
Nevertheless, their use in type 2 diabetes therapy has been
limited by untoward e"ects. #us, a better understanding
of PPAR훾 signaling is crucial to develop more e"ective and
targeted therapeutic strategies to treat metabolic syndrome
and its complications.
However, to fully de$ne the landscape of PPAR훾 activity,
some relevant aspects need to be taken into account. One of
the most relevant features is the ability of PPARG gene to give
rise to di"erent transcripts. Indeed, the human PPARG gene
consists of nine exons and—by di"erential promoter’s usage
and alternative splicing—generates at least four main splice
variants (i.e., PPARG1, PPARG2, PPARG3, and PPARG4).
#ese transcripts display di"erent 5耠 untranslated regions
(UTRs), followed by six coding exons. However, despite the
presence of such a variable number ofPPARG transcripts, this
gene encodes only two protein isoforms. Indeed, PPARG1,
PPARG3, and PPARG4 encode the same protein PPAR훾1—
localized in the adipose tissue, liver, heart, and skeletal
muscle—whereas PPARG2 yields a proteinwith 28 additional
amino acids at theN-terminus, known as PPAR훾2, exclusively
localized in the adipose tissue [21–23].
Di"erent ability to induce adipogenesis has been shown
for PPAR훾1 and PPAR훾2, indicating a more relevant adi-
pogenic activity for PPAR훾2. Although both isoforms are
thought to be essential during adipocyte di"erentiation, their
relative contribution is not yet well clari$ed [24–27].
More recently, our group identi$ed in sporadic colorectal
cancers two novel PPARG transcripts harboring a read-
through in intron 4, named 훾2ORF4 and 훾3ORF4, displaying
the same 5耠UTRs of PPARG2 and PPARG3, respectively [28].
#e protein products lack the ligand binding domain (LBD)
and act as dominant negative toward PPAR훾. Although it
has been shown that 훾ORF4 plays a role in pathogenesis of
colorectal cancer, its presence and expression levels have not
yet been investigated in other cells and/or tissues.
To date, accurate analyses of the expression pattern of
each PPARG transcript are still missing. For instance, to the
best of our knowledge, this consideration holds true particu-
larly for the adipogenesis, in which PPAR훾 is the main driver
[4, 7, 29]. Alterations of adipocyte di"erentiation are strictly
associatedwith obesity andmetabolism-related disorders and
therefore intimately linked to the physiopathology of the
metabolic syndrome [30, 31]. Describing in detail the relative
contribution of all currently known PPARG transcripts—and
its dominant negative isoforms—in adipogenesis, as well as
in tissues and cells related to processes altered in metabolic
syndrome, will provide a solid basis to rule out if, and how,
they may account for metabolism-related diseases.
Here we describe a complete expression analysis of all
annotated PPARG transcripts—PPARG1, PPARG2, PPARG3,
and PPARG4—as well as its dominant negative isoform훾ORF4 in human tissues and cells a"ected in metabolic
syndrome. In particular, we focus on their di"erential expres-
sion during human adipogenesis, using human mesenchy-
mal stem cells (hMSCs) isolated from the stromal vascular
fraction of adipose tissue [32]. A-er in vitro di"erentiation of
hMSCs in adipose cells, by using transcript-speci$c RT-PCR
and Quantitative Real-Time PCR assays, we measured the
expression of PPARG transcripts at various time points from
the induction of adipocyte di"erentiation, demonstrating the
di"erential contribution of each alternative splice variant.
A similar pattern of expression was also observed for total
PPAR훾 and 훾ORF proteins. In addition, here we describe, for
the $rst time, a novel transcript of PPARG, named 훾1ORF4,
similar to the dominant negative 훾2ORF4 and 훾3ORF4,
previously identi$ed [28]. Finally, we evaluated the abun-
dance of all ORF4 variants during adipocytes’ di"erentiation,
also suggesting—for the $rst time—the involvement of these
dominant negative isoforms in human adipogenesis.
2. Materials and Methods
2.1. Cell Cultures. Media, sera, and antibiotics for cell culture
were from Lonza (Basel, Switzerland). Human Embryonic
Kidney 293 cells (HEK239) were cultured in Dulbecco’s
modi$ed Eagle’s medium (DMEM) supplemented with 10%
fetal bovine serum (FBS), 2mmol/L glutamine, 100 units/mL
penicillin, and 100 units/mL streptomycin.
HumanMesenchymal StemCells (hMSCs) were obtained
by abdominal biopsy and cultures established as described
previously [33]. #e cells were grown in DMEM-F12 (1 : 1)
with 10% FBS, 2mmol/L glutamine, 100 units/mL penicillin,
and 100 units/mL streptomycin. Cultures were maintained in
a humidi$ed atmosphere of 95% air and 5% CO2 at 37∘C.
2.1.1. Adipocyte Di#erentiation. Adipocyte di"erentiation
was achieved as previously described [34]. Brie.y, hMSCs
were seeded (10,000 cells/cm2) and cultured in six-well plates
until con.uence. Adipocyte di"erentiation was induced with
a di"erentiation cocktail consisting of 850 nmol/L insulin,
10 휇mol/L dexamethasone, 0.5mmol/L IBMX (isobutyl-
methylxanthine), 10 휇mol/L pioglitazone, 33 휇mol/L biotin,
and 17 휇mol/L pantothenate in DMEM-F12 (1 : 1) supple-
mented with 3% FBS, 2mmol/L glutamine, and antibiotics.
A-er 3 days, the medium was changed to a medium con-
taining only insulin and pioglitazone in DMEM-F12 (1 : 1)
supplemented with 10% FBS, glutamine, and antibiotics.
Culture medium was then changed every 2 days for another
8 days up to obtain a complete adipocyte di"erentiation
of hMSCs. Lipid accumulation was determined by Oil Red
O staining as described by Isakson and colleagues [34].
Adipocyte di"erentiation from hMSCs was performed in
triplicate.
2.2. RNA Extraction and RT-PCR Assays. Total RNA was
isolated from HEK239 and hMSCs at di"erent stages of
adipocyte di"erentiation, using TRIzol solution (Invitrogen)
according to the manufacturer’s instructions. RNA extracted
from the other human tissues, heart, liver, and thyroid,
and cells, human colon carcinoma, endothelial progenitor
(EPCs), macrophages, and breast cancer (MCF7), employed
in our analysis, was obtained in previous studies [28, 33, 35,
36]. For each sample, total RNA (1000 ng) was reverse tran-
scribed using “high-capacity cDNA reverse-transcription kit”
(Applied Biosystems, Foster City, CA). cDNAs obtained
from human tissues and cells were used as template for
RT-PCR assays. PCR ampli$cation with speci$c primer
PPAR Research 3
Table 1: Primer pairs for canonical and dominant negative PPARG variants.
Transcript Oligonucleotide pairs Size (bp)
Forward Reverse
tPPARG GAGAAGGAGAAGCTGTTGGC ATGGCCACCTCTTTGCTCT 272
PPARG1 CGAGGACACCGGAGAGGG TGTGGTTTAGTGTTGGCTTCTT 69
PPARG2 TTTTAACGGATTGATCTTTTGC AGGAGTGGGAGTGGTCTTCC 255
PPARG3 TTCTGCTTAATTCCCTTTCC AGGAGTGGGAGTGGTCTTCC 194
PPARG1/4 CGAGGACACCGGAGAGGG AGGAGTGGGAGTGGTCTTCC 211/137
tORF4 CTTGCAGTGGGGATGTCTCA AAACCCAAAACAACTTCCCG 279훾1ORF4 CGAGGACACCGGAGAGGG AAACCCAAAACAACTTCCCG 906훾2ORF4 TTTTAACGGATTGATCTTTTG AAACCCAAAACAACTTCCCG 950훾3ORF4 TTCTGCTTAATTCCCTTTCC AAACCCAAAACAACTTCCCG 889
pairs—designed using Oligo 4.0 and listed in Table 1—was
performed using 1 휇L of the reverse transcription reaction
as template in PCR reactions set up with AmpliTaq Gold
(Perkin Elmer). PCR assays have been performed using these
ampli/cation conditions: 95∘C for 10 minutes, followed by
35 cycles at 95∘C for 40 sec, 60∘C for 40 sec, 72∘C for 30 sec,
and 70∘C for 7min. RT-PCR products were of expected
length (see Table 1). In each experiment, a sample without
reverse transcriptase was used as negative control and it
was ampli/ed under the same conditions as the reverse-
transcribed RNA.
2.3. Cloning and Sequencing. 0e multiple PCR products (of
about 211 and 137 bp, resp.), obtained in RT-PCR assays of
PPARG1/PPARG4, have been cloned into Topo Vector II
(Invitrogen) according to the manufacturer’s instructions.
Clones and other RT-PCR products were directly sequenced
by Sanger method, con/rming the speci/city of reactions.
2.4. Real-Time PCR. Quantitative Real-Time PCRs were per-
formed on cDNA samples of hMSCs and undi1erentiated at
di1erent stages of adipocyte di1erentiation (6hours, 12hours,
24 hours, 2 days, 4 days, 7 days, and 10 days a2er induction of
the process). Ampli/cation reaction mix contained 1x SYBR
Green PCR master mix (Applied Biosystems), 160 nM of
each primer, and 50 ng of cDNA (RNA equivalent) as tem-
plate. Quantitative Real-Time PCR assays were performed in
according to the manufacturer’s instructions for the 7900HT
Real-Time PCR system (Applied Biosystems) in the same
conditions described in [37]. Each assay for the 5 analyzed
transcripts was performed in three biological replicates for all
the time points. For each cell replicate, Real-Time assays were
performed in two duplicated wells. Relative gene expression
was measured by using 2−ΔΔCt method. For each assay,
expression levels were normalized for the reference values
(time point at 0 hours or 6 hours) using glyceraldehyde 3-
phosphate dehydrogenase (GAPDH) as housekeeping gene.
qRT-PCRs data were reported as mean values and standard
deviation of three biological replicates and results analyzed
by paired Student 푡 test. 푃 value < 0.05 was considered
statistically signi/cant.
2.5. Immunoblot Procedure. Total cell lysates were obtained
and separated by sodium dodecyl sulfate—polyacrylamide
gel electrophoresis (SDS-PAGE) as previously described [38].
Brie3y, hMSCs undi1erentiated and at di1erent stages of
adipocyte di1erentiation (2 and 10 days) were solubilized for
2 hours at 4∘C with lysis bu1er containing 50mM HEPES,
150mMNaCl, 10mMEDTA, 10mMNa4P2O7, 2mMsodium
orthovanadate, 50mM NaF, 1mM phenyl-methyl-sulfonyl
3uoride, 10 휇g/mL aprotinin, 10휇g/mL leupeptin, pH 7.4,
and 1% (v/v) Triton X-100 (all reagents for lysis bu1er were
from Sigma-Aldrich, St Louis, MO, USA). 0e lysates were
clari/ed by centrifugation at 12,000 rpm for 20min at 4∘C.
Proteins were separated by SDS-PAGE (Bio-Rad Hercules,
CA, USA) and blotted on Immobilon-P membranes (Mil-
lipore, Billerica, MA). Membranes were incubated with a
polyclonal antibody directed against the N-terminal domain
of PPAR훾 (Santa Cruz Biotechnology, CA, USA) and with
antiactin antibodies (Santa Cruz Biotechnology, CA, USA).
Detection of blotted proteins was performed by enhanced
chemiluminescence (ECL,AmershamBiosciences, Arlington
Heights, IL, USA) according to the manufacturer’s instruc-
tions. Densitometric analysis was performed using Image Lab
So2ware (Bio-Rad, Hercules, CA, USA). For each protein
isoform (PPAR훾 and 훾ORF4), data are shown as pixel density
ratio versus control protein (actin).
3. Results
3.1. Expression Pro&le of PPARG Transcripts. Four main
PPARG transcripts are currently known, as described by
Costa et al. [3]. Additionally, our group has recently identi/ed
two isoforms acting asdominant negative toward PPAR훾 [28],
transcribed by the same promoters of PPARG2 and PPARG3
transcripts, respectively (details in Figure 1).
Using speci/c primers pairs (Table 1), we performed an
extensive expression analysis of PPARG1, PPARG2, PPARG3,
PPARG4, and ORF4 in tissues and cells related to com-
plications of metabolic syndrome—such as altered glu-
cose and lipids’ metabolism (liver), increased in3ammatory
response (macrophages), atherosclerosis (EPCs, heart, and
macrophages), cancer (colon carcinoma and MCF7), and
thyroid dysfunction (thyroid)—and in a widely used cell
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Figure 1: Schematic representation of human PPARG gene, transcripts, and protein isoforms. In the upper part the genomic localization of
PPARG gene is indicated, with chromosome indication, cytogenetic band, and surrounding genes. Below is depicted the exon/intron structure
of PPARG gene with transcribed splicing variants. Transcripts encoding both the canonical and dominant negative proteins are illustrated in
the le( panel.)e right panel shows a schematic representation of the encoded proteins with the functional domains.
model, HEK293 [3, 6, 17, 39, 40]. Given the high similarity
between the 5耠UTRs of PPARG1 and PPARG4 transcripts, the
primers employed to analyze PPARG4 amplify both variants
(distinguishable as PCR products of di1erent size), whereas
we could design PPARG1 speci2c primers.
)e tissue-speci2c expression pattern of PPARG alterna-
tive variants, including also transcripts encoding the same
protein (PPARG1, PPARG3, and PPARG4), is shown in
Figure 2. Such analysis revealed that PPARG1 transcript is
expressed in all analyzed tissues and cell lines, con2rming
that it is abundantly and almost ubiquitously expressed in
human tissues [21]. Similarly, PPARG4—which is transcribed
from the same promoter—is expressed in almost all analyzed
samples, albeit at lower levels than PPARG1. )erefore, we
demonstrated that, in most of examined samples, PPARG1
and PPARG4 contribute to the translation of PPAR훾1 protein,
whereas PPARG3 is expressed at low levels only in EPCs
and heart. Noteworthy, also PPARG2 transcript is expressed
in EPCs, as well as in the heart, whereas its expression
is undetectable in other examined tissues and cell lines.
)is 2nding—possibly correlated to the anti-in3ammatory
role of this nuclear receptor in the cardiovascular system
[41–43]—suggests that PPAR훾2 is predominantly expressed
in these adult tissues. Surprisingly, the dominant negative
isoform 훾ORF4, till now associated with tumor pathogenesis,
is expressed in all analyzed tissues and cell lines, suggesting
a not negligible contribute to PPARG activity also in other
physiologic and pathological cell processes. Of note, the
results shown in Figure 2 refer to ORF4 transcripts’ total
expression.
3.2. Expression of PPARGVariants during Adipogenesis. A(er
in vitro induction of hMSCs toward adipogenic di1erentia-
tion (see Methods), we selected seven di1erent time points
(Figure 3). In particular, we investigated the “early stages” of
adipocyte di1erentiation (6, 12, and 24 hours a(er induction),
an intermediate time point (2 days), and “late stages” (4 and
7 days) according to visible changes in cell morphology and
an endpoint at 10 days when cells di1erentiate into adipocytes
(Figure 3).
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Figure 2: Expression pattern of PPARG variants in tissues and cells a(ected in the metabolic syndrome. For each PPARG transcript, speci)c
primer pairs were used for PCR reactions. Given the similarity between PPARG1/4 5耠UTRs primers ampli)es both variants (distinguishable as
PCR products of di(erent sizes). “ORF4t” indicates the entire pool of ORF4 transcripts. Amplicons’ sizes are shown (in bp) below transcripts’
names. On the bottom panel, negative PCR controls are shown for each primer pair.
RT-PCR assay revealed that, )rst of all, total PPARG
expression (i.e., of the entire pool of canonical PPARG
transcripts) is very high throughout the process. In detail,
using variant-speci)c primers we observed that all PPARG
transcripts are expressed—albeit at variable levels—in the
examined di(erentiation stages (Figure 4(a)). Interestingly,
PPARG2 is not expressed in hMSCs, whereas its expression
is remarkably higher in the early stages a,er induction
toward adipocyte di(erentiation. Particularly, as shown in
Figure 4(a), this transcript reaches its highest expression
a,er 2 days from the induction and is completely silenced
at the end of the process. Similarly, PPARG3 has a mild
but detectable expression only in the intermediate and late
stages of cells’ di(erentiation, with its highest expression at
2 days. .is analysis revealed that PPARG1 and PPARG4
are the only canonical transcripts contributing to the )nal
expression of PPAR훾 protein in undi(erentiated hMSCs and
therefore that these cells express only PPAR훾1 isoform. In
particular, PPARG1 is expressed at much higher levels than
PPARG4 variant and, given the absence of the PPARG3 splice
variant, it can be considered as the main contributor to the
synthesis of functional PPAR훾1 protein in undi(erentiated
cells (Figure 4(a)).
However, PPARG1 and PPARG4 are expressed also
throughout the adipocyte di(erentiation, although the for-
mer is the most expressed PPARG transcript at all the stages.
3.2.1. Identi$cation of 훾1ORF4 and Analysis of PPARG Dom-
inant Negative Transcripts. Given the existence of two dif-
ferent isoforms of 훾ORF4, previously described as dominant
negative of PPAR훾 [28], we asked whether other ORF4
variants may be transcribed from the promoter upstream the
A1.1 exon of PPARG gene. .us, using speci)c primers pairs
(described in Table 1), we were able to identify in hMSCs
a novel ORF4 variant, named 훾1ORF4 (accession number
still in process; see Figure 1 for details). Similarly to PPARG1,
its 5耠UTR consists of A1.1 and A2 exons, whereas its coding
region extends from exon 1 to 4, with a read-through in intron
4, identical to the other ORF4 transcripts (structural details
in Figure 1).
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Figure 3: Phenotypic characteristics of undi(erentiated, di(erentiating, and di(erentiated hMSCs (h = hours; d = days). Adipocyte
di(erentiation was determined at 10 days from adipogenesis induction by Oil Red O staining of lipids vacuoles, as shown.
Given the discovery of such new transcript in hMSCs,
we decided to investigate the expression of the entire pool
of ORF4 variants (ORF4t in Figure 4(b)) during in vitro
adipogenesis. Of note, RT-PCR assay revealed that these
variants are expressed along adipocytes’ di(erentiation and
particularly in the crucial stages of this process (24 hours,
2 and 4 days). Subsequent independent analysis of the
three ORF4 transcripts revealed that 훾3ORF4 variant is
expressed throughout the process, whereas 훾2ORF4 mRNA
undergoes a dramatic increase at 2 days from di(erentiation’s
induction.Noteworthy, the novel variant 훾1ORF4—identi-ed
in undi(erentiated hMSCs—is expressed at variable levels
during adipogenesis, although it is undetectable at some
stages (Figure 4(b)).
3.3. Quantitative Analysis of Canonical and Dominant Neg-
ative PPARG Splice Variants during Adipogenesis. To have a
quantitative estimate of PPARG transcripts a.er induction
of the adipogenic process, we performed Quantitative Real-
Time analysis with speci-c primer pairs at the time points
above described. Such quantitative analysis con-rmed the
-ndings of RT-PCR assay, showing that the expression of total
PPARG increases up to 2 days by adipogenesis induction.
Indeed, at this stage, total PPARG expression is about 20-
fold increase compared to undi(erentiated cells and it linearly
decreases a.er 7 days, reaching expression levels comparable
to undi(erentiated cells (Figure 5(a)).
However, the most relevant -ndings derive from the
canonical transcript-speci-c analysis. Indeed, it revealed that
all PPARG canonical transcripts have a similar trend of
expression but exhibit di(erent fold increase during the
process (Figure S1 see supplementary materials available
online at http://dx.doi.org/10.1155/2014/537865). For PPARG2
and PPARG3 the expression values at 6 hours were used
as baseline, since they are not expressed in undi(erentiated
hMSCs (Figure 5(a)). However, despite their low expression
levels, these transcripts exhibit an increase of expression
considerably higher than PPARG1. Indeed, at 2 days by
di(erentiations’ induction, the expression of PPARG2 and
PPARG3 raises of about 110- and 45-fold, respectively,
whereas PPARG1 increase is of about 10-fold (Figure 5(a)).
To quantitatively study ORF4 transcripts, the only way
to discriminate among the di(erent variants is through
the analysis of large PCR amplicons (about 900–1000 bp,
Figure 4(b)), unfeasible with qRT-PCR. 3us, quantitative
data for ORF4, shown in Figure 5(a), refer to the pool of
ORF4 transcripts. Particularly, we observed, for these vari-
ants, a di(erent trend of expression throughout the process
compared to PPARG canonical transcripts, con-rming RT-
PCR assays (Figure 4(b)). Indeed, ORF4 total expression is
signi-cantly downregulated in early stages of di(erentiation
and reaches its highest values at 2 days. Nonetheless, its
increase is considerably lower than the canonical transcripts
(fold increase = 4; Figure 5(a)).
Finally, pairwise comparison of fold changes’ variation,
that is, between two subsequent time points, revealed that the
most signi-cant increase of the expression values occurs in
the transition fromday 1 to day 2 upon induction of adipocyte
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di)erentiation (Figure S1). Notably, themost striking increase
has been observed for PPARG2 and PPARG3 variants (about
90 and 40 fold, resp.), suggesting the inducible nature of
their promoters during this process. On the opposite, highly
signi(cant decreases were observed—for these two splice
variants—immediately a*er day 2 from the induction of
the process. A common behavior was observed for PPARG1
and ORF4 transcripts. In particular, these variants undergo
mild expression changes in the transitions among the stages,
showing a quite constant basal expression throughout the adi-
pogenic process (Figure 5(a) and S1). Since the most evident
changes in PPARG transcripts’ abundance were detected a*er
2 days by di)erentiation induction, we investigated protein
levels on three time points, day 0 (undi)erentiated cells), day
2 (i.e., the highest peak of PPARG expression), and day 10 (i.e.,
di)erentiated cells). As no commercially available antibodies
exist for ORF4 protein, we used a polyclonal antibody
directed against the N-terminal domain, able to recognize
both the canonical and the shortest PPARG isoforms. We
detected canonical PPAR훾 at 67 kDa and immunoreactive
bands at 40 kDa, the predicted weight of ORF4 protein
isoform. As expected, consistently with the changes in
mRNA levels, a*er 2 days by di)erentiation induction, the
expressions of PPAR훾—and of the shortest isoforms—were
higher compared to both undi)erentiated and completely
di)erentiated cells (Figure 5(b)).
4. Conclusions
Epidemiological studies demonstrate that the prevalence of
the metabolic syndrome is increasing in the Western world
and developing countries, and to date an adequate therapy
has not been yet established [17, 44].
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Undoubtedly, PPARG is one of the most studied genes
accounting for metabolic disorders. Indeed, it modulates the
expression of several genes with a crucial role in glucose,
lipid and cholesterol metabolism, insulin signaling, and
adipokines’ production, whose imbalance leads to insulin
resistance, obesity, type 2 diabetes, and cardiovascular dis-
eases [3, 4, 7, 14]. PPAR훾 is also a drug target and, currently,
its synthetic ligands are used to treat hyperlipidemia and
as insulin-sensitizing antidiabetic agents [18]. 2us, de,n-
ing PPARG activity in tissues and cells related to energy
metabolism may provide useful insights to develop new
and e(ective therapeutic strategies to treat the metabolic
syndrome and its complications.
It is currently known that—by di(erent promoter usage
and alternative splicing—the human PPARG gene gener-
ates multiple variants encoding two proteins, PPAR훾1 and
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PPAR훾2. Since di#erent PPARG splice variants encode the
same protein isoform, their di#erential expression, both
spatial and temporal, may re$ect a di#erent regulation, trans-
lation, mRNA stability, and/or localization. To complicate
the picture, the recent identi%cation of 훾ORF4 isoform—able
to act as dominant-negative and with a tumorigenic e#ect
[28]—suggests that PPAR훾 activity is modulated through
transcript-speci%c regulation.
(erefore, our e#ort has been to investigate PPARG
expression in di#erent tissues and cells—a#ected in meta-
bolic syndrome—and during hMSCs’ adipocyte di#erentia-
tion. Other than focusing on canonical PPARG transcripts, a
particular emphasis was posed toward de%ning the expres-
sion pattern of its variants encoding dominant negative
isoforms. In our study we identi%ed 훾1ORF4, a novel PPARG
transcript that, similarly to the previously described 훾2ORF4
and 훾3ORF4 [28], may act as dominant negative toward
PPAR훾.
Our expression analysis has clearly demonstrated that the
di#erent promoters of PPARG have a peculiar transcriptional
activity. Such %nding is particularly relevant in the adipocyte
di#erentiation, in which PPAR훾 is a key player [4, 9, 29].
(e almost ubiquitous PPARG1/PPARG4 expression, partic-
ularly throughout adipogenesis, indicates amore pronounced
activity of their promoter compared to the others, suggesting
it as the main contributor to PPAR훾 protein synthesis.
Furthermore, the mild expression changes of PPARG1 along
adipocyte di#erentiation strengthen the hypothesis that its
promoter provides constitutive levels of PPARG messengers.
On the opposite, the tissue- and stage-speci%c PPARG2
expression, as well as its dramatic variations throughout the
adipogenesis, clearly demonstrate its inducible nature.
Interestingly, the almost ubiquitous expressions of ORF4
variants in tissues and cells, as well as during adipogenesis,
support the hypothesis that PPARG regulates itself through
dominant negative isoforms. Furthermore, our results sug-
gest that similarly to PPARG canonical transcripts, the three
ORF4 variants give a di#erent contribution to PPAR훾 activity.
Indeed, whereas 훾1ORF4 and 훾2ORF4 exhibit stage-speci%c
expression, 훾3ORF4 is constantly expressed along adipocyte
di#erentiation but not in mature adipose cells. (ese %nd-
ings, strictly correlated with those regarding the canonical
isoforms, suggest that (1) the promoter upstream exon B
is inducible for both the canonical and ORF4 variants, (2)
constitutive levels of PPARG variants, encoding dominant
negative isoforms, are provided throughout di#erentiation
by the promoter upstream noncoding exon A1.2, and (3)
it almost exclusively transcribes 훾3ORF4 rather than the
canonical PPARG3. (erefore, such evidences suggest a
relevant—if not exclusive—role of promoter of 훾3ORF4 and
PPARG3 variants in negative PPAR훾 regulation. In addition,
protein analysis con%rmed that a+er 2 days by di#erentiation
induction PPAR훾 protein has a higher expression compared
to undi#erentiated and completely di#erentiated cells. More-
over, we observed the same trend of expression also for a
shorter protein of 40 kDa, corresponding to the predicted
weight of ORF4 isoform.
Although the results described herein represent only a
starting point to understand the impact of PPARG transcripts
along human adipogenesis, they support the notion that
this generegulates such crucial process through balancing
the levels of its di#erent splicing variants. Further studies—
particularly taking into account PPARG protein products—
are strictly required to de%nitely establish the role of all
splicing variants in adipocyte di#erentiation. Notably, our
results shed light on previously underestimated aspects of
PPARG regulation and propose a yet unexplored role of its
dominant negative isoforms during adipogenesis. Indeed,
the %nding that—during a crucial process in which PPARG
is a “master gene”—both the transcripts and the proteins
encoding dominant negative isoforms are constitutively
expressed and/or can bemodulated similarly to the canonical
PPARG variants, enforces the need to investigate toward
this direction. Understanding more about PPARG activity
in the adipogenic process is directly linked to its possible
contribution to the onset and progression of metabolism-
related pathologies, including themetabolic syndrome and its
complications.
Finally, we cannot exclude that the presence of transcripts
encodingPPARG dominant negative proteins in other human
tissues may underlie their interesting roles in physiological
processes as well as in other pathological conditions.
Conflict of Interests
(e authors declare that there is no con$ict of interests
regarding the publication of this paper.
Authors’ Contribution
M. Aprile and M. R. Ambrosio contributed equally to this
work.
Acknowledgments
(e authors thank the FLAGSHIP “InterOmics” Project
(PB.P05) to A. Ciccodicola, funded and supported by the
Italian MIUR and CNR organizations and the Italian Min-
istry of Education, University and Research (MIUR) Project
National Operational Programme for “Research and Com-
petitiveness” 2007–2013 PON01 02460 to A. Ciccodicola, P.
Formisano and F. Beguinot. (e %nancial support through
the projects ORTO11TSM3 to F. Beguinot and the FIRB
project RBNE08NKH7 (MERIT initiative) to F. Beguinot
and P. Formisano is gratefully acknowledged. M. Aprile is
PhD student in molecular and cellular biotechnology at
the Department of Environmental Sciences and Technolo-
gies, biological, and pharmaceutical “DISTABiF” at Second
University of Naples. M. R. Ambrosio is PhD student in
Molecular Oncology and Endocrinology at the Department
of Translational Medical Sciences, University of Naples “Fed-
erico II”.
References
[1] T. M. Willson, P. J. Brown, D. D. Sternbach, and B. R. Henke,
“(e PPARs: from orphan receptors to drug discovery,” Journal
of Medicinal Chemistry, vol. 43, no. 4, pp. 527–550, 2000.
10 PPAR Research
[2] M. C. Cho, K. Lee, S. G. Paik, and D. Y. Yoon, “Peroxi-
some proliferators-activated receptor (PPAR) modulators and
metabolic disorders,” PPAR Research, vol. 2008, Article ID
679137, 14 pages, 2008.
[3] V. Costa,M. A. Gallo, F. Letizia, M. Aprile, A. Casamassimi, and
A. Ciccodicola, “PPARG: gene expression regulation and next-
generation sequencing for unsolved issues,” PPAR Research, vol.
2010, Article ID 409168, 17 pages, 2010.
[4] E. D. Rosen and B. M. Spiegelman, “PPAR훾: a nuclear regulator
of metabolism, di*erentiation, and cell growth,” Journal of
Biological Chemistry, vol. 276, no. 41, pp. 37731–37734, 2001.
[5] W. Ahmed, O. Ziouzenkova, J. Brown et al., “PPARs and their
metabolic modulation: new mechanisms for transcriptional
regulation?” Journal of Internal Medicine, vol. 262, no. 2, pp.
184–198, 2007.
[6] L. Sze´les, D. To¨ro¨csik, and L. Nagy, “PPAR훾 in immunity and
in,ammation: cell types and diseases,” Biochimica et Biophysica
Acta—Molecular and Cell Biology of Lipids, vol. 1771, no. 8, pp.
1014–1030, 2007.
[7] M. Ahmadian, J. M. Suh, N. Hah et al., “PPAR훾 signaling and
metabolism: the good, the bad and the future,”NatureMedicine,
vol. 19, no. 5, pp. 557–566, 2013.
[8] Y. Barak, M. C. Nelson, E. S. Ong et al., “PPAR훾 is required for
placental, cardiac, and adipose tissue development,” Molecular
Cell, vol. 4, no. 4, pp. 585–595, 1999.
[9] E.D. Rosen, P. Sarraf, A. E. Troy et al., “PPAR훾 is required for the
di*erentiation of adipose tissue in vivo and in vitro,”Molecular
Cell, vol. 4, no. 4, pp. 611–617, 1999.
[10] Y. L. Muller, C. Bogardus, B. A. Beamer, A. R. Shuldiner, and L.
J. Baier, “A functional variant in the peroxisome proliferator—
activated receptor 훾2 promoter is associated with predictors of
obesity and type 2 diabetes in Pima Indians,” Diabetes, vol. 52,
no. 7, pp. 1864–1871, 2003.
[11] D. Altshuler, J. N. Hirschhorn, M. Klannemark et al., “-e
common PPAR훾 Pro12Ala polymorphism is associated with
decreased risk of type 2 diabetes,” Nature Genetics, vol. 26, no.
1, pp. 76–80, 2000.
[12] H. Mori, H. Ikegami, Y. Kawaguchi et al., “-e Pro12→
Ala substitution in PPAR-훾 is associated with resistance to
development of diabetes in the general population: possible
involvement in impairment of insulin secretion in individuals
with type 2 diabetes,” Diabetes, vol. 50, no. 4, pp. 891–894, 2001.
[13] V. Costa, A. Casamassimi, K. Esposito et al., “Characterization
of a novel polymorphism in PPARG regulatory region asso-
ciated with type 2 diabetes and diabetic retinopathy in italy,”
Journal of Biomedicine and Biotechnology, vol. 2009, Article ID
126917, 7 pages, 2009.
[14] J. I. Odegaard, R. R. Ricardo-Gonzalez, M. H. Goforth et
al., “Macrophage-speci.c PPAR훾 controls alternative activation
and improves insulin resistance,” Nature, vol. 447, no. 7148, pp.
1116–1120, 2007.
[15] S. Azhar, “Peroxisome proliferator-activated receptors, meta-
bolic syndrome and cardiovascular disease,” Future Cardiology,
vol. 6, no. 5, pp. 657–691, 2010.
[16] I. Barroso, M. Gurnell, V. E. F. Crowley et al., “Dominant
negative mutations in human PPAR훾 associated with severe
insulin resistance, diabetes mellitus and hypertension,” Nature,
vol. 402, no. 6764, pp. 880–883, 1999.
[17] D. Capaccio, A. Ciccodicola, L. Sabatino et al., “A novel
germlinemutation in peroxisome proliferator-Activated Recep-
tor 훾 gene associated with large intestine polyp formation and
dyslipidemia,” Biochimica et Biophysica Acta—Molecular Basis
of Disease, vol. 1802, no. 6, pp. 572–581, 2010.
[18] A. Raji and J. Plutzky, “Insulin resistance, diabetes, and
atherosclerosis: thiazolidinediones as therapeutic interven-
tions,” Current Cardiology Reports, vol. 4, no. 6, pp. 514–521,
2002.
[19] M. C. Bragt and H. E. Popeijus, “Peroxisome proliferator-
activated receptors and the metabolic syndrome,” Physiology
and Behavior, vol. 94, no. 2, pp. 187–197, 2008.
[20] H. Shahbazian, S. M. Lati., M. T. Jalali et al., “Metabolic
syndrome and its correlated factors in an urban population in
South West of Iran.,” Journal of Diabetes & Metabolic Disorders,
vol. 12, no. 1, p. 11, 2013.
[21] L. Fajas, D. Auboeuf, E. Raspe´ et al., “-e organization,
promoter analysis, and expression of the human PPAR훾 gene,”
Journal of Biological Chemistry, vol. 272, no. 30, pp. 18779–18789,
1997.
[22] L. Fajas, J. C. Fruchart, and J. Auwerx, “PPAR훾3 mRNA: a dis-
tinct PPAR훾 mRNA subtype transcribed from an independent
promoter,” FEBS Letters, vol. 438, no. 1-2, pp. 55–60, 1998.
[23] C. Knou* and J. Auwerx, “Peroxisome proliferator-activated
receptor-훾 calls for activation in moderation: lessons from
genetics and pharmacology,” Endocrine Reviews, vol. 25, no. 6,
pp. 899–918, 2004.
[24] A. Werman, A. Hollenberg, G. Solanes, C. Bjørbæk, A. J. Vidal-
Puig, and J. S. Flier, “Ligand-independent activation domain in
the N terminus of peroxisome proliferator-activated receptor 훾
(PPAR훾). Di*erential activity of PPAR훾1 and -2 isoforms and
in,uence of insulin,” Journal of Biological Chemistry, vol. 272,
no. 32, pp. 20230–20235, 1997.
[25] D. Ren, T. N. Collingwood, E. J. Rebar, A. P. Wol*e, and H. S.
Camp, “PPAR훾 knockdownby engineered transcription factors:
Exogenous PPAR훾2 but not PPAR훾1 reactivates adipogenesis,”
Genes and Development, vol. 16, no. 1, pp. 27–32, 2002.
[26] S. Yu, N. Viswakarma, S. K. Batra, M. Sambasiva Rao, and J. K.
Reddy, “Identi.cation of promethin and PGLP as two novel up-
regulated genes in PPAR훾1-induced adipogenic mouse liver,”
Biochimie, vol. 86, no. 11, pp. 743–761, 2004.
[27] E. Powell, P. Kuhn, and W. Xu, “Nuclear receptor cofac-
tors in PPAR훾-mediated adipogenesis and adipocyte energy
metabolism,” PPAR Research, vol. 2007, Article ID 53843, 11
pages, 2007.
[28] L. Sabatino, A. Casamassimi, G. Peluso et al., “A novel peroxi-
some proliferator-activated receptor 훾 isoform with dominant
negative activity generated by alternative splicing,” Journal of
Biological Chemistry, vol. 280, no. 28, pp. 26517–26525, 2005.
[29] A. Chawla, E. J. Schwarz, D. D. Dimaculangan, andM. A. Lazar,
“Peroxisome proliferator-activated receptor (PPAR) 훾: adipose-
predominant expression and induction early in adipocyte dif-
ferentiation,” Endocrinology, vol. 135, no. 2, pp. 798–800, 1994.
[30] R. M. Evans, G. D. Barish, and Y. X. Wang, “PPARs and the
complex journey to obesity,” Nature Medicine, vol. 10, no. 4, pp.
355–361, 2004.
[31] S. Kersten, B. Desvergne, and W. Wahli, “Roles of PPARS in
health and disease,” Nature, vol. 405, no. 6785, pp. 421–424,
2000.
[32] A. Armani, C. Mammi, V. Marzolla et al., “Cellular models for
understanding adipogenesis, adipose dysfunction, and obesity,”
Journal of Cellular Biochemistry, vol. 110, no. 3, pp. 564–572,
2010.
PPAR Research 11
[33] V. D’Esposito, F. Passaretti, A. Hammarstedt et al., “Adipocyte-
released insulin-like growth factor-1 is regulated by glucose
and fatty acids and controls breast cancer cell growth in vitro,”
Diabetologia, vol. 55, no. 10, pp. 2811–2822, 2012.
[34] P. Isakson, A. Hammarstedt, B. Gustafson, and U. Smith,
“Impaired preadipocyte di(erentiation in human abdominal
obesity: role of Wnt, tumor necrosis factor-훼, and in)amma-
tion,” Diabetes, vol. 58, no. 7, pp. 1550–1557, 2009.
[35] V. Costa, I. Conte, C. Ziviello et al., “Identi,cation and expres-
sion analysis of novel Jakmip1 transcripts,” Gene, vol. 402, no.
1-2, pp. 1–8, 2007.
[36] V. Costa, L. Sommese, A. Casamassimi et al., “Impairment of
circulating endothelial progenitors in Down syndrome,” BMC
Medical Genomics, vol. 3, article 40, 2010.
[37] V. Costa, C. Angelini, L. D’Apice et al., “Massive-scale rna-seq
analysis of non ribosomal transcriptome in human trisomy 21,”
PLoS ONE, vol. 6, no. 4, Article ID e18493, 2011.
[38] A. T. Alberobello, V. D’Esposito, D. Marasco et al., “Selective
disruption of insulin-like growth factor-1 (IGF-1) signaling via
phosphoinositide-dependent kinase-1 prevents the protective
e(ect of IGF-1 on human cancer cell death,” Journal of Biological
Chemistry, vol. 285, no. 9, pp. 6563–6572, 2010.
[39] S. B. Park, H. C. Choi, and N. S. Joo, “.e relation of thyroid
function to components of the metabolic syndrome in Korean
men andwomen,” Journal of KoreanMedical Science, vol. 26, no.
4, pp. 540–545, 2011.
[40] H. P. Koe/er, “Peroxisome proliferator-activated receptor 훾 and
cancers,” Clinical Cancer Research, vol. 9, no. 1, pp. 1–9, 2003.
[41] M. D. Rollins, S. Sudarshan, M. A. Firpo et al., “Anti-in)amma-
tory e(ects of PPAR-훾 agonists directly correlate with PPAR-훾
expression during acute pancreatitis,” Journal of Gastrointestinal
Surgery, vol. 10, no. 8, pp. 1120–1130, 2006.
[42] R. B. Clark, “.e role of PPARs in in)ammation and immunity,”
Journal of Leukocyte Biology, vol. 71, no. 3, pp. 388–400, 2002.
[43] N. Marx, B. Kehrle, K. Kohlhammer et al., “PPAR activa-
tors as antiin)ammatory mediators in human T lymphocytes:
implications for atherosclerosis and transplantation-associated
arteriosclerosis,” Circulation Research, vol. 90, no. 6, pp. 703–
710, 2002.
[44] N. Gupta, K. Goel, P. Shah, and A. Misra, “Childhood obesity
in developing countries: epidemiology, determinants, and pre-
vention,” Endocrine Reviews, vol. 33, no. 1, pp. 48–70, 2012.
! 59!
Platelet-rich plasma increases growth and motility of adipose tissue-
derived mesenchymal stem cells and controls adipocyte survival and 
secretory function. 
Vittoria D'Esposito1, Federica Passaretti1, Giuseppe Perruolo2, Maria Rosaria 
Ambrosio1, Rossella Valentino2, Francesco Oriente1, Gregory A. Raciti2, 
Cecilia Nigro2, Claudia Miele2, Gilberto Sammartino3, Francesco Beguinot1,2, 
Pietro Formisano*1,2 
1Department of Translational Medicine, Federico II University of Naples, 
Naples, Italy. 2Institute of Experimental Endocrinology and Oncology, 
National Council of Research (CNR), Naples, Italy. 3Department of 
Neurosciences, Reproductive and Odonto-stomatological Sciences, Federico II 
University of Naples, Naples, Italy. 
 
 
*Corresponding author: 
Prof. Pietro Formisano 
Department of Translational Medicine, Federico II University of Naples, 
Naples, Italy 
Via Pansini 5, 80131 Naples, Italy 
Tel. +39-0817464450 
FAX +39-0817464334 
e-mail: fpietro@unina.it 
Running head: Platelet factors and Mesechymal stem cells 
Keywords: Growth Factors, Tissue regeneration, Adipose tissue, Cytokines 
Total number of text figures: 4 
Total number of tables: 3 
Contract grant sponsor: Associazione Italiana per la Ricerca sul Cancro 
(AIRC), European Foundation for the Study of Diabetes (EFSD), Italian 
Minisrtry of Education (MIUR)  
Contract grant number: AIRC n. IG 12136; EFSD Diabetes and Cancer 
Programme 2011 #; MIUR – PRIN n.2010MCLBCZ; MIUR - FIRB MERIT n. 
RBNE08NKH7 
 
 
! 60!
ABSTRACT 
Adipose tissue-derived mesenchymal stem cells (Ad-MSC) and platelet 
derivatives have been used alone or in combination to achieve regeneration of 
injured tissues. We have tested the effect of platelet-rich plasma (PRP) on Ad-
MSC and adipocyte function. PRP increased Ad-MSC viability, proliferation 
rate and G1- S cell cycle progression, by at least 7-, 2-, and 2.2-fold, 
respectively. Higher PRP concentrations or PRPs derived from individuals 
with higher platelet counts were more effective in increasing Ad-MSC growth. 
PRP also accelerated cell migration by at least 1.5-fold. However, PRP did not 
significantly affect adipocyte differentiation and expression levels of PPAR-γ 
and AP-2 mRNAs, while it increased leptin production by 3.5-fold. 
Interestingly, Ad-MSC-derived adipocytes displayed increased viability and 
cell size following exposure to PRP. PRP treatment of mature adipocytes also 
enhanced the release of Interleukin (IL)-6, IL-8, IL-10, Interferon-γ and 
Vascular Endothelial Growth Factor. At variance, Platelet-derived Growth 
Factor, IL-4 and the chemokine CCL5/RANTES, which were mainly released 
by platelets, were reduced in the media of PRP-treated adipocytes. Thus, data 
are consistent with a stimulatory effect of platelet derivatives on Ad-MSC 
growth and motility. Moreover, PRP sustained adipocyte survival and release 
of pro-angiogenic factors, which may facilitate tissue regeneration processes.   
 
INTRODUCTION 
The use of platelet derivatives represents a novel approach in tissue 
regeneration (Burnouf et al., 2013). Although the mechanisms involved are still 
poorly understood, the relative ease and safety of application of platelet 
products in clinical practice and the potential beneficial outcomes, including 
regeneration of bone and soft tissues, reduction of bleeding, and acceleration or 
promotion of wound healing, hold promise for new therapeutic approaches 
(Burnouf et al., 2013; Lacci and Dardik, 2010; Nikolidakis and Jansen, 2008). 
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The rationale for the use of platelet products is mostly based on the production 
and release of multiple growth factors upon platelet activation. Primary factors 
associated with platelets include Platelet Derived Growth Factor (PDGF) and 
Transforming Growth Factor β (TGF-β), which have been mostly involved in 
cell proliferation, chemotaxis and extracellular matrix production/angiogenesis 
(Burnouf et al., 2013; Lubkowska et al., 2012). Other growth factors 
discharged from the platelets are Fibroblast Growth Factors (FGF) 1 and 2 and 
Vascular Endothelial Growth Factor (VEGF) which play critical roles in the 
hemostasis, proliferative, and remodeling phases of wound healing (Demidova-
Rice et al., 2012; Intini, 2009; Lacci and Dardik, 2010; Lubkowska et al., 
2012). More than 95% of the pre-synthesized growth factors are secreted 
within 1 h from the beginning of the clotting process. After the initial burst, the 
platelets secrete additional growth factors for the remaining 7 days of their life 
span (Marx RE, 2004). Platelet degranulation also leads to the release of 
cytokines and chemokines, further contributing to the healing process 
(Demidova-Rice et al., 2012; Passaretti et al., 2014). 
Several technical procedures have been developed to obtain platelet 
concentrates (Dohan Ehrenfest et al., 2009). Different procedures lead to 
variable yield of platelets and may contain different cellular components 
(Cieslik-Bielecka et al., 2012; Prakash and Thakur, 2011). Consistently, they 
also differ for the qualitative and quantitative release of growth factors, 
cytokines and chemokines and may find different indications (Galliera et al., 
2012; Lubkowskaet al., 2012; Passaretti et al., 2014). Attention has also been 
given to the clinical utilization of individual growth factors. However, the 
overall experience has not been satisfactory, most likely since wound healing 
and tissue repair are outcomes of an intricate network of circulating and tissue 
elements. Combination of multiple growth factors, timing of their release, and 
cell-specific response to individual growth factors are indeed essential 
requirements for a successful wound healing (Giacco et al., 2006). 
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Auto-transplantation of adipose tissue is commonly used for the treatment of 
tissue defects in plastic and reconstructive surgery. The reduced survival of the 
transplanted adipose tissue remains an unsolved issue. This is due, at least in 
part, to accelerated apoptosis of the implanted pre-adipocytes. Several reports 
have indicated that application of Platelet-Rich Plasma (PRP) may improve the 
outcome of adipose tissue transplantation (Cervelli et al., 2009; Fukaya et al., 
2012). The molecular mechanisms may possibly involve interactions of PRP 
factors with either adipocytes and mesenchymal stem cells, which are 
embedded within adipose tissue (Ad-MSC) (Liuet al., 2008). MSCs are 
multipotent, non hematopoietic stem cells that are typically obtained from bone 
marrow but can also be isolated from several other tissues such as umbilical 
cord and adipose tissue (de Girolamo et al., 2013). Human Ad-MSCs are 
attractive candidates for clinical use because of their ease of isolation, 
extensive proliferation and differentiation capacity, and hypoimmunogenic 
nature. Ad-MSCs display the ability to differentiate into multiple mesoderm-
derived cells, such as adipocytes, osteocytes, and chondrocytes, but they may 
also give rise to cells of nonmesodermal origin, such as hepatocyte-like and 
neuronal-like cells. The multilineage capacity of Ad-MSC offers the potential 
to repair, maintain or enhance regeneration of various tissues (Kocaoemeret al., 
2007; Phinneyand Prockop, 2007; Schäffler and Büchler, 2007; Tran and 
Kahn, 2010). However, the poor viability of Ad-MSCs at the transplanted site 
often decreases their therapeutic potential (Nakamuraet al., 2013). Thus, it is 
important to improve Ad-MSC survival and enhance their biological functions. 
The combined use of PRP and Ad-MSC offers the advantage that they both 
could be autologous products, prepared from the patient’s own tissues, thereby 
eliminating concerns about immunogenic reactions and disease transmission. 
Nevertheless, in some cases, preparations from donors could be needed 
(Everts, 2007; Liuet al., 2008). 
Despite the large utilization of platelet derivatives as therapeutic tools in 
conditions requiring tissue repair, little has been reported about the molecular 
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mechanisms elicited by PRP on adipose tissue function. In this paper, we have 
described that PRP affects Ad-MSC growth and migration without interfering 
with their ability to differentiate into mature adipocytes. Moreover, the 
exposure to PRP sustains adipocyte viability and increases adipocyte size and 
production of specific factors, thereby contributing to the induction of tissue 
repair processes. 
 
MATERIALS AND METHODS 
Materials. Media, sera, and antibiotics for cell culture were from Lonza (Lonza 
Group Ltd, Basel, Switzerland). Antibodies against phospho-Ser473PKB/Akt1, 
ERK and actin were purchased from Santa Cruz Biotechnology (Santa Cruz 
Biotechnology, Santa Cruz, CA, USA). Phospho-Thr202/Tyr204ERK, phosphor-
Ser15 p53 and p53 antibodies were obtained from Cell Signaling Technology 
(Danvers, MA, USA). PKB/Akt antibody was from Millipore (Millipore, 
Billerica, MA, USA). Sodium dodecyl sulfate-polyacrylamide gel 
electrophoresis (SDS-PAGE) reagents from Bio-Rad (Bio-Rad, Hercules, CA, 
USA). All the other chemicals were from Sigma-Aldrich (Sigma-Aldrich, St. 
Louis, MO, USA).  
Subject recruitment and Platelet-Rich plasma (PRP) preparation. 10 subjects 
undergoing biliary surgery (M/F:4/6; age 24 – 40) were enrolled in the study. 
All were non-smokers, non-obese (BMI range: 20.4- 28.3) and with a platelet 
count >180.000/mm3.  None of them were under any medication for the last 21 
days. Informed consent was obtained from every subject before the surgical 
procedure. This procedure was approved by the ethical committee of the 
University of Naples. 
Blood was drawn from each subject and was collected in a Vacutainer tube 
(Vacutainer; Becton Dickinson, East Rutherford, NJ, USA) containing 10% 
trisodium citrate anticoagulant solution for the preparation of Platelet-Rich 
plasma (PRP). Tubes were centrifuged at 350 g for 15 min. The upper fraction 
containing platelet-poor plasma (PPP) was discarded and the preparation 
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procedure for PRP were performed as previously described (Passaretti et al., 
2014). 
For platelet gel preparations, autologous thrombin (0.1 NIH unit/ml final 
concentration) and calcium gluconate (10 mg/ml final concentration) were 
added to PRP for 5 min at room temperature to allow clot formation (Giacco et 
al., 2006). 
Human adipose tissue-derived mesenchymal stem cell culture, growth and 
viability. Human adipose tissue biopsies were digested with collagenase and 
Mesenchymal Stem Cells (Ad-MSC) were isolated and differentiated as 
previously reported (D'Esposito et al., 2012). For growth evaluation, Ad-MSCs 
were seeded in 6-well culture plates in a complete medium. The following day, 
the cells were starved in serum-free DMEM (Dulbecco’s modified Eagle’s 
Medium) -F12 (1:1) 0.25% BSA for 16 h and incubated with PRP gel, obtained 
as described above, for different times. Cell count was performed either by 
Bürker chamber and with the TC10TM Automated Cell Counter (Bio-Rad, 
Hercules, CA, USA) according to the manufacturer’s protocol. Sulforhodamine 
assay was used for cell viability determination (Chiba et al., 1998); cells were 
fixed with 10% trichloroacetic acid for at least 2 h at 4 C and then washed 5 
times with distilled and de-ionized water. After air drying, sulforhodamine was 
added to the cells and incubated for 30 min. Cells were then washed with 1% 
acetic acid 5 times. After air drying, 10 mmol/l Tris solution (pH 7.5) was 
added to dissolve the bound dye. Cell viability was assessed by optical density 
(OD) determination at 510 nm using a microplate reader. Three replicate wells 
were used for each data point. 
Cell cycle analysis. Ad-MSCs were seeded in 10 cm2 culture plates in a 
complete medium. The following day, the cells were starved in serum-free 
DMEM F12 (1:1) 0.25% BSA for 16 h and incubated with PRP gel obtained as 
described above. Bromodeoxyuridine (BrdU)/Propidium Iodide (PI) analysis 
was performed as previously reported (Ma, Y et al, 2013). Briefly, cells were 
labeled with 10 µM BrdU for 30 min and fixed over-night in ice-cold 70% 
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ethanol at -20 C. Cells were then washed once with PBS and incubated for 15 
min at room temperature with 2N HCl. Next, cells were washed with PBT 
(0.5% BSA, 0.1% Tween20 in PBS) and resuspended in PBT containing anti-
BrdU antibody (1:40, Dako, Carpinteria CA, USA). After 30 min, cells were 
washed twice with PBT and then resuspended in PBT containing Alexa488 
anti-mouse (1:100, Life Technologies, Carlsbad, CA, USA) in the dark for 30 
min. Cells were washed twice with PBS, resuspended in Propidium Iodide (PI) 
0.015 M (Sigma-Aldrich) in PBS for 20 min and analyzed for the emission in 
FL1 and FL3 channels. The samples were acquired by a BD LSRFortessa (BD 
Biosciences, San Jose, CA, USA) and analyzed using BD FACSDiva Software. 
Cell migration. Cell migration was performed using 8-µm pore polycarbonate 
membranes (Costar, Cambridge, MA, USA). Ad-MSCs were loaded at 50,000 
cells per insert (upper chamber) and PRP gel was added to the lower chamber 
in DMEM F12 (1:1) 0.25% BSA. The cells were allowed to migrate into the 
lower chamber at 37 C in a 5% CO2 atmosphere saturated with H2O for 24 h. 
At the end of incubation, cells that had migrated to the lower side of the filter 
were fixed with 11% glutaraldehyde for 15 min at room temperature, washed 
three times with PBS, and stained with 0.1% crystal violet-20% methanol for 
20 min at room temperature. After three PBS washes and complete drying at 
room temperature, the crystal violet was solubilized by immersing the filters in 
10% acetic acid. The concentration of the solubilized crystal violet was 
evaluated as absorbance at 540 nm.  
Adipocyte differentiation markers and real-time RT-PCR analysis. Adipocyte 
differentiation was assessed by the analysis of real-time RT-PCR of adipocyte-
specific (aP2 or PPARγ) mRNAs (see below) and by lipid accumulation using 
Oil Red O staining, as described by Ramirez-Zacarias et al. (1992). Total RNA 
was isolated from either undifferentiated Ad-MSC and differentiated 
adipocytes, after removal of PRP gels, by using the RNeasy Kit (Qiagen, 
Valencia, CA, USA) according to the manufacturer’s instruction. For real-time 
RT-PCR analysis, 1µg cell RNA was reverse transcribed using SuperScript III 
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Reverse Transcriptase (Life Technologies, Carlsbad, CA, USA). PCR were 
analyzed using SYBR Green mix (Bio-Rad, Hercules, CA, USA). Reactions 
were performed using Platinum SYBR Green Quantitative PCR Super-UDG 
using an iCycler IQ multicolor Real-Time PCR Detection System (Bio-Rad, 
Hercules, CA, USA). All reactions were performed in triplicate and β-actin 
was used as an internal standard. Primer sequences are described in Table 1. 
Immunoblot procedure. Total cell lysates were obtained and separated by SDS-
PAGE as previously described (Alberobello et al., 2010). Briefly, cells were 
solubilized for 20 min at 4 C with lysis buffer containing 50 mM HEPES, 150 
mM NaCl, 10 mM EDTA, 10 mM Na4P2O7, 2 mM sodium orthovanadate, 50 
mM NaF, 1 mM phenylmethylsulfonyl fluoride,10 µg/ml aprotinin, 10 µg/ml 
leupeptin, pH 7.4, and 1% (v/v) Triton X-100. Lysates were clarified by 
centrifugation at 12,000g for 20 min at 4 C. Proteins were separated by SDS-
polyacrylamide gel electrophoresis and blotted on Immobilon-P membranes 
(Millipore, Billerica, MA, USA). Membranes were blocked for 1 h in TBS (10 
mM Tris-HCl, pH 7.4, and 140 mM NaCl) containing 3% (w/v) bovine serum 
albumin and then incubated with the indicated antibodies. Detection of blotted 
proteins was performed by ECL according to the manufacturer's instruction. 
Densitometric analysis was performed using Image Lab software (Bio-Rad, 
Hercules, CA, USA). 
Conditioned media collection. Adipocytes were incubated with PRP gels, 
obtained as described above, for 24 h. Next, PRP gels were removed and the 
cells were starved in serum-free DMEM F12 (1:1) 0.25% BSA. As control, 
PRP gels, without cells, were maintained in serum-free DMEM F12 (1:1) 
0.25% BSA. After 24 h media were collected and centrifuged at 14,000g to 
remove cellular debris and analyzed for cytokines and growth factor content, as 
described below. 
Determination of cytokine and growth factor release. PRP and adipocyte 
conditioned media were screened for the concentration of IL-2, IL-4, IL-6, IL-
8, IL-10, GM-CSF, IFN-γ, MIP-1α, MIP-1β, RANTES, TNF-α, bFGF, PDGF, 
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VEGF using the Bioplex multiplex Human Cytokine and Growth factor assay 
kit (Bio-Rad, Hercules, CA, USA) according to the manufacturer’s protocol.  
Statistical analysis.  Data were analyzed with Statview software (Abacus 
Concepts Piscataway, NJ, USA) by one-factor analysis of variance. p values of 
less than 0.05 were considered statistically significant. 
 
RESULTS 
PRP promotes Ad-MSC growth, survival and migration. We have first 
analyzed the impact of PRP-released factors on human Mesenchymal Stem 
Cells isolated from stromal-vascular fraction of subcutaneous adipose tissue 
biopsies (Ad-MSC). PRP was activated with thrombin and applied onto 
cultured human Ad-MSCs as PRP gel. PRP gels were applied onto cells 
isolated either from the same donor (autologous PRP; n=5) or from other 
individuals (homologous PRP; n=5). The application of both autologous and 
homologous PRP gel to the Ad-MSC cultures was capable to induce cell 
growth in the absence of serum in a concentration dependent fashion (Fig. 1a). 
Ad-MSC growth in the presence of 20% PRP was comparable to that achieved 
with 10% FBS medium (Fig. 1a). 
To further investigate whether PRP growth promoting action was dependent on 
blood platelet count, Ad-MSCs derived from one subject were incubated with 
PRP gels obtained from grouped subjects according to concentration of blood 
platelets; those with “low” (200,000 - 300,000/µl) platelet count (n=5) and 
those with “high” (400,000 - 500,000/µl) platelet count (n=5). Ad-MSC growth 
was significantly higher upon incubation with the PRP obtained from 
individuals with a higher concentration of platelets (Fig. 1b).  
As assessed by sulforhodamine assay, Ad-MSC viability was strongly 
increased in presence of 5% or 20% PRP gel, compared to that measured in 
serum deprivation and was about 3- and 4-fold higher, respectively, compared 
to cells cultured in 10% FBS (Fig. 1c). 
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Moreover, BrdU/PI staining revealed that both 5% and 20% PRP gel addition 
increased the amount of Ad-MSCs in S-phase, compared to cells cultured in 
serum-free medium without PRP (Fig. 1d). PRP gel reduced the number of 
cells in G1 phase without affecting G2-M and sub G1 phases (Supplementary 
Online Table). 
To investigate whether PRP could also ameliorate Ad-MSC migration, cells 
were placed in the upper chamber of a transwell system, while the lower 
chamber was filled up with PRP-gel in serum-free medium. Cells that migrated 
across the filter were detected and quantified. 5% and 20% PRP increased Ad-
MSC migration by 1.5- and up to 2-fold (Fig.2a-b). 
We next tested whether PRP could activate intracellular signaling pathways 
involved in cell survival and growth. To this aim, Ad-MSC were incubated 
with PRP gel for 12 h. Western blot analysis with phospho-specific antibodies 
revealed that 5% and 20% PRP increased PKB/AKT, ERK and p53 
phosphorylation compared to the control untreated cells (Fig. 2c). 
 
PRP does not interfere with Ad-MSC adipogenic differentiation, survival 
and function. Ad-MSCs readily differentiate into cells of the adipocyte lineage 
and retain differentiation potential through multiple passages (Schäfflerand 
Büchler, 2007). In order to evaluate whether PRP treatment may interfere with 
adipocyte differentiation, Ad-MSC were incubated with PRP along with the 
induction of the differentiation procedure as described in Materials and 
Methods. Adipogenesis was assessed by analysis of lipid accumulation using 
oil red O staining (Fig. 3a) and by the expression of adipocyte-specific genes 
(aP2 and Peroxisome Proliferator-Activated Receptor γ –PPARγ) (Fig. 3b). 
Ad-MSC differentiation in presence of 20%PRP was comparable to that 
observed for cells differentiated with the standard procedures (Fig. 3a and b), 
with a slight increase of cell size. 
In addition, we have tested the effect of PRP on mature adipocytes. 
Sulforhodamine assay revealed that 20% PRP gels lightly increased adipocyte 
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viability (Fig. 3c). Interestingly, leptin expression was 3-fold higher in 
differentiated adipocytes exposed to PRP (Fig. 3d). 
 
Release of cytokines/chemokines and growth factors by human adipocytes 
upon PRP stimulation. As previously reported, PRP released a variety of 
cytokines/chemokines and growth factors (Passaretti, F. et al., 2014). Here, we 
have shown that PRP secreted IL-4, IL-8, CCL5/RANTES and PDGF in a 
concentration dependent fashion (Table 2). IL-6 and INF-γ were found only in 
conditioned media from 20% PRP. No statistically significant differences were 
observed for the amount of VEGF between 5% PRP and 20% PRP medium 
(Table 2). We have therefore investigated whether PRP may affect the ability 
of human adipocytes to release cytokines/chemokines and growth factors. As 
expected, several inflammatory cytokines and growth factors were detected in 
the medium of untreated adipocytes. Interestingly, the amount of IL-6, IL-8, 
IL-10, IFN-γ and VEGF was significantly increased in PRP-treated adipocytes. 
However, while the increase of IFN-γ and VEGF levels was consistent with an 
additive release by PRP and adipocytes separately, the increase of IL-6, IL-8 
and IL-10 was likely due to the PRP stimulation of release by adipocytes. 
Moreover, the concentrations of IL-4, PDGF and CCL5/RANTES were 
significantly reduced in PRP-treated adipocyte medium, compared to PRP 
alone, suggesting a consumption of those platelet-released factors by the 
adipocytes (Fig. 4). 
 
DISCUSSION 
Platelet derivatives are widely used in regenerative medicine (Burnouf et al, 
2013; Lacci and Dardik, 2010; Nikolidakis and Jansen, 2008). For instance, the 
simultaneous application of fat explants and PRP has hold a great deal of 
promise to ameliorate “lipofilling” procedures and the outcome of fat 
engraftment (Kølle et al., 2013; Nakamura et al., 2010). Indeed, one of the 
main limitations of adipose tissue transfer is the rapid loss of fat at the site of 
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engraftment (Nakamura et al., 2010). This is possibly due to several factors: i) 
very low capability of adipose tissue to engraft and to repopulate at the site of 
implantation; ii) reduced life span of terminally differentiated mature 
adipocytes; iii)  reduced blood supply mainly due to insufficient tissue-driven 
angiogenesis.  
Here, we have tested the effect of PRP-released factors on Ad-MSCs and on 
mature adipocytes in cultured models. PRP-released factors had an incremental 
effect on Ad-MSCs, since they improved cell viability, induced S-phase and 
increased cell number. This is consistent with previous reports indicating a 
positive effect of PRP on growth of mesenchymal stem cell, either from 
adipose tissue (Kocaoemer et al., 2007) and from bone marrow (Murphy et al., 
2012), as well as of other cultured cell types (Gassling et al., 2009; Giacco et 
al., 2006; Kakudo et al., 2008; Lucarelli et al., 2003; Passaretti et al., 2014). 
The molecular mechanisms responsible for increased cell growth likely involve 
PKB/Akt and ERK (Fig. 2) activation by platelet released growth factors and 
the potential regulation of apoptosis-related genes, such as p53 (Fig. 2), as also 
recently described (Fukaya et al., 2012).  
Growth effect on Ad-MSC is not limited to the exposure to autologous PRP, 
but is also elicited by PRPs obtained from different donors. Moreover, Ad-
MSC growth is elicited at higher levels by PRP preparations from donors with 
higher platelet count. Thus, as also previously suggested (Lucarelli et al., 
2003), the concentration of platelet factors may be crucial in inducing cell 
proliferation. Indeed, Murphy and coworkers (2012) have recently described 
that PRP obtained by umbilical cord (uc-PRP) is more potent than that 
obtained by peripheral blood in inducing BM-MSC growth. This is possibly 
due to the release of higher concentrations of specific growth factors by uc-
PRP. Nevertheless, growth  effect is most likely cell-specific, since different 
types of platelet preparations  release different amount of growth factors and 
cytokines/chemokines (Passaretti et al., 2014). 
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We have now provided further evidence that PRP can exert a chemo-attractant 
action on Ad-MSCs. Increased motility could also be driven by PKB/Akt 
activation (Bulj et al., 2013). Other mechanisms however could not be 
excluded. One might argue that PRP increases cellularity at the site of implant, 
both by inducing proliferation and recruiting more Ad-MSC. The higher 
amount of precursor cells may then lead to increased tissue formation, thereby 
contributing to improve the outcome of fat transplantation. Furthermore, our 
data provided, at the best of our knowledge, the first evidence that PRP 
increased viability of mature adipocytes, whose improved survival might be 
beneficial for the stability of fat tissue, reducing fat loss at the site of 
engraftment. 
Thus, PRP treatment of adipose tissue may facilitate the recruitment of Ad-
MSCs and induce their proliferation, and may increase, as well, the survival of 
mature adipocytes. The combination of these effects supports the hypothesis of 
a beneficial action of PRP products in adipose tissue regeneration and filling 
procedures. 
Based on morphological data and on expression of specific markers, PRP-
treated Ad-MSCs retain their ability to differentiate into adipocytes, as well as 
into osteogenic lineage (data not shown; Tavakolinejad et al., 2014), at least in 
cultured models. These data suggested that the adipose tissue obtained in the 
presence of platelet factors preserved its architecture and its functional 
features. Slightly higher cell size and lipid content were observed for PRP-
treated adipocytes. Interestingly, however, we also detected an increase of 
leptin in PRP-treated differentiated adipocytes and increased levels of VEGF, 
IL-6, IL-8, IL-10 and IFN-γ in the conditioned media. In particular, the 
increase of IL-6, IL-8 and IL-10 levels are more than additive and likely results 
from PRP stimulation of adipocyte release. On the other end, PDGF, IL-4 and 
CCL5/RANTES, which are robustly produced by platelets, were reduced in the 
medium of PRP-treated adipocytes. Thus, it could be hypothesized that PRP-
released factors (i.e. PDGF) are taken and consumed by adipocytes, which in 
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turn release more pro-angiogenic factors (i.e. VEGF and IL-6), thereby 
facilitating new vessel formation and further contributing to the stabilization of 
the transplanted fat. Alternatively, a bi-directional cross talk could be 
envisioned, by which adipocytes enhance degradation or inhibit production of 
platelet factors, although the latter appears as a less likely possibility. 
Platelet secretome analysis has released a very large amount of proteins, which 
may independently ad coordinately act on processes involved in wound healing 
and tissue repair (Demidova-Rice et al., 2012; Intini, 2009; Lacci and Dardik, 
2010; Lubkowska et al., 2012). Different procedures of platelet preparations 
may  vary in the abundance of growth factors and cytokines (Horn et al., 2010; 
Passaretti et al., 2014), and this may be taken into account for the variability of 
the outcomes of platelet-based therapies (Prakash and Thakur, 2011). The use 
of individual factors, such as PDGF for example, has proven largely 
unsuccessful (Park et al., 2014). More recently, peptides derived from human 
PRP have been isolated and tested for promoting cutaneous wound healing in 
animal models (Demidova-Rice et al., 2012).  
We have now provided evidence that PRP may elicit chemo-attractant and 
proliferative effects on Ad-MSC, as well as survival effect on mature 
adipocytes. PRP-treated adipocytes may then become more potent in secreting 
pro-angiogenic factors, including leptin and VEGF, and ameliorate the 
outcome of autologous fat implants. More studies are needed to elucidate the 
individual factors involved in the intricate cross-talk among cell types 
responsible for wound healing and tissue regeneration.   
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FIGURE LEGENDS 
 
Figure 1. Effect of PRP on Ad-MSC growth, survival and cell cycle. a) Ad-
MSCs isolated by adipose tissue biopsy (n=5) have been serum-starved for 18 
h and then incubated for 24 h with PRP gel (5% or 20% vol/vol in DMEM F12 
1:1) obtained from the same donor of adipose tissue (homologous PRP; n=5) or 
from other donors (autologous PRP; n=5). As a control, Ad-MSCs have been 
incubated with DMEM F12 (1:1) without serum supplementation (MEDIUM 
BSA) or with 10% fetal bovine serum (MEDIUM 10% FBS). Then, cells have 
been counted as described in Materials and Methods and the results have been 
reported as fold-increase over basal (cell count in MEDIUM BSA). * denote 
statistically significant values over basal (* p<0.05; ** p<0.01).# denote 
statistically significant differences of 20% autPRP vs 5% autPRP (# p <0.05) 
).§ denote statistically significant differences of 20% homPRP vs 5% homPRP 
(§ p <0.05). b) PRP gel (20% vol/vol in DMEM F12 1:1) obtained from donors 
with different hematic platelet counts (Low Platelet – LP:2-3 x 105 platelets per 
µl; High Platelet – HP:4-5 x 105 platelets perµl) were directly applied onto the 
culture plate containing serum-starved Ad-MSCs for 6, 12, 24 and 48h. As 
control, Ad-MSCs have been incubated with DMEM F12 (1:1) without serum 
supplementation (MEDIUM BSA) or with 10% fetal bovine serum (MEDIUM 
10% FBS). Then, cells have been counted as described in Materials and 
Methods and the results have been reported as fold-increase over basal (cell 
count in MEDIUM BSA). * denote statistically significant values over basal (* 
p<0.05; ** p<0.01). # denote statistically significant differences of HP-PRP vs 
LP- PRP (# p <0.05). c) PRP gel (5% or 20% vol/vol in DMEM F12 1:1) has 
been added to serum-starved Ad-MSCs for 48 h. Cell viability has been 
assessed by sulforhodamine assay as described in Materials and Methods and 
the results reported as percentage of viable cells compared to cells in DMEM 
F12 10% FBS, considered as 100% viable cells.* denote statistically 
significant values over basal, considered as cells kept in 10% FBS medium 
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(*** p<0.001). # denote statistically significant differences of 20% PRP vs 5% 
PRP (# p <0.05).d) PRP gel (5% or 20% vol/vol in DMEM F12 1:1) has been 
added to serum-starved Ad-MSCs for 48 h. Cells have been pulse-labeled with 
BrdU for 30 min. FACS analysis of samples stained for BrdU and for 
propidium iodide, to quantify the amount of DNA, was performed. Numbers 
represent the percentage of  BrdU positive cells ± SD.* denote statistically 
significant values over DMEM-BSA (* p<0.05). # denote statistically 
significant differences of 20% PRP vs 5% PRP (# p <0.05). 
Figure 2. Effect of PRP on Ad-MSC migration and intracellular pathway 
activation. Ad-MSCs have been serum-starved for 18 h and then seeded on the 
polycarbonate membrane in the upper compartment of the transwell, whereas 
PRP gel (5% and 20% vol/vol in DMEM F12 1:1) has been added to the lower 
compartment in presence of DMEM F12 (1:1) without serum supplementation. 
As control, DMEM F12 (1:1) without serum supplementation (MEDIUM 
BSA) or with 10% fetal bovine serum (MEDIUM 10% FBS) has been added to 
the lower compartment. Migratory cells on the bottom of the polycarbonate 
membrane were stained (a) and quantified at OD 540 nm after extraction (b). 
Asterisks denote statistically significant values over basal (** p<0.01; *** 
p<0.001). c) Ad-MSCs were exposed to PRP (5% and 20% vol/vol in DMEM 
F12 1:1) for 24 h and then solubilized as described in Materials and Methods. 
Cell lysates (50 µg protein/sample) were blotted with phospho- Ser473PKB/Akt, 
phospho-Thr202/Tyr204ERK and phospho-Ser15 p53 antibodies and then 
reblotted with anti-PKB/Akt, anti-ERK and anti p53 antibodies. To ensure the 
equal protein transfer, membranes were blotted with actin antibodies. The 
filters were revealed by ECL and autoradiography. The autoradiographs shown 
are representative of four independent experiments. 
Figure 3. Effect of PRP on adipocyte differentiation, viability and function. 
Ad-MSCs have been differentiated in adipocytes as described in Materials and 
Methods, in presence or absence of PRP gel (20% vol/vol in DMEM F12 1:1). 
a) Lipid accumulation has been observed by Oil Red O staining 
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microscopically. mRNA levels of PPARγ, AP2 (b) and Leptin (d) were 
determined by real-time RT-PCR analysis on RNA preparations obtained from 
adipocytes after complete removal of PRP gels. Data have been normalized on 
β-actin as internal standard. Bars show the mRNA levels in these cells relative 
to those in Ad-MSCs differentiated without 20% PRP gel addition. c) 
Adipocyte viability has been assessed by sulforhodamine assay and the results 
reported as percentage of viable cells compared to cells differentiated without 
20% PRP gel addition, considered as 100% viable cells. 
Figure 5. Effect of PRP on adipocyte-released cytokines and growth 
factors. Human adipocytes have been incubated with PRP gel (20% vol/vol in 
DMEM F12 1:1) for 24 h. Media have been collected (CM) and tested by using 
the Bioplex multiplex Human Cytokine and Growth factor assay kit. Values ± 
SD are reported in the bar graph. Asterisks denote statistically significant 
values (* p<0.05; ** p<0.01; *** p<0.001). 
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ABSTRACT 
In this paper we propose polysaccharide hydrogels combining alginate (ALG) 
and hyaluronan sodium (HA) as biofunctional platform for dermal wound 
repair. Hydrogel produced by internal gelation were homogeneous and easy to 
handle. Rheological evaluation of gelation kinetics of ALG/HA mixtures at 
different ratios allowed understanding the HA effect on ALG gelation. Disk-
shaped hydrogels, at different ALG/HA ratio, were characterised for 
morphology, homogeneity and mechanical properties. The in vitro activity of 
ALG/HA dressings were tested on adipose derived multipotent adult stem cells 
(Ad-MSC) and an immortalized keratinocyte cell line (HaCaT). Hydrogels did 
not interfere with cell viability in both cells lines, but significantly promoted 
wound closure at early (24 h) and later (5 days) stages as compared to 
hydrogels made of ALG alone. In vivo wound healing studies, conducted on rat 
dorsal wounds, indicated that after 5 days hydrogels could significantly 
accelerate wound healing process also in vivo. Overall results demonstrate that 
integration of HA in a physically cross-linked alginate hydrogels can be a 
versatile strategy to promote wound healing process that can be easily 
translated in a clinical setting.  
 
INTRODUCTION 
Wound repair is one of the most complex biological processes during witch 
various intracellular and intercellular pathways are activated to restore tissue 
integrity and homeostasis (Gurtner, Werner, Barrandon & Longaker, 2008). 
Dressings have been applied to open wounds for centuries to prevent further 
injury and bacteria invasion, but nowadays their design has evolved toward 
multifunctionality to better control potential infections and to aid healing 
process (Queen, Orsted, Sanada & Sussman, 2004). A key property of modern 
dressings is their ability to retain and create a moist environment around the 
wound to facilitate healing and at this purpose a number of new materials have 
been developed and tested. Amid modern dressings, hydrogels cover a large 
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area due to their well-recognized compatibility (Boateng, Matthews, Stevens & 
Eccleston, 2008) and the capacity to absorb the exuding liquids and debris 
from the wound area. Furthermore above their glass transition temperature, 
hydrogels are typically soft and elastic due to their thermodynamic 
compatibility with water (Peppas, Huang, Torres-Lugo, Ward & Zhang, 2000; 
Slaughter, Khurshid, Fisher, Khademhosseini & Peppas, 2009). Hydrogels 
have shown excellent potential in a variety of biomedical applications, 
including scaffolds for tissue engineering or carriers for drug delivery systems 
(Lee & Mooney, 2012). Alginates (ALGs), a whole family of water-soluble 
polysaccharides extracted from brown seaweed, are linear blocks copolymers 
composed of α-l-guluronate (GGGGGG), β-d-mannuronate (MMMMMM), or 
alternating M and G residues (GMGMGM) linked through (1,4) bonds. The 
proportional and sequential arrangements of the M and G residues depend upon 
the type of algae tissue from which the polysaccharide is extracted, as well as 
on the season in which the algae is collected (Tonnesen & Karlsen, 2002). Due 
to its biocompatibility and bioresorption properties, ALG has been widely used 
in regenerative medicine (Slaughter, Khurshid, Fisher, Khademhosseini & 
Peppas, 2009) and successfully applied to treat a wide variety of secreting 
lesions. The high water absorption limits wound secretions and minimizes 
bacterial contamination (Gilchrist & Martin, 1983). Furthermore, ALG 
dressings maintain a physiologically moist microenvironment that promotes 
healing and formation of granulation tissue. ALGs can be rinsed away from 
wound bed with saline irrigation, so that removal of the dressing does not 
interfere with healing granulation tissue and making dressing changes virtually 
painless. Another important aspect of ALG dressing is related to management 
of wound exudate, allowing  significant limitation of maceration phenomena at 
wound periphery. ALG dressings can be designed to absorb large volumes of 
exudate, whilst continuing to provide a moist wound environment. ALG-based 
absorbent wound dressing may be used on multiple wound types, including but 
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not limited to diabetic wounds, venous wounds, pressure ulcers, cavity 
wounds, and some bleeding wounds. 
Ionically cross-linked ALG hydrogels can be formed in the presence of several 
divalent cations such as Ca2+, Ba2+, Sr2+, Zn2+, Cu2+, Cd2+, and Co2+ (Morch, 
Donati, Strand & Skjak-Braek, 2006). Divalent cations allow ionic interactions 
between G-rich regions of adjacent polymer chains resulting in the formation 
of a bulk structure in a shape of an ‘egg-box’ (Grant, Morris, Rees, Smith & 
Thom, 1973). As the sequence patterns and lengths of ALG blocks heavily 
depend on the biological source, alginate hydrogels may possess a wide range 
of gel properties, such as final modulus and crosslinking kinetics. 
Control over material properties of a hydrogel is crucial for many biomedical 
applications. Covalent crosslinking is an elective way to stabilize three 
dimensional polymer networks for a variety of applications and has also been 
used in hydrogel formation with permanent 3-D structures. However, chemical 
crosslinking reagents can show severe toxicity resulting in limited application 
in the biomedical field. Soluble calcium salts are widely employed to cross-
link ALGs, but these methods typically lead to rapid and inadequately 
controlled gelation, resulting in the formation of hydrogels with scarce 
structural homogeneity and poor mechanical properties (Kuo & Ma, 2001) 
(Skjakbraek, Grasdalen & Smidsrod, 1989). To overcome this drawback, 
internal gelation of ALG through CaCO3-GDL (D-glucono-δ-lactone) system 
has been proposed to obtain homogenous hydrogels useful as scaffolding 
materials for wound healing applications. The kinetics of the ALG gelation 
process has been studied extensively (Draget, Ostgaard & Smidsrod, 1989, 
1990; Draget, Simensen, Onsoyen & Smidsrod, 1993), and the final properties 
of the hydrogels have proved to be affected by the M/G ratio, alginate 
concentration, and particle size of the calcium salts.  
Hyaluronan sodium (HA) is a nonsulfated, linear glycosaminoglycan (GAG), 
consisting of repeating units of (β, 1–4) glucuronic acid and (β, 1-3)-N-acetyl 
glucosamine. HA is present in most living tissues as a high molecular mass 
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polymer (> 100 kDa) and in large amounts in the skin (dermis and epidermis), 
brain and central nervous system (Toole, 2004). Beyond the physical properties 
of a structural ECM molecule, it has become increasingly clear that HA 
provides cellular cues to regulate inflammation and tissue repair (Petrey & de 
la Motte, 2014). Several studies have shown that exogenous HA exerts 
beneficial effects on the wound-healing process (Frenkel, 2014). Topically 
applied HA has been shown to accelerate skin wound healing in rats (Foschi et 
al., 1990) and hamsters (King, Hickerson & Proctor, 1991). HA and its 
fragments may play crucial roles in the skin wound-healing process by 
modulating the expression of fibroblast genes involved in remodeling and 
repair of extracellular matrix (David-Raoudi et al., 2008). Furthermore, HA 
may also play a role in the control of angiogenesis during tissue repair (West, 
Hampson, Arnold & Kumar, 1985), and has been proposed that HA may 
protect granulation tissue from the deleterious effects of oxygen free radical by 
its ability to scavenge reactive oxygen species (ROS) (Trabucchi et al., 2002).  
In the present study, we develop an ALG/HA hydrogel with enhanced wound 
healing activity potentially useful as platform for wound dressing. Internal 
gelation technique was used for cross-linking ALG/HA solutions at different 
HA ratio, and the resulting disk-shaped hydrogels were fully characterized. 
The gelation dynamics were monitored through rheological measurements to 
evaluate the influence of HA on the cross-linking process. Biocompatibility 
and wound healing potential of ALG/HA were evaluated on different cell lines. 
Human adipose-derived Mesenchymal Stem Cells (AdMSCs), a multipotent 
non hematopoietic stem cell line was selected due to its overwhelming interest 
in cell therapy and tissue engineering (Kocaoemer, Kern, Kluter & Bieback, 
2007). Then, the effect on a human keratinocytes cell line HaCaT, a well-
known systems modeling very closely the repairing process during re-
epithelialization (Singer & Clark, 1999) (Gurtner, Werner, Barrandon & 
Longaker, 2008). In vivo wound healing activity of the most promising 
formulation has been evaluated in a rat model. 
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MATERIALS AND METHODS 
Materials. Sodium alginate (ALG) (viscosity 360cps) was purchased from 
Farmalabor (Italy). Analysis-grade ethanol was purchased from Carlo Erba 
(Italy). Hyaluronic acid (HA) sodium salt from Streptococcus equi (1.5-1.8 * 
106 Da), calcium carbonate, calcium chloride dihydrate (CaCl2 * 2H2O), 
sodium chloride (NaCl), potassium chloride (KCl), sodium phosphate dibasic 
(Na2HPO4), D-glucono-δ-lactone (GDL) and all reagents used for 
sulforhodamine assay were obtained from Sigma-Aldrich (St. Louis, MO). 
Media, sera, and antibiotics for cell cultures were from Lonza (Lonza Group 
Ltd, Basel, Switzerland). Distilled water was used throughout this study.   
ALG/HA hydrogel preparation. Structurally homogeneous ALG hydrogels 
were prepared according the Kuo and Ma method (Kuo & Ma, 2001). Briefly, 
ALG (1% w/v) was dissolved in deionized water and mixed with 30 mM 
calcium carbonate to form a suspension. A fresh aqueous 64 mM GDL solution 
was then added to the suspension and vortex-mixed to initiate gelation. A 
calcium carbonate to GDL molar ratio of 0.5 was maintained to achieve a 
neutral pH post-crosslinking. HA was dissolved directly in the alginate solution 
to obtain a 10% (ALG/HA10) and a 20% (ALG/HA20) w/w concentration. 
Solutions were cast in 96-well culture plate (50 µl, well size: 5 mm diameter, 
20 mm height) or in 24-well culture plate (1 ml, well size: 15 mm diameter, 20 
mm height) to form circular disk 2 mm in thickness and 5 mm in diameter and 
5 mm in thickness and 15 mm in diameter, respectively. The well plate were 
capped, sealed with Parafilm®, and gelled on a level surface at room 
temperature for 24 h. After gelation the ALG disk were washed with water and 
stored at 4°C. 
Hydrogel characterization. Homogeneity of the cylindrical ALG gels was 
evaluated from dry to wet weight ratios. Gels were cut perpendicular to the 
cylinder axis into 4 slices with approximately the same thickness. The slices 
were labeled 1-4 from top to bottom. After measuring their wet weights, the 
slices were dried at 45° C for 48 h. The specimens were weighed again and 
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their dry/wet weight ratio calculated. Gelation time and viscoelastic properties 
of gels were measured using a strain-controlled rotational rheometer (ARES, 
Rheometric Scientific Inc. USA) equipped with a dual-range force rebalance 
transducer (2KFRT). Measurements were performed using 25 mm parallel 
plates geometry and maintaining the samples at 22 °C. Cross-linking degree of 
the ALG hydrogels was evaluated by soaking the hydrogel gel disc in 15 mL of 
a 1, 3 or 5 mM calcium chloride solution to vary calcium ion concentrations. 
The swelling experiments were carried out at 37° C by keeping the samples in 
a thermostatic bath under gentle shaking. The medium was changed every day. 
At scheduled times, the specimens were retrieved and hydrogel surface was 
quickly blotted twice on a filter paper. The specimens were weighed on an 
analytical balance. The initial wet weight (W0) was obtained after 24 h 
gelation. Wet weight (W) during immersion experiment was recorded at 
designated times. The swelling ratio was defined as W/W0.  
In vitro studies. Mesenchymal Stem Cells (Ad-MSCs) were isolated from 
human adipose tissue biopsies as previously described (D'Esposito et al., 
2012). Cells were cultured at 37°C with Dulbecco's modified Eagle's medium 
(DMEM) and Ham's F12 (1:1) with 10% Fetal Bovine Serum (FBS), 2 mM 
glutamine, 100 IU/ml penicillin, and 100 IU/ml streptomycin. Cultures were 
maintained in humidified atmosphere of 95% air and 5% CO2 at 37 °C. 
Immortalized keratinocyte cell line HaCaT (CRL2309) was obtained from 
American Type Culture Collection (Manassas, VA, USA). HaCaT were 
cultured in DMEM containing 10% FBS, penicillin/streptomycin (10.000 
U/ml), L-glutamine (2 mM) and placed in a humidified incubator under of 95% 
air and 5% CO2 at 37° C. Cells were passaged at confluence using a solution of 
0.5% trypsin and 0.2% EDTA. 
Evaluation of In vitro toxicity of hydrogels on Ad-MSCs. Ad-MSC viability 
was assessed using 24-transwell culture system 0.4-µm pore polycarbonate 
membranes (Costar, Cambridge, MA). Cells were loaded at 50,000 cells per 
insert in the lower chamber. The following day, the hydrogels were added to 
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the upper chamber in complete medium. Upon 24 h, sulforhodamine assay was 
used to determinate their viability (Chiba, Kawakami & Tohyama, 1998). 
Briefly, the upper chamber was removed and the cells were fixed with 50% 
trichloroacetic acid for at least 2 h at 4 °C. Then, cells were washed 5 times 
with distilled and de-ionized water. After air-drying, cells were stained for 30 
min with 0.4% sulforhodamine dissolved in 1% acetic acid. Unbound dye was 
removed by five washes with 1% acetic acid. After air-drying, 10 mM Tris 
solution (pH 7.5) was added to dissolve the protein-bound dye. Cell survival 
was assessed by optical density (OD) determination at 510 nm using a 
microplate reader.  
Cell motility - Wound healing Assay. For in vitro wound healing assay, HaCaT 
cells (50.000 cells/well) were seeded into 12-well plates in DMEM 
supplemented with 10% FBS and allowed to adhere for 24 h. Ad-MSCs were 
seeded into six-well microplates and grown in the same complete medium to a 
confluent monolayer. The monolayer was then carefully scratched with a 
sterile pipette tip, washed twice with sterile phosphate buffer saline (PBS) and 
incubated at 37 °C with a medium containing 1% FBS with or without the 
hydrogels. Reference points near the “scratch” were marked to guarantee the 
same area of image acquisition. Images of wound gap were taken at 0, 1 day 
and 5 days by a DFC295 camera (Leica) coupled to the microscope and the 
percentage of closure was calculated with NIH IMAGE J.  
In vivo wound healing studies. A full-thickness excision wound model was 
used to monitor wound closure. Male Wistar albino rats weighing 300-350 g 
(Harlan, Italy) were housed singly to prevent fighting and attack on the wounds 
in Plexiglas cage for one week at temperature of 22 ± 1° C, with alternate cycle 
of 12 h of light and 12 h of dark. All animals received food and water ad 
libitum throughout the experimental period. All manipulations were performed 
using aseptic techniques. This study was carried out in strict accordance with 
the Institutional Guidelines and complied with the Italian D.L. no.116 of 
January 27, 1992 of Ministero della Salute and associated guidelines in the 
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European Communities Council Directive of November 24, 1986 
(86/609/ECC). All the animals were anesthetized with ketamine hydrochloride 
(100 mg/kg body weight) and xylazine (5 mg/Kg) by intraperitoneal 
administration, and the dorsal hair was shaved using a shaving machine. The 
dorsal region was chosen to avoid animal access to their own wound and 
animals were housed one per box to prevent cross-access to the lesions. The 
surgical area was disinfected with Betadine R 10%. A full-thickness wound 
with a diameter of 2.5 cm was excised from the back of the rats using sterile 
scissors at the depth of loose subcutaneous tissues and the wounds were left 
open. Hemostasis was obtained by direct pressure using sterile gauze. Before 
hydrogel application the wound was moistened with 300 µL of saline. Animals 
(n=3) were divided into four groups and wounds were treated with a single 
application of hydrogels (ALG, ALG/HA20). Wound site was finally closed 
with TegadermTM (3M, USA) to prevent the rats from removing the hydrogel. 
For wound closure study, changes in wound area were measured on day 1 and 
5 and wound contraction was calculated according to equation: 
!% Wound contraction=A0 -At
A0
X 100 
Where A0 is the initial wound area and At is the open area of wound at day 1 
and 5 after biopsy.  
 
RESULTS AND DISCUSSION 
Internal gelation of ALG and ALG/HA hydrogels. Control over material 
properties of a hydrogel is crucial for many biomedical applications. Covalent 
crosslinking is an elective way to stabilize three dimensional polymer networks 
for a variety of applications and has also been used in hydrogel formation with 
permanent 3-D structures. However, chemical crosslinking reagents can show 
severe toxicity resulting in limited application in the biomedical field. As an 
alternative method, electrostatic cross-linking is a versatile and simple strategy 
to produce hydrogels for biomedical applications. In this case, the chemical 
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composition of ALG can greatly influence hydrogel properties. Indeed, the 
affinity of certain ions with the G units, the M/G ratio and the number of 
repeated sequential G and M units strongly affect the gelation process and, in 
turn, hydrogel physical structure (strength and porosity). Furthermore, it has 
been shown that ALG with a high G content have a high in vivo stability 
(Kong, Alsberg, Kaigler, Lee & Mooney, 2004), whereas ALGs with high M 
content were reported to show greater biocompatibility and recommended as 
suitable biomaterials for implants (Orive, Ponce, Hernandez, Gascon, Igartua 
& Pedraz, 2002). Although, M/G ratio of the raw ALG employed in this study 
was 1.54, a value corresponding reasonably well with those previously 
reported for ALG produced by Macrocystis pyrifera (Moe S.T., 1995), we tried 
to produce ALG/HA hydrogels with suitable mechanical properties through an 
internal gelation technique where the release of calcium ions directly in the 
ALG solution occurs (Draget, Ostgaard & Smidsrod, 1990).  
As a first step of the study, we tried to evaluate if addition of HA could modify 
gelation properties of Alg. Indeed, Gelation time is an important variable in 
hydrogel formulation previous studies have shown that a fast gelation time can 
lead to a poorly homogeneous gel structure (Kuo & Ma, 2001). To determine 
the liquid-to-solid transition point (i.e., the so called “critical gel” state) 
samples were subjected to a continuous series of frequency sweeps (in the 
range 0.03–100 rad/s) and the gel time was determined as the instant where G’ 
and G’’ are parallel to each other or equivalently where the loss phase angle is 
frequency independent (Chambon & Winter, 1987). The time-evolution of 
viscoelastic moduli for the ALG/HA20 system is reported in Figure 1A. Other 
systems show similar behaviors and corresponding data are not shown. For 
times shorter than 3 minutes, the sample shows a liquid-like behavior with a 
viscous modulus (G’’) higher than the elastic component (G’) and a strong 
dependency upon frequency. At 7 minutes, the sample shows a critical gel 
behavior with G’ and G’’ parallel to one another and a power-law dynamics. 
At this condition the material behaves not as a liquid (as it has an infinite shear 
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viscosity) and not yet as a solid (as it has a null equilibrium modulus). At 
longer times (see for instance the curves referring to 21 minutes in Figure 2), 
the material shows a solid-like behavior with elastic modulus higher than 
viscous modulus and a less pronounced dependency upon frequency. Gelation 
time (left y-axis) and initial viscosity of the solutions (right y-axis) were 
plotted as a function of HA content (Figure 1B) where both data-sets show a 
monotonic increasing behavior. The gelation process is controlled by the 
mobility of G-blocks (of ALG chains) and calcium ions that interact to from 
cross-links and give rise to an “egg box” structure. In this view it is expected 
that an increase of the viscosity of the initial solution would result in a 
decreased mobility and, consequently, in a longer gelation time. These 
previsions are in line with the experimental data collected.  
At the end of the gelation process, the resulting hydrogels have elastic shear 
moduli (G’) of the order of a few kPa, viscous shear moduli (G’’) about one 
order of magnitude smaller, and a weak frequency dependency. Furthermore, 
while viscoelastic properties of initial solution and of critical gels do strongly 
depend upon HA content (with higher contents corresponding to more elastic 
systems), after the gelation has completed all the systems have similar behavior 
and similar moduli. Compressive tests performed in quasi-static conditions 
confirm these observations (data not shown) with all samples showing similar 
(strain-hardening) behavior and stress at 10% deformation ranging between 
200 and 300 Pa.  
Uniform and transparent ALG hydrogels were easily obtained at calcium 
carbonate/GDL molar ratio of 2 (Figure 2), which guarantees also that pH of 
the final hydrogel is close to neutrality (Draget, Ostgaard & Smidsrod, 1989). 
One of the aims of this study was to formulate compact hydrogels able to 
remain intact after gelation and with sufficient strength to be easily placed on 
the wound bed during the dressing change. The investigated hydrogels showed 
sufficient strength to be handled, cut with scissors or packed without 
difficulties making them suitable as wound dressing.  
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Hydrogel homogeneity. Amid the large number of factors that can influence 
ALG gelation time (Alexander, Murphy, Gallagher, Farrell & Taggart, 2012), 
concentration of calcium carbonate in the polymer solution is of utmost 
importance since it controls availability of calcium ions for crosslinking. On 
the other hand, calcium carbonate is dispersed in polymer medium and can 
progressively accumulate at the bottom of recipient giving non-homogeneous 
cross-linking. It is worth of note that structural uniformity is crucial for 
biomedical applications not only from a drug delivery point of view to achieve 
uniform distribution of the drug in the matrix, but especially to get good 
material properties. To evaluate the homogeneity of hydrogels made with 
CaCO3-GDL, cylindrical gels with varying compositions were prepared, sliced 
along the vertical axis and dry/wet ratio evaluated. Comparable homogeneity 
profiles of ALG gels at different HA concentrations indicated that the presence 
of HA did not affect gel homogeneity in the concentration range studied 
(Figure 3). 
Cross-linking degree. The swelling behavior of ALG hydrogels is a function 
of crosslink density, ALG concentration and ALG chemical composition (Kuo 
& Ma, 2008). In particular, structural integrity and mechanical properties are 
highly dependent on crosslinking of G-blocks, that in presence of calcium ions 
form more highly ordered regions (Smidsrod & Skjak-Braek, 1990). During 
the internal gelation, calcium ions are released directly inside the ALG solution 
and, for this reason, their diffusion in the solution is essential to control cross-
linking degree and in turn swelling. To determine whether hydrogels 
composition affected cross-linking degree, the effects of calcium chloride 
addition on equilibrium swelling (7 days) of different hydrogels were 
investigated (Figure 4). It was found that independently of the presence of HA 
all hydrogel gave a similar swelling behavior with a shrinking that directly 
depended from the calcium concentration in the medium. The W/W0 ratio was 
similar for all the formulation suggesting that the presence of HA had a 
minimum influence on the crosslinking degree. 
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Biological evaluation of ALG and ALG/HA hydrogels. In order to evaluate 
the in vitro toxicity of hydrogels, Ad-MSCs previously isolated from 
subcutaneous adipose tissue biopsies (D'Esposito et al., 2012) were used. 
Indeed, in vitro predictive toxicological assays based on human stem cells and 
their derivatives offer significant vantages over animal models largely due to 
improved relevance and greater versatility. The use of human stem cell systems 
might dramatically increase the ability to predict toxic responses in humans 
while decreasing the need for extensive toxicity tests in animals (Liu, Deng, 
Liu, Gong & Deng, 2013). Ad-MSCs viability was investigated using a 
transwell system. The upper chamber was filled up with the hydrogels, while 
the lower chamber was loaded with a cell suspension in DMEM F12 (1:1) 10% 
FBS. Sulforhodamine assay revealed that Ad-MSC viability in the presence of 
ALG and ALG/HA hydrogels was comparable to that achieved in complete 
medium (Figure 5) indicating that hydrogels do not interfere with cell viability. 
Next, to investigate whether ALG and ALG/HA hydrogels could affect cell 
motility a wound healing assay was performed. On the basis of toxicity data, 
ALG/HA20 with the highest HA concentration was selected for further 
experiments. Ad-MSCs were scratched and incubated with ALG and 
ALG/HA20 hydrogels in medium without serum supplementation (DMEM 
F12 -0.25% BSA). Images were taken at 0 and 24 h after wounding. As shown 
in figure 6, serum induced an almost complete wound closure. Even in absence 
of serum, ALG and ALG/HA hydrogels significantly promoted wound closure 
as compared to serum-free medium.  Results demonstrated that ALG/HA 
hydrogels do not impair Ad-MSC viability suggesting that combination of 
ALG and HA does not represent a toxic environment for Ad-MSCs. 
Interestingly, however, we observed an improvement of wound healing, which 
is most likely due to increased cell motility, rather than cell proliferation.  
The same experiment was replicated using confluent monolayers of HaCaT 
allowing to extend the temporal window of wound closure assessment. In 
analogy to Ad-MSC, hydrogels did not interfere with HaCaT cell viability 
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(data not shown). Confluent monolayers of HaCaT were scratched and 
incubated with ALG and ALG/HA hydrogels in medium with 1% FBS. Images 
were taken at 0 h, 24 h (day 1) and 120 h (day 5) after wounding. As shown in 
figure 7, ALG and ALG/HA20 hydrogels significantly promoted wound 
closure at 24 h as compared to medium with 1% FBS. This effect was more 
significant at 120 h (day 5) and it is most likely due to increased cell motility, 
since the experiments were carried out with low serum concentrations, in order 
to reduce cell proliferation. These data support the hypothesis that ALG/HA 
hydrogels could potentiate regeneration of wounded tissues by stimulation of 
Ad-MSC and HaCaT motility and may be useful for tissue engineering 
procedures. 
The wound healing effect of hydrogels was evaluated also in vivo using the full 
excision wound model in rats. ALG and ALG/HA hydrogels were applied on 
rat backs and the capacity of hydrogels to heal the wound was evaluated. As 
reported in figure 8, ALG/HA20 hydrogel induced a significant reduction of 
wound extension after 1 and 5 days from to application (p<0.05 and p<0.01, 
respectively) whereas, no evident effect was detectable using ALG alone.  
 
CONCLUSIONS 
Hydrogels based on ALG and HA, a polysaccharide with a crucial role in 
wound healing process, have been successfully produced and characterized. 
The internal gelation method allowed production of hydrogels with good 
handling characteristics and suitable mechanical properties as wound dressing. 
Although the presence of HA affected alginate gelation time, its limited 
influence on the overall properties of hydrogels was found. In vitro 
experiments on different cell lines highlighted that HA incorporation into ALG 
hydrogels promoted in vitro wound closure without affecting cell viability. 
Finally, a significant reduction of wound area in a excision wound model in 
rats at 1 day and more significantly at 5 days after skin application was found 
for a HA content of 20%. Taken together, these results demonstrate that 
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integration of HA in a physically cross-linked alginate matrix can be a simple 
and valid strategy to promote wound healing process and to translate in a 
clinical setting. Furthermore, these systems can be useful as potential platform 
for the release of drugs directly in the wound site avoiding systemic 
administration. 
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FIGURE LEGENDS 
 
Figure 1. Rheological characterization of gelation process. A) Viscoelastic 
moduli as a function of frequency for ALG/HA20 at different times after 
beginning of internal gelation process. B) Gelation time and initial viscosity of 
ALG/HA solutions at different HA concentration.  
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Figure 2. ALG hydrogel obtained by internal gelation. 
Figure 3. Dry/wet weight ratios of ALG hydrogel slices with varying 
ALG/HA concentrations numbered 1-4, from top to bottom. 
Figure 4. Equilibrium swelling of ALG hydrogels immersed for 7 days in 
medium containing different concentration of calcium chloride. 
Figure 5. Effect of ALG and ALG/HA hydrogels on Ad-MSCs viability. 
ALG or ALG/HA hydrogels (ALG/HA10 - ALG/HA20) have been added in 
the upper chamber of the transwell in DMEM F12 (1:1) 10% FBS. Upon 24 
hours, cell viability has been determined. The results have been reported as 
percentage of viable cells compared with cells incubated in DMEM F12 (1:1) 
10% FBS in the absence of hydrogels (considered as 100% viable cells). Bars 
represent the mean ± SD of triplicate determination in three independent 
experiments.  
Figure 6. Effect of ALG and ALG/HA hydrogels on Ad-MSCs motility. 
Confluent monolayers of Ad-MSCs have been subjected to scratch assays, 
washed twice with PBS and incubated at 37°C in presence of ALG or 
ALG/HA (ALG/HA20%) hydrogels in DMEM F12 (1:1) 0.25% BSA. Images 
of wound gap have been taken at 0 and 24 h by a digital camera coupled to the 
microscope and percentage of closure was calculated with NIH IMAGE J. The 
results are reported as percentage of wound distance at 24 h compared with the 
time 0. Bars represent the mean ± SD of triplicate determination in three 
independent experiments. Statistically significant differences respect to cells in 
DMEM F12 (1:1) 0.25% BSA (*p < 0.05; **p < 0.01; ***p < 0.001 ).  
Figure 7. Effect of ALG and ALG/HA20 hydrogels on HaCaT motility. 
Confluent monolayers of HaCaT have been subjected to scratch assays, washed 
twice with PBS and incubated at 37°C in presence of ALG or ALG/HA20 
hydrogels in DMEM with 1% FBS. Images of wound gap have been taken at 0 
and 24 h and 120 h by a digital camera coupled to the microscope and 
percentage of closure was calculated with IMAGE J. The results have been 
reported as percentage of wound distance at 24 h (day 1) and 120 h (day 5) 
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compared with the starting point (time 0). Data are shown as mean ± SEM of 
triplicate determination in three independent experiments. *** P<0.001, and * 
P<0.05 vs. DMEM with 1% FBS; ### P<0.001 vs. ALG. 
Figure 8. Effects of ALG hydrogels on wound healing process in a rat 
wound model. A full-thickness wound was excised from the back of the rats 
(n=3) using sterile scissors and the wounds were left open. Wounds were 
treated with hydrogels (ALG, ALG/HA20) and closed with TegadermTM. 
wound contraction on day 1 and 5. *P<0.05; **P<0.001 vs ALG hydrogel. 
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Glucose-induced ccl5 release by human adipocytes promotes breast cancer 
invasiveness and distant metastasis  
 
D’Esposito V, Liguoro D, Ambrosio MR, Cantile M, Collina F, Beguinot F, Di 
Bonito M, Franco R, Formisano P. 
 
Type 2 diabetes (T2D) is associated with an excess risk of incidence and 
mortality for overall and a number of site-specific cancers. Women with 
(versus without) diabetes have a statistically significant 20% increased risk of 
breast cancer. Additionally, the patients with breast cancer and preexisting 
diabetes had an increased risk for distant metastasis and for all-cause  mortality 
compared with their nondiabetic counterparts. Breast cancer grows and 
metastasizes to a predominantly adipocyte-dominated host environment. T2D 
associated derangements induce adipocyte alterations leading to an imbalanced 
adipokine production that in turn may promote cancer phenotypes. We have 
studied the mechanisms by which adipocytes integrate inputs from T2D-
associated alterations and promote breast cancer cell motility and invasiveness. 
We have obtained evidence that human adipocytes grown in 25 mM glucose, a 
concentration corresponding to hyperglycemia in humans, significantly 
induced breast cancer cell proliferation, migration and invasion. Screening of 
several cytokines revealed that adipocytes cultured in high glucose medium (25 
mM) released 1.5 and 2-fold higher amount of IGF1 and CCL5, respectively, 
compared to those cultured in low glucose medium (5.5 mM glucose). 
Moreover, adipocyte-released factors controlled IGF1, but not CCL5 
expression in cancer cells. Inhibition of IGF-1 pathway almost completely 
prevented the effect of adipocytes on breast cancer cell growth but only 
slightly interfered with cancer cell motility. At variance, inhibition of CCL5 
action by specific peptides and antibodies significantly reduced adipocyte 
promoting effect on breast cancer cell migration and invasion. Interestingly, 
CCL5/RANTES expression in peritumoral adipose tissue of women with 
Triple Negative Breast Cancer correlated with lymph node (p-value = 0.04) 
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and distant metastases (p-value=0.001). A positive trend with the presence of 
T2D was also observed. Finally, Kaplan-Meier curves showed a significant 
negative correlation between CCL5 staining in the peritumoral adipose tissue 
and overall survival of patients (p-value= 0.039). Hence, hyperglycemia 
induces adipocyte release of CCL5 that, in turn contributes to cancer cell 
motility, cancer lymph node and distant metastases, reducing the overall 
survival of patients. 
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New insights into PPARG regulation: the unexplored impact of alternative 
splicing on its function 
 
Aprile M., Ambrosio M.R., D’Esposito V., Formisano P., Ciccodicola A., 
Costa V. 
 
PPARγ is the most studied member of PPAR family. This nuclear receptor is a 
ligand-dependent transcriptional factor regulating the expression of a wide 
number of target genes. It represents the master regulator of adipocyte 
differentiation and metabolic processes. Indeed, defects in PPARγ signaling are 
implicated in metabolic syndrome and its complications. PPARγ synthetic 
ligands (including the class of thiazolidinediones) are used to treat 
hyperlipidemia and as insulin-sensitizing antidiabetic agents, although they 
produce adverse side effects. The existence of different isoforms, combined to 
the wide number of potential ligands, coregulators and target genes, determines 
the complexity of PPARγ biological role. In addition, by different promoter 
usage and alternative splicing the human PPARG gene generates at least four 
canonical transcript variants encoding two proteins, PPARγ1 and PPARγ2. 
Therefore, different PPARG splice variants encode the same protein isoform 
and, their differential spatial/temporal expression may reflect a different 
regulation, translation, mRNA stability and/or localization. To complicate the 
picture, the recent identification of γORF4 isoform – able to act as dominant-
negative and with a tumorigenic effect – strengthen the hypothesis that PPARγ 
activity is modulated through transcript-specific regulation. However, the 
regulation of human PPARG gene – particularly through alternative splicing – 
still represents an unexplored aspect of PPARγ signalling. We identified, in 
normal cells and tissues, a new PPARG isoform, named γ∆5, that lacks the 
entire ligand binding domain. Similarly to γORF4 isoform, γ∆5 shows a 
reduced transactivation ability and an inhibitory activity toward PPARγ 
transcriptional activity. Whole-transcriptome analysis of cells overexpressing 
! 113!
γ∆5 revealed that this physiologically transcribed dominant negative isoform 
alters the expression of PPARγ target genes. The translation of protein 
isoforms lacking the ligand-binding domain, causing a reduction in the levels 
of functional PPARγ protein and a simultaneous increase in the levels of 
proteins with dominant negative effect, may be a new mechanism in self-
regulatory loop of PPARγ activity. Interestingly, the activation of this 
negative-feedback on PPARγ activity could potentially determine unwanted 
side effects of the thiazolidinediones. Furthermore, the increased levels of γ∆5 
mRNAs in patients with impaired glucose tolerance or type 2 diabetes suggest 
that they may contribute to the onset or worsen diseases in which PPARG is 
involved. This effect may be caused by a wide deregulation of alternative 
splicing mechanism in pathological conditions, that in turn may have a 
dramatic impact on PPARγ function. Targeted studies will potentially lead to 
refine the current therapies for metabolic syndrome and related complications, 
in which this gene is crucially involved. 
